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Vagus nerve stimulation (VNS) has been on the forefront of inflammatory disorder research for
the better part of the last three decades and has yielded many promising results. There remains,
however, much debate about the actual biological mechanisms of such treatments, as well as,
questions about inconsistencies in methods used in many research efforts.

In this work, I identify shortcomings in past VNS methods and submit new developments and
findings that can progress the research community towards more selective and relevant VNS
research and treatments. In Aim 1, I present the most recent advancements in the capabilities of
our fully implantable Bionode stimulation device platform for use in VNS studies to include
stimulation circuitry, device packaging, and stimulation cuff design. In Aim 2, I characterize the
inflammatory cytokine response of rats to intraperitoneally injected endotoxin utilizing new data
analysis methods and demonstrate the modulatory effects of VNS applied by the Bionode
stimulator to subdiaphragmatic branches of the left vagus nerve in an acute study. In Aim 3,
using fully implanted Bionode devices, I expose a previously unidentified effect of chronically
cuffing the left cervical vagus nerve to suppress efferent Fluorogold transport and cause
unintended attenuation to physiological effects of VNS. Finally, in accordance with our findings
from Aims 1, 2, and 3, I present results from new and promising techniques we have explored for
future use of VNS in inflammation studies.
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1. INTRODUCTION

Background and Motivation
1.1.1

The vagus nerve

The vagus nerve, often referred to as the wandering nerve due to the Latin definition of “vagus”
and the fact that it is the longest nerve and reaches parts of virtually every part of the body (see
Figure 1.1), could be the key to treating countless ailments, diseases, and syndromes [1]. The
vagus nerve has been connected to cough reflexes in the respiratory tract, seizures in epilepsy
patients, cardiac function and heart failure, hearing issues such as tinnitus, and many others such
as Alzheimer’s, migraines, stroke, obesity, and even hiccups [1].

Of specific interest to our research aims, however, is the connection of the vagus nerve to the
gastrointestinal (GI) region of the body and its effect on the systemic inflammation originating in
that region. The left cervical vagus nerve trunk separates into three primary branches below the
diaphragm, which are most commonly associated with inflammatory controls. These
subdiaphragmatic branches are the anterior gastric, accessory celiac, and hepatic branches, and
have their routes outlined well in Figure 1.2. The anterior gastric branch terminals lead mainly to
the stomach, while the accessory celiac branch reaches multiple locations including the spleen,
intestines, and pancreas. The hepatic branch primarily innervates the liver, while also reaching to
the pancreas.
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Figure 1.1 Representation of the distribution and central connections of the vagus nerve. All
cervical and thoracic branches are bilateral and may have been omitted for clarity. The right
recurrent laryngeal nerve (not shown) passes round the right subclavian artery instead of the arch
of the aorta. Left and right vagus nerves form the oesophageal plexus and then become anterior
and posterior trunks as they pass through the diaphragm to supply the abdominal viscera up to
two-thirds along the transverse colon. Abbreviations: DNV, dorsal nucleus of the vagus; NA,
nucleus ambiguus; NTS, nucleus tractus solitarii; and SpV N, spinal trigeminal nucleus [1]. Note
that the Splenic branch is a synonymous part of the Accessory Celiac branch.
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Figure 1.2 Distribution of the vagus nerve and central distribution of vagal afferents from NTS.
Abbreviations for periphery: ac, celiac artery; agd, right gastric artery; ags, left gastric artery;
ahc, common hepatic artery; al, splenic artery; ams, superior mesenteric artery; la, larynx; ph,
pharynx; tr, trachea. Abbreviations for brain areas: Amb, nucleus ambiguus; AP, area postrema;
BST, bed nucleus of stria terminalis; DM, dorsomedial nucleus of thalamus; CeA, central
nucleus of amygdala; LHA, lateral hypothalamic area; NTS, nucleus tractus solitarius; PAG,
periaqueductal gray; PVN, paraventricular nucleus of hypothalamus; PBN, parabrachial nucleus;
RVL, rostroventrolateral medulla; SN, substantia nigra; VPM, ventral posteriomedial nucleus of
thalamus; 5, trigeminal nucleus; 7, facial nucleus; 10 (dmnX), dorsal motor nucleus of vagus [2].
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The presumed key to controlling inflammatory ailments in the body is the modulation of
inflammation, specifically the inflammatory cytokines produced in the subdiaphragmatic region.
It was hypothesized by Tracey in 2002 [3] that vagal efferent fibers to the spleen modulated
cytokine release through an “inflammatory reflex” that could produce a therapeutic antiinflammatory effect (see Figure 1.3). Since then, there has been ample research conducted to
explore and dispute details of this inflammatory reflex [4-8], but much of the specific
mechanisms for cytokine modulation remain undefined.

Figure 1.3 The functional anatomy of the inflammatory reflex (according to Pavlov & Tracey,
2015) AChE, acetylcholinesterase; AP, area postrema; DMN, dorsal motor nucleus of the vagus
nerve; LPS, lipopolysaccharide (endotoxin); mAChR, muscarinic acetylcholine receptor; NA,
nucleus ambiguus; NLRs, nucleotide-binding oligomerization domain-like receptors;
NTS, nucleus tractus solitarii; TLR4, Toll-like receptor 4 [9].
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1.1.2

Vagus nerve stimulation

Vagal nerve stimulation (VNS) therapy has become a prominent fixture in treatment research
and has been proposed as a therapy for ailments such as depression [10], rheumatoid arthritis
[11], obesity [12], and many others. While the U.S. Food and Drug Administration (FDA) has
approved VNS for seizure prevention in epilepsy and as an alternative for drug-resistant
depression [13, 14], the exact mechanics of much of the body’s response to VNS has yet to be
characterized. This is also true for anti-inflammatory treatments for ailments stemming from the
GI tract and other subdiaphragmatic regions.

There are two major aspects to consider when studying effects of VNS. The first is that the
cervical vagus is populated with both sensory afferent fibers (~80%) and efferent motor fibers
(~20%). Afferent fibers collect in the nodose ganglia of the vagus nerve before reaching to the
nucleus of the solitary tract (NTS) in the medulla oblongata, while efferent motor fibers originate
from the dorsal motor nucleus (DMN) of the medulla, as is represented in Figure 1.4. These
fibers serve many separate and distinct functions of the nervous system, but are also connected
within a parasympathetic system that contributes to the inflammatory reflex [9] and could cause
possible conflicting effects between the two fiber types with VNS. Some studies have
circumvented this potential offset by chemically or electrically attenuating the functionality of a
specific fiber type [15-17].

The second major aspect to consider is whether to attempt a chronic or acute study. There are
ample acute studies that have been performed on the topic of anti-inflammatory pathways using
rodent models [5, 15, 18-20]. Nonrecovery studies give researchers the ability to evaluate the
physiological effects of rats in a controlled environment, allowing idealized set-ups for surgical
processes, precise stimulation electrode placement with reduced noise (due to shorter electrical
leads), and easier use of faradaic cages. Long term effects of treatment over days, weeks, and
even years cannot be accurately studied acutely. Also, due to the nature of the anesthetic used in
acute surgical procedures, potential unintended and detrimental physiological effects on the
body’s normal state can be caused [21]. As was explored by Picq et al [22], the
immunoregulatory effects of isoflurane can influence the results of studies aimed at antiinflammatory effects of VNS.
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Figure 1.4 Comparison of afferent versus efferent fibers in the cervical vagus nerve.
We resolve that the best option for studying the true effects of VNS for the treatment of
inflammation and many other physiological effects remains a reliable long-term chronic study on
an awake and freely moving subject. However, such a study adds many complexities including
implantable device design considerations such as powering and noise, surgical implantation
factors of device migration and leaks, and biological ramifications such as potential infections.

In addition, the research community is plagued by inconsistency in experimental methods in both
the acute and chronic realms. Devices and protocols used vary greatly between labs and research
projects. This makes it difficult to replicate results and translate them into future research and
treatments.
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Aims
There are three primary aims demonstrated by my research:

1. Developing and improving devices and equipment for VNS studies. A significant effort
was made by myself and the Center for Implantable Devices (CID) to build a fully
implantable Bionode device and that could be used reliably for multiple experiments. I
played a vital role in the development of the Bionode stimulator, as well as the
manufacturing and packaging techniques. In addition, I was the primary developer and
tester of stimulation electrodes in the CID.

2. Exploring underlying biology behind endotoxin induced inflammation and subsequent
VNS treatment. I, in conjunction with Kelsey Wasilczuk, performed an in-depth acute
study of the effects on cytokine levels in the plasma of rats following an
intraperitoneally (IP) injected dose of endotoxin, and a subsequent VNS treatment of the
individual subdiaphragmatic nerve branches. New analysis methods were developed by
myself to deal with high temporal variations in our data.

3. Exploring the challenges of chronic applications of VNS. In an attempt to complete a
chronic study on the effects of cervical VNS, we discovered an unexplored issue of
attenuated efferent transport of a retrograde tracer in chronically cuffed nerves. This
signaled a potentially larger issue of underlying damage to the cuffed nerves. I defined
this new discovery and addressed the larger potential issues it presents to the VNS
community.

In addition to the primary aims, I also spent a portion of time dedicated to looking at alternate
methods of VNS research and applications for potential future research. Those are presented in a
separate “Future Work” section.

Together, the works presented in this thesis tell a story of progress towards more consistent and
reliable studies of VNS for treatment of inflammation in the future.
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2. AIM 1: VNS DEVICE DEVELOPMENT

Motivation
As with any research effort, having the appropriate tools, materials, and facilities to properly
accomplish the research task is vital to obtaining reliable results. In the case of VNS research,
those tools include devices to stimulate the appropriate biological target, and to record, if
desired, the physiological outcomes of the stimulation therapy. There are plenty of options for
stimulation devices that can be found commercially for these uses, however, as is explained in
the following subsections, many of those options are made for specific applications or interfaces,
with specific software, and are not easily adjustable for custom research applications.

Along with the electronics to do said stimulation and recording, an appropriate package is
needed if desiring to test the device chronically in an animal, as well as an effective set of
electrodes to interface with the biology being studied.

Our Aim 1 addresses these issues with respect to our specific studies by outlining the
development of critical portions of the Bionode’s development in our lab. I was intricately
involved in many pivotal junctures of the Bionode’s evolution over the past three years. Those
research efforts are documented here. In addition, I was our lab’s lead researcher in development
and characterization of stimulation cuffs for effective VNS and other stimulation studies. Those
efforts are outlined in section 2.3.

Material in section 2.2 (except for 2.2.2.4, 2.2.2.5, and 2.2.4) come directly from our lab’s paper
titled “The Bionode: A Closed-Loop Neuromodulation Implant,” lead authored by Dan Pederson
and submitted to Association for Computing Machinery (ACM) Transactions on Embedded
Computing Systems in January of 2018 [23]. Used sections include portions of the paper either
directly authored by myself, or that I played an integral part in developing. Formatting changes
have been made as were appropriate and some updates and additions were made to section
2.2.3.4. Additional sections have been added to clarify more recent developments that have been
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made to our devices. Many figures for section 2.2.2.4 were made in conjunction with Gang Seo
for his thesis and are used here also. They are referenced as such.

Bionode Introduction
Wireless implantable devices with the ability to record biopotential signals and electrically
stimulate the nervous system have been used to study and treat a wide variety of neurological
and neuropsychiatric disorders in humans including epilepsy, Parkinson’s disease, depression,
and drug addiction [24-28]. To further research these disorders in rodent models, various
miniature wireless implantable devices have been developed [29-33]. To achieve a small size and
reduce power requirements, many of these devices rely on application specific integrated circuits
(ASICs), specifically designed packaging methods, and/or proprietary technologies. While these
techniques can provide for sufficiently small and power efficient implantable devices, reliability
is low and the ability to reproduce them in a typical laboratory setting is often prohibitively
difficult and expensive. Additionally, the application-specific nature of such devices introduces
problems when adapting them to alternative applications. This paper documents the design,
fabrication, and deployment of a miniature wireless implantable device for rodent through
clinical models called the Bionode. The Bionode features fully customizable recording and
stimulation channels in a flexible, modifiable, and re-useable package to accommodate a wide
variety of use cases.

The Bionode was developed over the course of four years at the CID at Purdue University. With
the ability to record up to four differential biopotential signals and provide up to 10 mA (limited
by 10 V headroom) of biphasic constant current electric stimulation, its capabilities and
performance exceeds that of currently available implantable devices for rodent models [29, 31,
32, 34]. Each input channel contains multiple gain and filtering stages that can be modified to
accommodate a variety of input signal types. Bi- directional communication between the implant
and external systems allows for the real-time specification of stimulation wave-forms, providing
a platform for closed-loop recording and stimulation studies. Furthermore, all components used
to construct the Bionode are available as commercial off-the-shelf (COTS) components with the
intent that any and all aspects of the Bionode’s design can be readily reproduced and used by a
typical university laboratory or small medical device company.
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Over the past four years, the Bionode has been used by researchers at Purdue University to study
epilepsy, Parkinson’s disease, glaucoma, urinary incontinence, and vagus nerve stimulation for
modulation of the inflammatory reflex and gastroparesis. Throughout the course of these studies,
76 Bionode implants have been successfully performed. The methods used to encapsulate the
Bionode for implantation have been refined to increase its ease of use and re-use.

2.2.1

Implant system overview

The Bionode implant consists of three printed circuit board assemblies (PCBAs): The Bionode
mainboard, the Powernode, and the Feedthrough board. The Bionode mainboard contains all
circuitry for the recording and stimulating channels as well as a microcontroller, radio, and
antenna for data transmission and reception. The Powernode provides power rails to the Bionode
mainboard. Electrodes are connected to the Bionode mainboard via the Feedthrough board. Fully
assembled and fully packaged Bionodes are pictured in Figure 2.1.

Figure 2.1 Bionode implant assembly (left) and Bionode inside glass packaging (right).
The Bionode is supported by various external systems as seen in Figure 2.2. A Wireless
Powering Transfer (WPT) chamber provides both power to the Bionode and a living space for
the implanted rodent (WPT details are not covered in this thesis). All data wirelessly transmitted
to and from the Bionode passes through an external Base Station that provides a communication
interface between the Bionode and a PC via a Wi-Fi link. A custom-designed cross-platform
application provides a graphical user interface allowing users to view and save data transmitted
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by the Bionode as well as specify various settings (i.e. stimulation waveform parameters) on the
Bionode.

Figure 2.2 Bionode settings are updated and acquired data is displayed via a custom designed
cross-platform application. Bi-directional communication is facilitated via the Base Station
which also provides the wireless power source that drives the WPT chamber. The WPT chamber
houses the implanted rodent and carries the circulating magnetic field that powers the device.
2.2.2

Stimulation

Many open loop implantable systems have been designed to either record biological signals [35]
or to produce a physiological response by means of electrical, mechanical, or optical excitations
[36, 37]. For a closed-loop study, however, both capabilities are required. Therefore, the Bionode
is designed with a flexible single electrical stimulation channel to supplement its recording
capabilities. Alternatively, the stimulation channel is able to drive an LED for optogenetic
stimulation if desired [38].

2.2.2.1 Stimulation circuit design considerations
When designing an electrical stimulator, the specific type of stimulation that is needed must be
considered. Constant voltage stimulation between a reference and counter electrode is relatively
easy to implement but suffers from the drawback of variable charge injection due to the
capacitive nature of the electrode/body interface, leading to variable and therefore unreliable
stimulation efficacy. Constant current (galvanostatic) stimulation is more difficult to implement,
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but has the advantage of attaining a consistent and knowable charge injection throughout a
stimulation pulse [39]. We implement a constant current stimulator on the Bionode using a
Howland current source to ensure stimulation consistency and efficacy.

Another consideration in electrical stimulation is the flexibility of the stimulation waveform
generated. Stimulation parameters such as amplitude, pulse width, frequency, and charge
balancing are adjusted to meet the safety and efficacy needs of a given study. For example, while
using a monophasic pulse train stimulus will likely result in an increased amount of action
potential responses in nerves, this stimulus waveform will also likely cause tissue damage and
electrode erosion over time. This might be sufficient for short-term acute studies, but for longterm chronic experiments, a charge-balanced biphasic pulse train is more appropriate to prevent
future tissue and electrode damage in the subject. The tradeoffs of efficacy and safety in
stimulation protocols are studied at length in the literature [40]. The Bionode allows the
stimulation amplitude, pulse width, and frequency to be defined by an outside user in real time
using its bidirectional communication capabilities. For the long-term safety reasons mentioned
previously these parameter choices force the stimulation to be biphasic and charge balanced,
although a simple firmware change will allow for non-balanced and/or monophasic stimulation if
needed or desired.

A final important consideration in electrical stimulation is the accuracy and precision of the
output of the stimulation circuit. Safe stimulation requires an accurate delivery of the desired
stimulation waveforms. Unbalanced pulses, inconsistent pulse delivery times, and direct current
(DC) offsets on the stimulation waveform can cause unintended damage to the nerve and
compromise electrode integrity. The Bionode is measured to have an acceptable charge balance
(<0.5% error), and has the added safety of a stimulation glitch switch built in to prevent
unintended charge release during device startup.

2.2.2.2 Stimulation circuit design
We construct the constant current stimulation waveform using a current source (LT6375) driven
by a DAC7551 digital to analog converter (DAC) as seen in Figure 2.3.
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Figure 2.3 Constant current stimulation is generated via an LT6375 Howland current source. The
output of the Howland current source is set by the microcontroller on the Bionode via a 12-bit
digital to analog converter (DAC7551). A normally grounded control switch is used to ensure
that unwanted stimulation does not occur during the Bionode power-on sequence. To ensure true
bi-phasic stimulation, the positive stimulation electrode swings around the negative stimulation
electrode which is directly tied to the Bionode’s ground.
The LT6375 improved Howland current source (HCS) converts a control voltage provided by the
DAC into a current waveform to achieve constant current stimulation [41]. We prefer the HCS
topology over other topologies like current mirroring or electrode polarity switching (where the
positive and negative electrodes are physically switched) because the HCS can generate reliable
symmetric bipolar current pulses. It is difficult to achieve symmetric pulses using current
mirroring topologies due to part tolerances, and electrode polarity switching can sometimes
create asymmetric responses in stimulated nerves due to the physical change in anodic and
cathodic electrode placement.
In the LT6375, the output current  is related to the control voltage CTRL by the equation (2.1):


 

(2.1)

Here, 0 is a current limiting resistor which we choose while populating the Bionode PCB such
that the specified stimulation current amplitude and precision are met. For example: let’s say the
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Bionode is designed to provide a maximum stimulation current of 1 mA through a 10 kΩ
electrode impedance. Because the output voltage range for the DAC which provides CTRL is
-0.9V to 0.9V,

S

is set to 800 Ω; allowing the HCS to provide current outputs ranging from

-1.125 mA to 1.125 mA. To drive this current across a 10 kΩ electrode impedance, the HCS is
powered by a ± 10.5 V supply allowing a maximum voltage of 10.5 V to appear at the output
terminal.

Stimulation waveforms are created by the 12-bit DAC7551 DAC which is controlled by the
Bionode’s onboard NRF51822 microcontroller via a serial peripheral interface (SPI). These
stimulation waveforms are biphasic rectangular pulses defined by the user in terms of amplitude,
pulse width (TPW), and pulse repeat time (TPRT) (See Figure 2.4).

Figure 2.4 The biphasic stimulation waveform is defined in real time by the user via the
Bionode’s bi-directional communication interface. The aspects of the stimulation waveform that
are settable by the user are its amplitude, pulse width (TPW), and pulse repeat time (TPRT).
The user defines these parameters using the Bionode Dataview application which subsequently
instructs the Bionode to set interrupt registers in its onboard NRF51822 microcontroller. These
interrupt registers define the stimulation waveform by specifying when DAC output voltage
updates must occur. To further increase the accuracy of the DAC output, calibration registers
may also be defined by the user and used by the NRF51822 to automatically compensate for any
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static DC offset voltages that may be present on the output of the DAC. The range of these DC
offset voltages is documented in the DAC7551 datasheet, and calibration values to compensate
for these offsets can be obtained experimentally during the fabrication of each Bionode.

A single-pull double-throw (SPDT) switch between the DAC output and the HCS input avoids a
documented start-up glitch on the output of the DAC that appears when the DAC is first powered
on. If not avoided, this glitch will cause the stimulator circuit to output an unwanted stimulus
pulse every time the Bionode is powered on. This switch is controlled by the onboard NRF51822
microcontroller and has a pull-down resistor attached to the control line which ensures that the
switch is in position 0 even when the microcontroller is powering on and not yet driving its
control voltage level. When at position 0, the switch connects the CTRL line of the HCS to
ground, causing the stimulator to not output any current. When at position 1, the switch connects
the output of the DAC to CTRL, allowing the DAC to control the current output of the stimulator
circuit. For safety reasons, the switch is only set to position 1 when the user has specified that
stimulation should occur. Error! Reference source not found. shows a list of key performance
specifications for the stimulator.

Table 2.1. Performance characteristics of the Bionode stimulator.
Value

Units

10.5

V

0.005 - 1.050

mA

Current amplitude resolution

4.4

μA

Pulse width (TPW)

50 - 8.36e6

μs

Pulse width resolution

1

μs

Pulse rate

1e-5 - 20

kHz

Charge balance error2

<0.5

%

Voltage headroom
Current amplitude

1

1

Over a 10 kΩ load
PW = 100 μs, amplitude = 1 mA

2
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2.2.2.3 In-vivo results
The Bionode’s ability to concurrently stimulate and record from the nervous system, canceling
stimulus artifacts in either software or hardware, is demonstrated by using a pair of cuff
electrodes to stimulate the vagus nerve of a rat and record the resulting compound nerve action
potentials (See Figure 2.5). Observed nerve fiber activations can be categorized by fiber type
(e.g. A, B, and C fibers) by using the distance between the stimulating and recording cuff
electrodes to calculate propagation velocities. The recorded activation of various nerve fibers
within a larger nerve indicates successful stimulation of the whole nerve, and allows selective
stimulation of specific fiber types within the nerve using our prior work implemented in this
device [42].

Figure 2.5 In-vivo vagus nerve stimulation using a 1 mA bi-phasic current pulse with a 1 ms
pulse width and a 25 ms pulse repeat time. The stimulation waveform was delivered to the vagus
nerve of a rat using a cuff electrode. (a) Voltage on the vagus nerve is recorded during
stimulation by a recording cuff electrode located 6.2 mm away from the stimulation cuff
electrode. (b) Compound nerve action potentials can be observed by averaging the vagus nerve
recordings in (a) over multiple stimulation pulses. The annotated nerve fiber activations are
consistent with known nerve fiber action potential propagation velocities.

2.2.2.4 Recent stimulation circuit improvements
The previous subsections covered in detail the implementation of the Bionode version 4.1 that
was used in experiments up until this year. I have since spent a great deal of effort to resolve
persisting issues that were found with that simulator implementation for the recently fabricated
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Bionode version 5.0. These issues prevented a robust use of the Bionode 4.1 for some
stimulation applications and prevented critical components needed for transition to a clinical use,
such as a DC blocking capacitor to be used. New improvements implemented by myself, with
the help of Dan Pederson and Grant Wang, to alleviate these issues have added various new
components to the stimulation circuitry, as are illustrated in Figure 2.6. Each problem is
described in detail below, along with the implemented solution.

Figure 2.6 Block diagram of the new stimulator circuitry for Bionode 5.0 [43].

2.2.2.4.1 Stimulation channel DC offset
The first issue addressed with the stimulation circuitry of the Bionode 4.1 was that of a DC offset
occurring in the stimulation channel when the stimulator was turned on. The cause of this DC
offset related back to the singular DAC that was used to create the voltage reference for the HCS
that produced the stimulation signals. When not turned on, the reference for the HCS was the
circuit’s ground, but when stimulation was initiated the reference changed to that of the DAC’s
virtual ground reference. The digital nature of a DAC meant that there was not a dedicated
“ground” reference for the DAC to create stimulation pulses around. Therefore, we set a digital
value of ‘2048’, which is the middle value to our DAC’s precision of 0 – 4096 digital steps, to be
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the “ground” reference during stimulations. Due to inherent limits of digital precision and part
variances, however, this artificial ground did not match the exact ground of the HCS and
stimulation circuity. Therefore, it created varying amounts of DC offset in the stimulation
channel, as shown in Figure 2.7.

Power On

Figure 2.7 Stimulator output showing a shift in the DC level when stimulation is turned on [43].
These DC offsets could be minimized by calibrating the DC midpoint utilized by the Bionode on
our Dataview software. However, this required testing by the user with an oscilloscope before
use of the device. In addition, the DC offset often shifted when aspects of the experimental setup
were changed, such as the load or stimulation parameters. Therefore, the user needed to test and
verify the stimulation each time the stimulator was used to ensure a minimized DC offset.

To mitigate this issue, I added a voltage comparator on the DAC output to compare its output to
the actual ground reference of the HCS circuitry. This comparator communicated directly with
the microcontroller to adjust the DAC’s digital ground level to fluctuate around that of the HCS
ground. This caused a constantly fluctuating DAC reference level that better approximated the
actual ground reference and could automatically adjust to new experimental setups without
requiring user involvement.
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We made a final firmware adjustment to account for the hysteresis levels of the voltage
comparator we used. The DAC reference level was constantly fluctuating to levels between the
upper and lower hysteresis limits. We saw that when the stimulator was turned on that the
stimulation was centered around whichever point the DAC was currently referenced at, which
could be multiple digital levels above or below the optimal “ground.” To alleviate this, we
programmed the Bionode to average the peaks of the reference fluctuation and use that value
instead when the stimulator was started. This effectively gave us an optimal, though still not
exact, digital approximation of the actual ground reference as can be seen in Figure 2.8.

Figure 2.8 Oscilloscope image of DAC stimulation outputs (which appear as solid green
sections) with and without hysteresis averaging.

2.2.2.4.2 Charge build-up on DC blocking capacitor
When transitioning a stimulation circuit to be used in animal studies or to clinical human trials, it
is extremely important to prevent any unintended electrical currents from reaching the subject.
Such stray currents can attenuate the physiology of the tissue you are trying to stimulate or even
damage it. To prevent stray DC charges from reaching the tissue, it is advantageous to utilize a
blocking capacitor in series with the stimulator load to absorb any DC currents that may be
present.
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In the Bionode 4.1, there were multiple sources that caused stray DC currents to pass through to
the stimulation line. The primary source was the previously described DC offset in the DAC
reference signals. While our voltage comparator feedback minimized this effect, there were still
small amounts of offset that would allow DC current to pass through during stimulation. In
addition, the HCS circuity allowed small amounts of stray current into the line even when the
stimulator was turned off. We could prevent these currents from reaching the load by inserting a
DC blocking capacitor into the stimulation circuit, but that capacitor would continually charge
until saturated. Once saturated, the capacitor would cause stimulation pulses to become charge
saturated and imbalanced, as can be seen in Figure 2.9. The result was that a DC blocking
capacitor could not effectively be used with the Bionode 4.1.

Figure 2.9 Stimulator output showing the effects of charge saturation of a DC blocking capacitor
in series with the stimulation line [43].

To alleviate this issue, we placed a normally closed and digitally controlled switch in the
stimulation output line parallel to the blocking capacitor and load. We programmed the switch to
open only at times when the stimulator was sending out a pulse. This effectively routed any stray
currents straight to the ground when stimulation was not occurring, both when the stimulation
was deactivated and between stimulation pulses when stimulation was activated. Additionally,
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any charge that would be built up on the capacitor during actual stimulation pulses was
discharged through this same route once the pulse was finished.

I must note that the capacitor discharge switch required a larger voltage to control than that of
the microcontroller output. We therefore added level shifters to the circuit to increase our switch
control signal from 1.8 V to 2.7 V, which was an already available power rail in our Bionode
circuit.

2.2.2.4.3 Transmission noise on stimulation channel
A third issue noted during testing and use of Bionode 4.1 was that of noise spikes appearing on
the stimulation channel. These spikes were traced back to transmission signals from the
microcontroller. Due to high levels of power needed for the microcontroller to transmit a data
packet, each time it transmitted, the power rails connected to the microcontroller would
experience an instantaneous fluctuation in the form of a power spike. Since the stimulator’s DAC
shared these power lines, specifically the low power rail (-0.9 V), these power spikes were
induced onto the DAC output and, subsequently, the HCS output as well. These spikes were
present at all times in various capacities, but when high impedance routes were introduced to the
power rails (such as with loose solder connections), the spikes increased greatly and interfered
with intended stimulation protocols. The issue was accentuated because these power spikes were
present even when the stimulator was not enabled. This effect can be seen in Figure 2.10.

Figure 2.10 Oscilloscope images of waveforms with severe transmission noise spikes during
stimulation (left) and while stimulation is off (right).
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This issue was mitigated in two ways. First, the previously added DC blocking capacitor
discharge switch forced any power spikes to be grounded whenever the switch was closed.
Thereby, the spikes were only present during actual stimulation pulses. Second, the remaining
pluses have been minimized by adjustments we have made in the power rails. We have changed
the DAC powering scheme from using -0.9 V to 0.9 V rails, to using 0 V (ground) to 1.8 V rails.
This shift has allowed the low reference of the DAC (the one most vulnerable to transmission
power spikes) to be on a more robust ground plane. In addition, we isolated all microcontroller
rails from those used in the recording and stimulating circuit.

While transmission spikes are still present in a very minimal amplitude on the Bionode 5.0, they
are no longer seen at significant levels on the stimulation channel.

2.2.2.4.4 Turn-on glitches
The final issue address in the stimulator circuit for Bionode 5.0 was that of turn-on glitches.
During initial power-up of the Bionode circuitry, we noted very large surges of charge delivered
to the load of the stimulation output, as can be seen in Figure 2.11. This glitch was present
despite the grounded control switch illustrated in Figure 2.3 and the normally closed DC
blocking capacitor discharge switch.

We traced the problem back to the power-up sequences of various component and the HCS
circuit itself. The DC blocking capacitor discharge switch required sufficient voltage to properly
“close” the switch. When not sufficiently powered, the switch would show a significant nominal
resistance in the channel. Therefore, upon device turn-on, stray currents in the HCS rails allowed
a quick and significant build-up of charge onto the stimulator’s DC blocking capacitor before the
discharge switch was able to activate and ground the connection.
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Figure 2.11 Stimulator output showing a large surge of current applied to the stimulation channel
when the Bionode circuit is turned on [43].

We mitigated this issue by adding normally open and digitally controlled switches to the power
rails of the HCS. Unlike the normally closed switches, the normally open switches did not
require power to act as open circuits. Therefore, we effectively created a separate power control
for the HCS that prevented it from diverting stray current during powering sequences to the
stimulation channel. The HCS can instead remain powered down until needed. This serves as a
solution to the turn-on glitch and provides a small overall power savings to the Bionode 5.0
device.

2.2.2.4.5 Stimulation circuit improvement results
Due to the multiple changes made to the stimulation circuit for the Bionode 5.0, the stimulator
has become much more robust. As can be seen in Figure 2.12, all issues are no longer present,
and a DC blocking capacitor can now be effectively used.
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(a)

(b)

(c)

(d)

Figure 2.12 Stimulator performance comparison between Bionode 4.1 and Bionode 5.0: (a,c)
results of stimulation with DC blocking cap, (b,d) Turn-on glitch test results [43].

2.2.2.5 Impedance measurement
In addition to making the multiple improvements to the stimulation circuit itself as previously
described, I also created a relative impedance measurement system to the stimulation output. I
worked Jay Shah to build and test the circuit and it has now been integrated into the Bionode.
This circuit consisted of separate current and voltage sensing circuits that utilized simple
operational amplifiers to accurately measure the instantaneous current flowing through the
stimulation output channels, as well as measure the instantaneous voltage being applied to the
stimulation load. A diagram of the circuit can be seen in Figure 2.13.

While this circuit does not provide a true potentiostatic impedance measurement that you would
get with a commercial system such as made by Gamry, it does give the user an instantaneous and
accurate estimate of the actual electrical waveforms that are passing through the load. Using the
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voltage and current measures, the user can easily estimate the resistance of the load by using
Ohm’s law. This provides the user a quick verification of correct operation of the device, as well
as, how the load may change throughout the use of the device.

Figure 2.13 Schematic of relative impedance measurement system added to Bionode 5.0. Circuit
consists of two operational amplifiers and nine resistors configured to accurately measure the
current and voltage being applied to the stimulation load.

Resistors values were determined by initial testing. A 500 Ω sense resistor was used to give an
increased accuracy on the current measurement. A smaller resistor could be substituted to
improve power consumption at the risk of losing some accuracy. Similarly, the voltage dividing
resistors of the current and voltage sense circuits were chosen at the mega-ohm or near megaohm levels to reduce the power consumption of the circuit. Lower values can be used but will
result in less stimulation charge being delivered to the load, which would then reduce the
accuracy of the intended stimulation command to the Bionode and require the software to be recalibrated. Alternately, the resistors could be increased further in value, but this will result in
more noise in the signal received by the user.
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The outputs of the current and voltage sense circuits were connected directly to input pins of the
integrated Bionode 5.0 microcontroller and can be seen in real-time using the Dataview software
GUI. Sample outputs from a stimulation pulse over a 5 kΩ load in Dataview can be seen in
Figure 2.14. It should be noted that the voltage spike is inverted from the current spike. This is
simply a factor of the circuit’s amplifier orientation and could be corrected with a simple
firmware change if desired. The amplitudes of the recorded spikes however give a good estimate
of the actual resistive load.

Figure 2.14 Bionode Dataview output of our current and voltage sensing circuits. The Bionode
was directed to apply a 300 μA stimulation pulse with a duration of 360 μs across a 5 kΩ
resistive load.

I have successfully estimated resistive loads in the range of 500 Ω to 40 kΩ to within 7%
accuracy, or better, using stimulation pulses ranging from 200 μA to 1 mA using this circuit.

2.2.3

Manufacturing/Packaging

Successfully fabricating and packaging a device for chronic implantable applications depends
greatly on miniaturized form factors and robust device encapsulation. All physical aspects of
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the Bionode implant are designed with the goal of creating an adaptable, inexpensive, robust, and
fully implantable device with a form factor allowing for long-term chronic implantation in
rodents or minimally invasive implantation in humans. These design considerations were further
constrained by the desire to use only COTS components as well as a need to maximize
manufacturing yield. The components of the Bionode that most define its form factor and
manufacturability are its printed circuit board assemblies (PCBAs), electrodes, wireless
powering coils, and packaging used to encapsulate the implant.

2.2.3.1 PCBA considerations
The Bionode implant contains two PCBAs: The Bionode motherboard, and the Powernode. The
motherboard contains the analog front end (AFE), stimulator, microcontroller, radio, and
antenna. The Powernode contains all circuitry necessary to provide power rails to the Bionode
mainboard and wirelessly recharge battery if used. Because these two boards were developed in
a modular fashion, each board could be designed, optimized, fabricated, and tested
independently. The ability to fabricate and test the two Bionode PCBAs separately made
manufacturing defects easier to find and repair, which increased device manufacturing yield.
This approach also allowed a modular design where different Powernodes (e.g. with and without
rechargeable batteries) could be used in different applications.

Both PCBAs were optimized for size by selecting small component packages and laying out all
pads and traces on the PCB using a minimum spacing and width of 0.127 mm wherever possible.
The Bionode mainboard is a 6-layer board, while the Powernode is a 2-layer board. Both PCBs
were fabricated by Advanced Circuits and hand populated by researchers and technicians at the
CID at Purdue University.

2.2.3.2 Electrode considerations
A variety of electrodes and leads can be successfully used with the Bionode for both recording
and stimulating including nerve cuffs, helical leads, pressure sensors, thermocouples, deep brain
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electrodes, and bone screws. All of these electrodes connect to the Bionode by means of lowimpedance commercial pins. This interface allows virtually any electrode to be terminated with a
0.46 mm – 0.51 mm diameter mating pin and connected to the Bionode.

2.2.3.3 Coil considerations
Wireless powering coils were hand-wound by the authors at the CID using 22-gauge wire. The
front-coil has a 7 mm inner diameter and the top-coil has a 5 mm inner diameter. These
dimensions were constrained so that the coils could fit inside the cylindrical package described
next.

2.2.3.4 Packaging considerations
To chronically implant the Bionode in a rodent model for any length of time, it must be
encapsulated in a package that insulates it from tissue. Many materials including polymers,
metals, ceramics, and glasses have been used in recent years for hermetic and non-hermetic
implantable device packaging [44-47]. While metal packages with glass or ceramic feedthroughs
have become popular for long term medical implants, the sealing processes often require
highly controlled environments and expensive precision equipment (i.e. infrared lasers to melt
glass or laser-beam welders to fusion weld metals). Metal packaging also may require powering
coils and communication antennas to be placed outside of the metal packaging to avoid power
and communication losses; further complicating the packaging process [44].

With these considerations in mind, the inexpensive and flexible option of using medical grade
epoxy to encapsulate the Bionode was chosen, which has been successfully verified as a
legitimate option in other research [45, 48]. Fully encapsulating the Bionode in medical grade
(Hysol Loctite M-31CL) epoxy was achieved using a multi-step process illustrated in Figure
2.15. Prior to encapsulation, a custom designed 3D printed case is created to shield the Bionode
electronics from the epoxy. All electrode connections are made via a feedthrough board which
electrically connects the electrode pin receptacles to the Bionode AFE inputs or stimulator
outputs. While this feedthrough board provides an easy way to attach various electrodes to the
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Bionode, its main function is to prevent leakage into the implant body via a faulty lead. Lead
breakages are often a cause for implant device failure [49]. The feedthrough board isolates the
leads from the inside of the implant case, which ensures that broken leads do not provide a path
for fluid to enter the implant.

Figure 2.15 This figure illustrates the packaging process of the Bionode via a cross-sectional
view. (A) A feedthrough cap containing receptacles for electrodes as well as a connector for the
Bionode Mainboard is constructed. (B) The fully assembled Bionode and Powernode are
connected to the feedthrough cap, and a 3D printed case is glued directly to the feedthrough
cap. (C) A plug is connected to the outside of the feedthrough cap to insulate the electrode
receptacles from epoxy, which is used to create a well above the feedthrough cap. (D) A second
coating of epoxy is applied around the entire 3D printed case and then the plug is removed. (E)
Electrodes are connected to the electrode receptacles, and the well above the feedthrough cap is
insulated with a layer of silicone. Once the silicone is cured, the entire implant is coated once
again in epoxy which fully encapsulates the implant.

The encapsulated Bionode package is 3.5 cm long with a diameter of 1.5 cm and weighs 9
grams, which is comparable to other non-application specific integrated circuit (ASIC) systems
[50, 51]. This packaging method has demonstrated excellent reliability for short to medium term
chronic animal testing. To date, using this packaging method, 76 Bionodes have been
successfully implanted for chronic studies lasting up to 71 days. No packaging failures have been
observed during the course of these studies.
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This packaging approach optimizes for customization and flexibility in the design and test cycle
of the implantable device. Changes in the board shape, size, and architecture can be
accommodated by quick changes to device casing and feedthrough board layout, providing fast
turn-around and implementation. In addition, the interconnects utilized by the feedthrough board
can be modified to meet the ever evolving attributes of future devices [52] such as capacitive
feed-through systems [53, 54]. Unlike other hermetic sealing examples [29, 46, 55] have used
alternative materials and methods, the materials and tools used in this method are relatively
inexpensive and easy to obtain and adopt.

In a recent study involving the long-term chronic implantation of the Bionode in rats, the 3D
printed case was replaced with a glass cylinder. This reduced the amount of medical grade epoxy
needed to seal the device because the glass case does not need to be fully encapsulated in epoxy.
One of these devices is pictured in Figure 2.1.

Explanted Bionodes can be recycled using various methods depending on the type of
adjustments needed between implantations. For devices that do not require any adjustments to
the Bionode hardware, the top layer of epoxy surrounding the feedthrough well can be removed
using a band-saw or rotary tool. Once the epoxy is removed, the silicon and leads can be
removed by hand, as in Figure 2.16. New leads can then be inserted, the well can be refilled with
silicon, and the device can be re-encapsulated in epoxy. For devices needing adjustments to the
Bionode hardware (i.e. devices needing different AFE passband values), the casing can be cut
below the feedthrough board, and the device can be removed, adjusted, and mounted to a new
feedthrough board for repackaging. To date, fifteen Bionodes have been successfully recycled
using this process, with some being successfully recycled multiple times.
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Figure 2.16 Explanted and dissasembled Bionode device. Top (left) has been removed with
silicon and pins in place. Bottom (right) contains working device and can be repopulated with
new electrodes, re-sealed, and re-implanted.
In addition to durability during implantation, I tested tether-powered versions of the Bionode
device packaged in medical grade epoxy for its ability to be sterilized using an autoclave (see
Figure 2.17). While it is unlikely that this technique could be used to prepare our new battery
powered devices, the non-battery powered implementation tests withstood ten separate cycles of
standard autoclave sterilization and still operated with no decreased ability.

2.2.4

Comparable Devices

As referenced earlier, there have been many stimulation and recording devices developed in
recent years for various applications. While many of them are well suited for the specific
applications that they were designed for, most do not share the capabilities of the Bionode to
serve diverse uses in animals studies.

We compared published literature on eight such devices [29-34, 56, 57] (presented in Appendix
A) and found that none of the reviewed devices could match the Bionode for inexpensive,
flexible, adaptable, configurable, implantable, recording and stimulating capabilities.
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Only three of the other reviewed devices provided both recording (only one provided more than
two recording channels) and stimulation capabilities and only one provided an impedance
measurement option. Those with better stimulation capability were only deemed so due to
having more than one stimulation channel available.

Virtually all reviewed devices had passive or pre-programmed controls versus the active
recording and stimulation control of the Bionode system. In addition, none of them offered both
battery and inductive powering options like the Bionode does. Those that were smaller in size
were so because they used ASIC electronics, making them less easily manufactured and
configured in a small laboratory setting at a low cost. Finally, not all the devices reviewed were
shown to be fully implantable or tested in-vivo on small animals as we require.

Nerve Cuffs
Possibly of equal importance to the stimulation circuitry are the electrodes used to deliver the
electrical charge to the intended load. There have been countless research efforts dedicated to the
design and development of stimulation electrodes [58-60]. For stimulation of peripheral nerves,
the most common electrode types are cuffs, flat interfaces, and intrafascicular electrodes.

In our studies, we have concentrated on the development and use of cuff electrodes. Cuff
electrodes are essentially a layer of flexible and biocompatible material that forms a “cuff” that
can be wrapped around the circumference of the intended nerve to be stimulated. Within that cuff
is one or more electrodes made of a conductive and biocompatible material. The electrode may
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Figure 2.17 Bionode devices after sterilization cycles in an autoclave. Device on the left
remained fully functional after ten standard cycles (20 psi, 250˚ F, 20 minutes). Device on the
right remained fully functional after one increased intensity cycle (30 psi, 270˚ F, 20 minutes).

be in the form of a wire, flat foil, or deposited thin film. Common conducting materials used for
stimulation and recording electrodes are platinum and platinum iridium, iridium oxide, tantalum,
titanium nitride, and PEDOT [59, 60]. In addition, the electrodes need a conductive lead that can
reach and connect to the stimulator device. These leads must be insulated, flexible, and can either
be welded to the cuff electrodes, or an extension of the electrode if made of wire. Literature on
aspects of cuff and other electrodes is extensive [59, 60].

In addition to mechanical and biocompatibility factors, electrical factors of the cuff electrodes
must be taken into consideration when designing them for experimental use. The most
commonly tested performance factors for stimulation electrode characterization are that of
electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV). These factors are
explained in detail by Stuart Cogan [59]. EIS is basically a measure of the electrical impedance
made over a broad frequency range of stimulation. Though even more important for recording
electrodes, it is also an important measure for stimulation electrodes as it helps to determine how
much charge must be applied by the stimulator to produce an intended stimulation charge to the
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load. A preliminary EIS measurement can be made in phosphate buffered saline (PBS) and the
standard characterization is done for the impedance measured at 1 kHz frequency. An in-vivo
measurement can also be done to determine the resistive contributions of the tissue the electrode
is attempting to stimulate. The CV measurement produces what amounts to a measure of chargeinjection capacity for neural stimulation. In essence, CV sweeps the potential of an electrode
within the water electrolysis window. The standard characterization measure is made by
calculating the area under the negative curve of the sweep that represents the cathodal charge
storage capacity (CSCC). This total value can be divided by the effective exposed surface area of
the electrode to give the CSCC per unit area of the electrode material.

2.3.1

Types of cuffs and electrodes tested

During the process of developing an implantable Bionode device for animal studies and
performing Defense Advanced Research Projects Agency (DARPA) testing for Aim 3 of this
study, I tested multiple variations of cuff electrodes made both in our lab and by outside industry
manufacturers and university labs. Many of those tested are pictured in Figure 2.18 and their EIS
and CV data can be seen in Table 2.2. I tested the following cuffs:


CorTec tunnel cuff with Platinum Iridium (PtIr) foil electrodes imbedded in silicon. Cuff
was 3 mm in length with a 0.6 mm inner diameter.



Shape memory polymer cuff fabricated by University of Texas – Dallas (UTD) as
presented in Figure 2g of Ware et al [61]. Shape memory makes the effective cuff
diameter variable depending on implementation factors.



Army Research Labs (ARL) conductive carbon nanofiber polymer “cuff.” The material
was obtained from ARL and was presented by Slipher et al [62]. An actual cuff was not
made, but a reasonable sized section of the material was formed to be tested for electrochemical properties. Both 4% and 7% carbon nanofiber makeups were tested.



Our own experimental thin film cuff electrodes were developed and tested in the CID
here at Purdue. The electrodes were created by Quan Yuan in our cleanroom by
depositing either gold or platinum electrode material onto 12 μm think parylene substrate
cuff material. These cuff electrodes were designed to be wrapped around the nerve to
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create ~1.5 mm diameter cuffs with a separate 11 mm tab to wrap around the nerve and
anchor to the carotid artery (for cervical implantation). A zip design originally presented
by Yu et al [63] was utilized to keep the cuff wrapped during implant, and quick curing
medical silicone material was used to seal the cuff in place.


Microprobe platinum wire cuff electrodes that were utilized for the acute Magnetic
Resonance Imaging (MRI) stimulation testing shown in Aim 3. These cuffs are very
similar in shape and form (~0.5 mm inner diameter) to our own CID wire cuffs but utilize
a single solid strand of 100 μm wire and have embedded suture materials to for closing
the cuff.



CID wire cuff electrodes. We tested multiple different variations of wire cuff electrodes
as are presented sections 2.3.2, 2.3.3, and 4.4.4.1.

Figure 2.18 Cuff electrode variants tested and used in this study. a) CorTec tunnel cuff with PtIr
foil electrode. b) UTD shape memory polymer cuff with thin film electrode. c) CID custom
zipping parylene cuff with thin film electrode. d) Microprobe silicon cuff with Pt wire electrode
and copper leads for use in MRI.
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Table 2.2. Electrochemical characterizations of cervical vagus nerve cuffs variants tested for use
in our studies. Averaged values of tested cuffs are presented.
Cuff
Variant

CorTec
UTD ThinFilm
ARL 4%
ARL 7%
CID ThinFilm

MRI
CID Wire

Electrode
Material and
Form
Platinum Foil on
silicone cuff
Gold layer on
shape memory
polymer
Conductive carbon
nanotube polymer
cuff

Gold layer on
Parylene
Platinum Film on
Parylene
Platinum wire in
silicone cuff
Platinum Iridium
wire (1x7 strand)
in silicone cuff

Measured
CSCC Total
(μC)

Exposed
Surface Area
(mm2)

CSCC Per
Area
(μC/mm2)

Impedance at
1 kHz (Ω)

9.05

0.3

30.18

3.66 k

0.97

0.7

1.39

1.21 k

26.2

36

0.72

2.32 k

7.69

36

0.21

1.15 k

9.58

1.48

6.47

476

15.46

1.13

13.65

1.77 k

5.35

0.49

10.87

2.11 k

9.33

0.5

18.62

1.52 k

Despite the multiple options available and tested, we primarily used, and continue to use, our
CID wire cuff electrodes. As can be seen above, they show comparable or superior electrochemical properties to the other available options we have tested. Their EIS impedance of 1.52
kΩ is better than other wire or foil options tested. The CID wire cuffs also have superior CSCC to
all but the CorTec electrodes, but the CorTec variant are also smaller and less suited for multiple
applications. In addition, the CID cuff electrodes can be made in-lab with no special equipment
requirements. This saves a lot of lab resources as custom industry electrodes are expensive and
follows the theme of the making the Bionode highly adaptable to many research needs.

2.3.2

Wire considerations

With respect to our in-house wire cuff electrodes, there have been multiple variations made in
the past 5 years. One of the many consideration in these electrodes are the type of wire used to
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form the electrodes themselves. We have had the luxury of a good working relationship with Fort
Wayne Metals of Fort Wayne, IN. They have supplied us with various samples to try and a
reliable supply of the actual 1x7 braided wire that we now most commonly use. When running
low on supplies, I worked with Fort Wayne Metals to acquire multiple wire samples, and tested
each for electro-chemical properties, as well and mechanical properties to determine the best
option for our cuffs going forward. Relative size comparisons can be seen in Figure 2.19 and
electrochemical test results can be found in Table 2.3. I tested the following wire variants (all
made from Platinum (90%) Iridium (10%)) in our cuffs:


1x1 solid strand wire showed sufficient size and EIS and CV characteristics to be used as
a stimulation electrode. It was also very flexible, but a bit too pliable to effectively hold a
cuff shape during the rigors of implantation. It often was manipulated and lost the ideal
cuff contours we desired.



1x7 braided wire showed very similar electro-chemical characteristics to the 1x1 solid
strand and proved to be a much better option as it was very flexible and pliable, but also
showed enough “bounce back” when manipulated so that it could keep its cuff contours
during implementation. This is the wire variant we have moved forward with for in-vivo
experiments.



1x19 braided wire was used in some early CID cuff electrodes as we had obtained a
sample spool of it. Successful in-vivo and chronic tests were performed with this variant
on the cervical vagus nerve (data now shown here). It showed superior EIS and CV
measures to the 1x1 and 1x7 variants as would be expected by its larger size, but also
proved to be harder to manipulate and form into cuffs. It would have been difficult to
form this variant into smaller cuffs such as those we used for subdiaphragmatic
stimulations in Aim 2. It was also not commonly made by Fort Wayne Metals and would
have been prohibitively expensive to obtain more of.



7x7 braided wire cable was basically 7 separate 1x7 wires braided together and was very
large for our purposes. A sample was sent and tested and, as expected, showed very good
electrochemical properties. However, it was much too large for any practical nerve cuff
purpose in rodent studies as it could not be bent into the appropriate cuff size even for
cervical uses.
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Figure 2.19 Relative size comparison of cross sections of wire variants tested for use in our cuff
electrodes. a) 1x1 solid strand PtIr wire. b) 1x19 braided PtIr wire bundle. c) 1x7 braided PtIr
wire bundle.
For surface area estimates of wire, we utilized equation (2.2) for the solid single strand as it is the
standard surface area equation of a cylinder minus the ends. Braided wire is more difficult to
estimate the surface area of, but we utilized equation (2.3) supplied to us by Fort Wayne Metals.
Equations contain variables of d as the diameter of a single wire fiber, L is the length of wire
exposure, and N is the number of peripheral strands of wire (if a braided variant).
   
˝

 ˘ˇˆ  ˙˛° ˜

(2.2)

(2.3)
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Table 2.3. Electrochemical characterizations of cervical vagus nerve cuffs made with wire
threaded to cover a length of ~70% of the inner circumference (0.76 mm) of silicone tubing with
a single strand. Averaged values of tested cuffs are presented.
Wire Variant
(Platinum Iridium)

Measured
CSCC Total
(μC)

Exposed
Surface Area
(mm2)

CSCC Per
Area
(μC/mm2)

Impedance at
1 kHz (Ω)

1x1 Wire – Single Strand

8.70

0.49

17.69

1.48 k

1x7 Wire – Single Strand

9.33

0.5

18.62

1.52 k

1x19 Wire – Single Strand

31.42

1.16

27.15

630

177

2.2

51.94

615

7x(1x7) Wire Cable – Single
Strand

2.3.3

Wire threading

During our studies utilizing cuff electrodes, it became known that the basic cuff design we were
utilizing was not sufficient for all applications we wished to use it on. For example, although a
single length of the 1x7 braided wire showed good properties for the majority of applications, we
found certain circumstances in while a greater exposed surface area and consequently, a lower
impedance were necessary.

One such instance was in applications where a higher amplitude of current was required to be
delivered to the biological interface. If the interface itself was of a high impedance such as a
relatively dry surface, then the ability of the Bionode to supply the required charge was limited
due to its voltage supply limits. Since the voltage limits were not easily adjustable in our
Bionode setup, we were required to find a way to lower the impedance of our electrodes.

Another instance of needing lower impedance and higher surface area was when we tried to
stimulate and record from the same nerve in the body of the animal, such as with the
Autonomous Neural Control (ANC) algorithm that is presented in more detail in sections 4.2.6.2
and 5.5. We found that the recordings in these instances were very noisy and that it was greatly
improved when an extra ground connection to the body of the animal was applied. We theorized
that since the ground for the entire system was based on the stimulator’s connection to the body
of the animal, then the exposed ground plane being supplied by the electrode was not sufficient.
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To solve this issue, I developed the strategy of using multiple wire thread lengths in our
electrodes. This was done by threading the wire through the inside and then outside of the cuff
electrode multiple times. Images of the threaded cuffs can be seen in Figure 2.20. We began by
testing and utilizing vertical threading patterns in the cuffs. This was very effective at increasing
the exposed surface area and reducing the cuff impedance, as can be seen in Table 2.4. The
external threading lengths were the most effective as they added the most length of exposed wire,
and we theorized the potential shunting of current to the outside of the cuff to be minimal if the
cuff was small and sealed shut. However, we also developed cuffs with no exposed external
thread lengths by either adjusting the threading pattern or by simply covering the external lengths
with fast curing silicone adhesive.

The downsides to vertical threading was that the lengths of wire were difficult to thread parallel
to each other and tended overlap each other which could potentially cause pinching of the nerve
fibers being cuffed. They also made it difficult to close and seal the cuffs due to multiple wire
strands holding the cuff opening open. Finally, the long lengths tended to be unintentionally
manipulated and damaged at times while trying to surgically attach the cuff.

Due to the issues mentioned, I came up with a strategy to utilize horizontal threading of the wire
in the cuff instead. While horizontal threading is more difficult to perform consistently, it
showed some significant advantages over that of vertical threading as well as showing similar
levels of impedance. Horizontally threaded cuffs were much easier to manipulate during surgery
and less apt to wire breakage. The largest disadvantages to threading horizontally were an
increased effort and time to manufacture as well as incomplete coverage of the wire around the
nerve. However, it can be argued that the overall coverage is better due to the ability to thread
the wire closer to the edges of the cuff opening. In addition, if a slight angle was added to the
threading, an overlap of nerve length could be covered, and, in essence, could create close to a
full coverage of nerve fibers. These advantages were critical when developing larger cuffs for
use in a pig model that will be covered in section 5.2.
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Figure 2.20 Threaded wire cuff variants used in cervical VNS on rats. a,b) Vertical threading of
1x7 PtIr wire into silicone cuffs. c,d) Horizontal threading of 1x7 PtIr wire into silicone cuffs.
Table 2.4. Measured impedance values for threaded 1x7 PtIr wire patterns in silicone tube cuffs.
Averaged values of tested cuffs are presented.
Wire Threading
Pattern
Vertical
Vertical
Vertical
Vertical
Vertical
Vertical
Vertical
Vertical
Vertical
Horizontal

Inside Wire
Lengths
1
2
3
4
5
2
3
4
6
~15-20

Outer Wire
Lengths
0
0
0
0
0
1
2
3
5
~15-20

Impedance at 1 kHz (Ω)
1.55 k
1.00 k
983
896
590
428
277
211
179
206
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Summary/Impact
In summary, Aim 1 accomplished a stated goal of making the Bionode stimulation interface
highly reliable, flexible, adaptable, and affordable. Virtually every aspect of the Bionode can be
manufactured in the laboratory with basic lab equipment and off the shelf parts.

The Bionode stimulator can deliver the desired level and precision of stimulation needed for
small animal experiments, and can be easily adjusted either during fabrication, or in many cases,
during the experiments with the Dataview software interface, to meet specific experimental
needs. Issues discovered in the earlier Bionode 4.1 version have been fixed for our latest
Bionode version 5.0, and a relative impedance measurement system has been added to give even
more insight into experiments.

Manufacturing and package improvement were made that make production of fully implantable
and operational Bionodes possible in both small and large animal subjects. The Bionode has
become modular in design allowing for easier troubleshooting and repair. Packaging now
includes feedthrough caps that stop previously prevalent leakages from occurring, and the use of
pre-formed 3D printed packages sealed with epoxy make a perfect platform for developmental
designs that could be upgraded to more robust packaging materials in the future.

The biological interface has also been improved with development of nerve cuffs that can be
made and adapted for multiple applications, affordably and in-house.
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3. AIM 2: STUDY OF ACUTE SUBDIAPHAGMATIC INFLAMMATORY
RESPONSE

Motivation
One of the primary purposes of our research was to explore the biology behind VNS. We wished
to explore not only physiological effects of cervical VNS, but to find the specific
subdiaphragmatic branches that contribute most to it and to what effect. Our lab therefore set out
to perform acute experiments in which we would stimulate specific subdiaphragmatic nerve
branches. This was originally attempted by Kaitlyn Neihouser and her results were presented in
her 2017 thesis titled “An Exploratory Study of How Acute Neuromodulation of the
Subdiaphragmatic Branches Regulates Inflammation.” While her results were interesting and
gave a good indication that effects of nerve branch stimulation could be analyzed, we determined
that the protocols used were insufficient to obtain a robust analysis.

I therefore set out to improve the methods used and re-do many of the subdiaphragmatic nerve
branch stimulations and perform new subsets that could be better analyzed. I also discovered a
large temporal variation in the time when inflammatory cytokines levels in plasma would rise
that was significantly complicating the data analysis, and I resolved to develop a better
methodology to handle this variation. In conjunction with Kelsey Wasilczuk, I produced the
work that follows in this chapter.

Material in sections 3.1.1 – 3.5 come directly from my paper titled “Characterization of cytokine
response to intraperitoneally administered LPS & subdiaphragmatic branch vagus nerve
stimulation in rat model,” and its supplemental data, co-authored by Kelsey Wasilczuk, to be
submitted to the Journal of Neural Engineering in 2018. Formatting changes and updates have
been made as appropriate.

3.1.1

Acute subdiaphragmatic stimulation study introduction

Central to many inflammation studies is the use of an inflammatory challenge, most commonly
using lipopolysaccharide (LPS) endotoxin, to induce an acute inflammatory response that can
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then be treated by a given drug or therapy. However, the LPS injection method, dosage, and
timing can vary greatly between studies, and the results of said experiments may indeed depend
in part on these variables. LPS administered through intraperitoneal (IP) and intravenous (IV)
injection are generally thought to produce similar inflammatory responses [64-66], but show
some differences likely due to distinct mechanisms in the delivery and creation of cytokines.

Steven et al [67] recently made a strong case for better methods characterization and
standardization by illustrating differences between LPS challenges in mice and rats. In addition,
the dosage of LPS shows different cytokine creation and timing in their responses [68]. We
submit that one important and under-characterized aspect in inflammatory research is that of LPS
administration method. In VNS research related to inflammation, we most commonly find IV
injections used on rat subjects [15, 19, 69, 70], while IP injection methods are reserved for
studies on mice [6, 71], presumably due to the technical difficulty of IV insertion into the smaller
blood vessels. Studies by Lenczowski et al. [72, 73] demonstrated high variability in response to
IP LPS usage in rats, and in discussion with other researches in this area, we found such
variability to be the main motivation to administer LPS IV in this animal model. We assert,
however, that IP administration presents a more physiologically relevant inflammatory
simulation. Whereas IP application represents a foreign infection that must be responded to by
the body in a more systematic way, IV delivery artificially adds LPS to the blood stream.
Therefore, developing methods to better utilize IP LPS injections and a better understanding of
the expected responses will benefit a large community of researchers.

In addition to pursuing a better understanding of the effects of the methods we use in
inflammation research, we must continue working to narrow in on physiological mechanisms
that can be manipulated to treat specific inflammatory responses. Prior work has postulated that
there exists an inflammatory reflex by which the nervous system regulates immune function. By
stimulating the efferent fibers of the vagus nerve, splenic macrophage release could be
controlled, thus regulating cytokine release. In this way, the inflammatory reflex could be
modified to produce an anti-inflammatory response [3]. However, direct innervation of the
spleen by the vagus nerve has been met with uncertainty as early as 1993 [74]. More recent
research has proposed that vagal innervation of the celiac ganglia is the first in a two part relay,
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in which vagal action potentials regulate T cell production, thus controlling the production of the
neurotransmitter acetylcholine [6]. A subsequent study showed that VNS inhibited splenic nerve
activity but produced no response when the nerve was severed cranial to the stimulation site.
This implies that the link between the vagus and spleen is an indirect connection through the
central nervous system (CNS) rather than a direct pathway [70].

We, along with others, suggest that the GI vagal innervation proposed by Berthoud et al. in 1991
[75] modulates the release of acetylcholine synthesizing T-lymphocytes in the blood. By
stimulating the vagus, distal gastrointestinal fibers stimulate lymphoid tissue into releasing cells
such as these acetylcholine-synthesizing T-lymphocytes. When taken up by the spleen, these
lymphocytes cause splenic macrophages to decrease their production of inflammatory cytokines,
leading to the desired therapeutic effect [76].

As the left cervical vagus nerve passes through the diaphragm of the body, it becomes the
anterior vagal trunk and splits into multiple branches [2]. Previous work by multiple groups have
shown left cervical vagus stimulation to attenuate cytokine levels [15, 19, 69, 77], but none have
analyzed the effects of stimulation of specific subdiaphragmatic branches. Berthoud and Powley
have previously postulated that vagal celiac branches contribute the most toward innervation of
the major ganglia that comprise the solar plexus, followed to a lesser extent by the gastric and
hepatic branches [78, 79]. Following this rationale, we hypothesized that stimulation of different
isolated subdiaphragmatic branches would mediate inflammation in unique ways. If true, then
utilization of vagal branch stimulation to regulate circulating cytokines produced by splenic
macrophages could allow selective symptoms of multiple inflammatory diseases to be alleviated,
leading to new potential treatment options.

3.1.2

Experimental objectives

Our study had three primary objectives. 1) To develop methods to effectively analyze the
cytokine cascades caused by an IP administered LPS challenge. We accomplished this by testing
and utilizing a curve-fitting and alignment method on temporal cytokine profiles. 2) To use these
methods to more fully characterize the time-varying effects over a 5.5-hour period of IP
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administered LPS on multiple systemic cytokine levels and the relationships between those
cytokines. In doing so, we were able to map the order and timing of seven cytokine responses. 3)
To apply the first two objectives to explore inflammatory effects of electrical neuromodulation
directly to the subdiaphragmatic anterior gastric branch (AGB), accessory celiac branch (ACB),
and hepatic branch (HB) of the left vagus nerve. We tested 58 total rats for verification and
analysis purposes and discovered distinct sets of modulatory effects caused by each branch.

Methods
3.2.1

Animals

The Purdue Animal Care and Use Committee (PACUC) approved all protocols in this study. We
used 58 adult male Sprague-Dawley rats weighing between 175 – 265 g. Animals were housed
under standard conditions with ad-libitum access to food and water, unless otherwise stated.

3.2.2

Electrical stimulation experiments

3.2.2.1 Animal groups
We performed two primary surgical groups – the first to study effects of stimulation of anterior
subdiaphragmatic branches of the left vagus nerve and the second to study comparative effects of
left cervical VNS. Rats undergoing subdiaphragmatic cuffing were separated into sub-groups as
illustrated in Table 3.1. For each anterior branch (anterior gastric, accessory celiac, hepatic),
animals received either an LPS challenge with no stimulation, LPS with electrical stimulation
treatment, or LPS with electrical stimulation and an efferent vagotomy. The final group consisted
of saline controls (n = 3), one animal per anterior branch, that were cuffed but received saline in
lieu of LPS and no stimulation. For statistical purposes, the subdiaphragmatic non-stimulation
subsets (SubD Sham) were grouped. Surgeries were randomized between sub-groups.

The cervical group was divided between animals that received an LPS challenge and a 5-minute
stimulation treatment and those that received LPS but did not receive stimulation. In addition, we
performed a sub-set of validation animals (n = 4) to verify our curve fitting methods.
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Table 3.1. Overview of Subgroups Used for Acute Electrical Stimulation Experiment Results.
Stimulation Cuff Location
Left Cervical Vagus Nerve

LPS & No
Stimulation
CVns
n=3

Anterior Gastric Branch
Accessory Celiac Branch
Hepatic Branch

SubD
Sham

n=8

LPS & Stimulation
CVes

n=5

LPS, Stimulation, &
Efferent Vagotomy
N/A
N/A

AGBes

n=5

AGBvx

n=5

ACBes

n=3

ACBvx

n=4

HBes

n=4

HBvx

n=5

3.2.2.2 Materials
We fabricated custom bi-polar stimulation cuffs (shown in Figure 3.1) using Platinum-Iridium
wire and medical grade silicone tubing as done previously [80]. The cervical cuffs used in this
study have been previously characterized [81]. Our cervical electrodes had a measured
impedance of 1.40 – 1.62 k at 1 kHz. The subdiaphragmatic cuff electrodes had a 0.02” inner
diameter, but no suture, and an impedance of 2.07 – 3.45 k at 1 kHz.

Figure 3.1 Photo of stimulation cuffs used in this study. Larger cuff for cervical vagus nerve
stimulation is shown on top with built-in suture to fasten it around a nerve. Smaller cuff for
subdiaphragmatic nerve branch stimulation is shown on the bottom.
An improved version of the Bionode stimulator used previously [80] was utilized for our acute
stimulation experiments. The stimulator output charge-balanced, bi-phasic, square wave pulses
of up to 1.1 mA constant current amplitude. To prevent stray current from permeating into the
animal, we added a DC blocking capacitor in series with the stimulator and added circuitry to
short the capacitor between stimulation pulses to prevent charge build-up.
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3.2.2.3 Acute surgical procedures
We anesthetized rats using 4-5% isoflurane for approximately 3 minutes, then weighed, and
injected the animals IP with a ketamine/xylazine cocktail consisting of a 75 mg/kg ketamine and
5 mg/kg xylazine ratio. A supplement of buprenorphine was administered subcutaneously (0.080.12 mg/kg). Anesthesia was maintained with IP injections of ketamine/xylazine every 30
minutes or as needed based on heart rate and toe pinch. We shaved and cleaned the incision sites
and applied artificial tears to the eyes. The animal was then placed supine on a heating pad and
placed under oxygen flowing at 2 L/min for the remainder of acute surgery and blood
collections. We euthanized animals at experiment completion via a lethal dose of Beuthanasia-D
Special (Merck; Kenilworth, NJ) (0.9 mL, IP).

Catheters for blood collection were placed before cuffing the vagus nerve branch. We followed
the general procedures outline in the Bioanalytical Systems, Inc. Culex surgical manual for
femoral cannulation in a rat [82]. Catheters in our experiment, however, were inserted into the
femoral artery instead of the vein and remained exposed on the benchtop for connection to the
Culex system versus being subcutaneously routed through the animal.

For animals in the cervical cuffing group, we made the initial incision at the midline of the jaw,
moving caudally. We exposed soft tissue until the sternohyoid and sternocleidomastoid muscles,
which sit on top of the carotid sheath, were visible. Via blunt dissection, we gently separated
connective tissues until the carotid artery sheath could be seen. The carotid sheath was carefully
dissected until the left vagus nerve was completely free from surrounding tissues. We then
placed the cuff electrode under the vagus nerve, slid the nerve into the cuff, and tied the attached
suture to secure the cuff in place. The area was kept moist with saline and covered with gauze for
the duration of the surgery when stimulation was not being applied.

Animals in the subdiaphragmatic cuffing group were fasted for 6-12 hours before surgery to
reduce stomach volume and ease access to the subdiaphragmatic nerve branches. To expose the
subdiaphragmatic branches of the vagus nerve we made an incision starting at the midline above
the xyphoid process and moved diagonally to the animal’s left. The muscle was blunt dissected
along the incision and held open using an elastic retraction system. We carefully retracted the left
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liver lobule, cut the hepatoduodenal ligament, and moved the right liver lobule aside to reveal the
esophagus. We then located and isolated either the anterior gastric, accessory celiac, or hepatic
branch of the left vagus nerve and carefully attached a subdiaphragmatic cuff electrode. The
incision site was left open through electrical stimulation therapy to ensure the cuff remained
secure on the nerve. For animals receiving an efferent vagotomy, we tied off the nerve branch
with 6-0 silk suture, caudal to the cuff, and cauterized the nerve fibers caudal to the suture tie.
The suture physically prevented the retraction of the nerve after cauterization and kept the cuff
from detaching from the nerve during stimulation.

3.2.2.4 Acute blood collection protocol
Prior to catheter placement, we primed the Culex Automatic Blood Collection System
(Bioanalytical Systems, Inc.; West Lafayette, IN) [83] with heparinized saline. Once the catheter
was placed in the animal, we connected it to the Culex for tending during the remaining surgical
procedure.

Our blood collection protocols followed those outlined in the National Institutes for Health
(NIH) Guidelines for Survival Bleeding of Mice and Rats. We programmed the Culex system to
automatically collect 12 separate 115 L blood samples, spaced 30 minutes apart after the
second collection, over a period of six-hours as outlined in Figure 3.2. An initial baseline
collection was done 30 minutes prior to LPS injection. In doing so, we did not exceed the
maximum allowed 10% of circulating blood volume. Blood was collected into vials containing
K3EDTA (1.75 mg/ml) and centrifuged at 2000x g for eight minutes after every two collections.
We then extracted the plasma, aliquoted it into 20 L samples, and stored them at -20˚C until
they could be processed.

Validation animals were performed in a similar fashion. Blood collections were doubled in
number (24 samples) but halved in volume to compensate. Saline was given periodically
throughout the procedure to replenish fluids lost with increased rate of blood collection.
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Figure 3.2 Time flow diagram outlines the process of blood collection, LPS administration, and
stimulation treatments (if applicable). Time points are based in relation to the acute LPS
challenge to the animal.

3.2.2.5 LPS preparation/administration
To ensure proper dosing (5 mg/kg) we prepared all LPS (Sigma-Aldrich, serotype O111:B4)
solutions for acute animals in advance. We systematically added 20 mL of sterile saline (0.9%
sodium chloride), mixed with a new 100 mg bottle of LPS lyophilized powder, and sonicated the
mixture for a total of 45 minutes to ensure complete dissolution. We then aliquoted ~400 L of
solution into individual 1.5 mL Eppendorf tubes, before freezing and storing them at -20˚C until
used.

Individual LPS aliquots were thawed by sonication for 30+ minutes at room-temperature 40 –
120 minutes before use. We then sonicated the aliquots for an additional 5 minutes directly
before administering the IP LPS challenge to the animal at the specified time during our
protocol.

3.2.2.6 Stimulation
Stimulation, when applicable, was performed 30 minutes after injecting LPS, following
completion of the second blood collection. The stimulator was connected to the surgically
affixed stimulation cuff, in parallel with an oscilloscope for recording pulses, and was powered
on promptly before stimulation therapy.
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We performed all stimulation treatments for 5 minutes with balanced bi-phasic, square wave
pluses, but utilized two separate sets of stimulation parameters. For the cervical vagus nerve, we
used a larger amplitude profile (1 mA, 200 s, 5 Hz) that corresponds closely to effective
electrical charge used in other literature [6, 15, 19] and that showed good action potential
response in our preliminary testing (not shown). The stimulation intensity was reduced for our
subdiaphragmatic stimulation treatments (100 A, 200 s, 5 Hz), due to the reduced size and
fiber makeup of the subdiaphragmatic nerve branches. This amplitude was shown to be sufficient
to affect the inflammatory response to LPS in a preliminary study [84].

Prior to each stimulation treatment, we verified the stimulator for consistency and balance using
a known resistive load and oscilloscope. During stimulation, we utilized the oscilloscope to
verify an active stimulation and to record voltage profiles of the stimulation pulses. Cervical
stimulations revealed voltage amplitudes ranging from 3.24 V – 3.93 V, resulting in relative
interface impedances of 3.24 k – 3.93 k. Alternately, subdiaphragmatic stimulations showed
voltage amplitudes ranging from 0.83 V – 1.40 V, with relative interface impedances of 8.3 k –
14.0 k.

3.2.2.7 Plasma processing
We analyzed plasma samples using a LEGENDplex™ Rat Th Cytokine Panel (13-plex)
(Biolegend, San Diego, CA), which allowed simultaneous analysis of 13 cytokines: Interleukin
(IL)-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-22, Granulocyte-macrophage
colony-stimulating factor (GM-CSF), Interferon (IFN)- and Tumor necrosis factor (TNF)-.
The cytokine kit was modified for use with 384-well plates and the samples processed, as
described previously [81]. Many of our IL-6 samples showed levels far above the upper limits of
our established flow cytometry methods. To compensate, we re-ran the saturated samples using
a 50:1 dilution factor over that of the 13-plex plates.

52
3.2.3

Data processing techniques

Due to limits on amount and timing of blood collections, along with a high temporal variation in
cytokine response to IP LPS injections, we pursued simple new techniques that would allow us
to better characterize resulting cytokine cascades.

3.2.3.1 Curve fitting
The first method we utilized was that of a smoothing spline interpolation of the 30-minute time
points. We ran our 12 recorded time samples through a piecewise polynomial smoothing spline
interpolation using Matlab (R2017b, Curve Fitting Toolbox 3.5.6) with a smoothing parameter of
p = 1 to ensure all sample values were preserved. From these interpolations, we pulled new sets
of values that could be defined by minute increments and allow a better estimate of peaks,
starting points, and areas under the curves. Other interpolation methods such as Gaussian and
Polynomial fitting, and cubic and shape preserving interpolants were tested, but the smoothing
spline provided the most accurate estimate of actual cytokine curves.

3.2.3.2 Curve alignment
The second method that we implemented was one of aligning the resulting cytokine curves to a
standard point. This is non-trivial as different cytokines display distinct temporal profiles in
amplitude and shape, as well as high animal to animal variation. After multiple tests, we settled
on using a starting point alignment, defining the starting point for a given cytokine uptake as the
point where it reaches 5% of its peak concentration value (or first peak, if there are multiple).
This effectively aligned all curves to a standard point in their respective uptake, while
minimizing the significance of varying temporal profiles, as can be seen in Figure 3.3. By
aligning all cytokine samples to the same starting point, we are also able to better analyze
temporal variances in cytokine uptake between subsets.

In the case of late rising cytokines, if a peak had not yet been reached, we utilized the last
concentration recorded as the effective peak for alignment purposes.
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Figure 3.3 Comparison of individual TNF- temporal profiles from all rats analyzed with LPS
administered IP. Top shows unaligned plots with highly variable starting points. Bottom shows
the result of aligning them utilizing our 5% of peak concentration technique as a starting point
where t = 0 minutes.

3.2.3.3 Verification of curve fitting and alignment
We ran validation tests on four rats to verify that our interpolation method accurately estimated
the actual cytokine cascade curves. For these tests we collected blood in 10 or 15-minute
increments for a more accurate estimate of the curve, and then split them into 30-minute
increment sets as we used in our study. Average variances in calculated starting point between
curves were less than three minutes, and average variances in calculated areas under the curve
were less than 3%. An example of this validation can be seen in Figure 3.4and quantitative
results can be found in Table 3.2.
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Figure 3.4 Representative figure demonstrating the effectiveness of our curve fitting method on a
TNF- cytokine cascade. Data points were taken every 10 minutes. Curve A utilized only points
at 60, 90, 120, 150, 180, and 210 minutes. Curve B utilized only points at 70, 100, 130, 160, 190,
and 220 minutes. Curve C utilized only points at 50, 80, 110, 140, 170, 200, and 230 minutes.

Table 3.2. Comparison of Curves Fitted With 30-minute Time Intervals vs with 10 or 15-minute
Time Intervals.
Average Difference of 5% of Max
Average Percent Difference of
Peak Starting Points
Area Under Curves
Cytokine
Minutes ± StDev
Percent Difference ± StDev
IL-10
-4.3 ± 4.1 (n = 11)
-2.6% ± 9.0% (n = 11)
+0.6
±
2.3
(n
=
11)
+0.5%
± 5.2% (n = 11)
TNF-
GM-CSF
-3.8 ± 4.6 (n = 6)
-2.9% ± 9.7% (n = 6)
IL-17F
No elevations detected*
No elevations detected*
IL-6
-2.6 ± 3.4 (n = 11)
+2.0% ± 14.1% (n = 11)
IL-22
+3.3 ± 7.1 (n = 3)
+2.7% ± 9.7% (n = 3)
+0.7
±
2.9
(n
=
3)
+1.3%
± 13.1% (n = 3)
IFN-
*No validation test animals had sufficient levels of IL-17F elevation for analysis.

3.2.4

Data and statistical analysis

Data analysis was performed after aligning each cytokine curve based on the 5% of peak
concentration methods outlined prior. We detected and removed outliers based on interquartile
range (IQR), or by biological and surgical anomalies, as appropriate, as outlined in Table 3.3.
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Analysis of variance (ANOVA) was performed for both time and concentration data and Welch
t-tests were performed to analyze statistical significance due to limited samples sizes in our
subsets. We considered confidence intervals of 90% and 95% as statistically significant
benchmarks, but we also noted other scientifically significant trends that did not meet these
thresholds.

Subgroup
ACBes
ACBes
ACBvx
HBes
AGBns
CVns
CVns

Table 3.3. List of Outliers Omitted from Formal Data Analysis.
Reason for Omission from Results
No elevated cytokine levels after IP LPS injection
No elevated cytokine levels after IP LPS injection
No cytokine elevation in 5 of 7 cytokines, statistically low outlier in remaining
cytokines
No elevated cytokine levels after IP LPS injection
Statistically high outlier in 4 of 7 cytokines, abnormally high levels in
remaining cytokines
Surgical anomaly, animal showed abnormally high heart rates prior to LPS
administration and throughout experiment
Surgical anomaly, animal struggled to breath throughout experiment and had to
be revived twice

We considered other methods of comparing cytokine profiles between animals and subgroups
such using a distance matrix with quadratic form distance or time warping distance measures,
which could present more robust statistical and quantitative differences between samples (not
shown). However, we found that these methods did not provide further clarity into the data over
those observed when separating the time and concentration variables as we present here.
Additionally, separating the variables allowed us to analyze intricacies of actual cytokine uptake
profiles in the time domain.
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Results
3.3.1

Temporal cytokine profiles and relationships

3.3.1.1 LPS induced cytokine cascade via IP injection
Through a combined subset analysis of recorded cytokine profiles, we detected significant
increases in seven out of the 13 cytokines tested during our 330-minute sampling period post IP
injection. IL-10, TNF-, IL-6, and INF- had the largest and most consistent elevations, while
GM-CSF, IL-22, and IL-17F showed less consistent elevations over the noise floors of our
cytometry methods.

Calculated starting times of each cytokine elevation are illustrated in Figure 3.5. IL-10 is the first
to rise at 49.2 (± 2.8 s.e.m, n = 44) minutes post-LPS injection, followed by TNF- at 72.1 (± 3.5
s.e.m, n = 44) minutes. We then saw an extended delay before elevations occurred in GM-CSF at
116.6 (± 4.3 s.e.m, n = 44) minutes, IL-17F at 125.2 (± 7.0 s.e.m, n = 29) minutes, and then IL-6
at 129.6 (± 3.8 s.e.m, n = 41) minutes post-LPS. Another hour-long delay then occurred before
the elevations of IL-22 at 182.6 (± 6.5 s.e.m, n = 26) minutes and IFN- at 186.6 (± 3.8 s.e.m, n =
44) minutes post-LPS injection. No statistical differences in recorded starting points were noted
between stimulation and control subsets; therefore, all samples were combined for a more robust
temporal characterization.

It is important to note that the observed temporal cascade of cytokines had a high overall
variability in initial start time, as can be seen in the high standard deviations of elevation starting
points in Table 2. However, we discovered that this variability was consistent through each
cytokine’s elevation in the cascade. For example, if IL-10 of a given rat elevated 10 minutes
earlier than our noted average, then all other cytokines would also elevate ~10 minutes earlier
than our presented averages.
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Figure 3.5 Mean starting times of cytokine elevations based on 5% of maximum elevation after
IP injection of LPS (5 mg/kg). Error bars, s.e.m.

3.3.1.2 IP to IV comparisons
To compare administration methods, we utilized cytokine data obtained from our previous
research, in which we performed IV injections of LPS with an identical experimental time
sequence and LPS concentration [80]. In that study, however, we only extended blood
collections to 150 minutes post-LPS injection and, therefore, the methods used here could only
be applied to IL-10 and TNF-. We did, however, note general elevations in GM-CFS, IL-6, and
IL-22 in the chronic data. Starting point times for both IV and IP data are presented in Table 3.4.

We found there to be significant differences between temporal cytokine responses to LPS when
administered IP versus IV. In general, plasma cytokine levels elevated much earlier and had
significantly smaller starting point deviations in IV compared to IP. TNF- levels showed
elevations 42 minutes earlier when LPS was injected IV and showed a standard deviation almost
three times smaller compared to IP administration. This disparity related to IP administration was
expected and emphasizes the need for better analysis method such as those we used in this study.
We noted similar earlier elevations of IL-6, GM-CSF, and IL-22 with IV injected LPS. The time
of elevations and delays are consistent with those noted in previous literature [66, 68].
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Interestingly, IL-10 was a glaring exception to the standard delays noted in the other cytokine
elevations. Instead, we found that IL-10 had very similar elevation starting point times and
standard deviations when using both IV and IP LPS injection methods. IL-10 levels began
elevating at around 50-minutes post LPS injection in both methods, and, while IP LPS injections
still produced a larger deviation in elevation start time, it was only 27% larger. We found it
compelling to note that this changed the order of cytokine cascades from IL-10 elevating ~23
minutes before TNF- when using IP LPS injections, to IL-10 elevating ~18 minutes after TNF when injecting LPS IV. This signals a distinct physiological mechanism of the body to
produce IL-10 in response to LPS, separate from that of TNF- and other cytokines, and less
dependent on endotoxin administration method.

Table 3.4. Comparison of Starting Points for Cytokine Elevations Using IP Injection vs IV
Injection Methods.
Starting Point Based on 5% of Peak Method ± StDev
Cytokine
Min After IP LPS Challenge (n = 44)
Min After IV LPS Challenge (n =
40)
IL-10
49.2 ± 18.6
48.1 ± 14.6
72.2
±
22.9
30.3 ±7.9
TNF-
GM-CSF
116.6 ± 28.4
60 - 90 min (n = 8)*#
IL-17F
125.2 ± 37.5 (n = 29)#
No elevations detected*
IL-6
129.6 ± 24.3 (n = 41)#
60 - 90 min (n = 40)*
#
IL-22
182.6 ± 33.3 (n = 26)
90 - 120 min (n = 14)*#
186.6 ± 25.2
No elevations detected*
IFN-
*Due to limited time points collected in IV LPS animals (0 – 150 min post LPS injection),
specific starting points could not be properly calculated for all cytokines using our methods.
Instead, a range of times in which elevations were detected over our noise thresholds, if detected,
in the reduced test period is given. #Had reduced number of samples showing calculable cytokine
elevations.

3.3.2

Subdiaphragmatic stimulation

The following sections outline effects on cytokine cascades seen between stimulation of separate
subdiaphragmatic branches. We aligned data from each animal so that time “zero” corresponded
to its 5% starting point and then plotted the cytokine cascades for the duration that included
samples from all animals. We then averaged the effective areas under the curves of samples in
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each subset for a quantitative measure of total cytokine concentration, used for statistical
analysis. Overall qualitative results are presented in Table 3.5.

Table 3.5. Summary of Cytokine Effects of Subdiaphragmatic Branch Stimulation.
IL-10 TNF-
IL-6
IFN- GM-CSF IL-17F IL-22
Accessory Intact
•
•
•
•
•
•
•
Celiac
(ACBes)
Branch
Vagotomy
•
•
•
•
•
•
•
(ACBvx)
Anterior
Intact
•
•
•
•
•
•
•*
Gastric
(AGBes)
Branch
Vagotomy
•
•
•
•
•
•
•
(AGBvx)
Hepatic
Intact
•
•
•
•
•
•*
•*
Branch
(HBes)
Vagotomy
•
•
•
•
•
•
•*
(HBvx)
Increases (•), decreases (•) and no change (•) are indicated.
Colors are used for simplified interpretation and are not meant to signify changes as desirable
or not.
*Indicates a statistically significant change in cytokine levels compared to sham group.

3.3.2.1 IL-10 profiles
We found IL-10 concentrations to be highly affected by subdiaphragmatic stimulation of all
three branches. IL-10 is primarily an anti-inflammatory cytokine, thus an increase in systemic
levels is desirable. Effects can be seen in Figure 3.6 and Figure 3.7.

Stimulation of the accessory celiac branch yielded highly variable IL-10 concentration responses
that averaged 146% (ACBes) and 157% (ACBvx) higher than sham controls. Concentrations on
the ACBes subset showed a high initial increase in IL-10 levels that dropped at the 90-minute
point. However, those with efferent vagotomies showed sustained elevations of IL-10 throughout
the tested period. Stimulation of the anterior gastric branch also showed highly variable but clear
elevations in IL-10 levels, with both subgroups averaging ~110% increases over sham control
levels. The AGBvx subset showed a quicker average uptake with a decrease after ~60 minutes,
while the AGBes subset had a much slower but extended uptake, not reaching a max level till
after 100 minutes. Hepatic branch stimulation displayed the most consistent results, revealing
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statistically significant IL-10 elevations of 73% (HBes) and 75% (HBvx) over that of sham
controls (p<0.05).

Figure 3.6 Averaged IL-10 cascade responses to IP injection of LPS (5 mg/kg). All samples were
curve fitted and aligned at the time they reached 5% of peak concentration, represented as time
“zero.” Time axis extends to the last time point in which all samples were still recorded.

Figure 3.7 Cumulative IL-10 concentration effects of subgroup responses to IP injection of LPS
(5 mg/kg). Values represent effective areas under the curve corresponding to time points
illustrated in Figure 3.6. Error bars, s.e.m. *P < 0.05 compared to SubD Sham group.
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The consistency in overall response between vagotomized and non-vagotomized subsets of all
three branches indicated this upturn in IL-10 response to be primarily a vagal afferent effect.

3.3.2.2 IL-6 profiles
Our data showed compelling trends related to IL-6 responses to subdiaphragmatic stimulation.
IL-6 is a commonly analyzed pro-inflammatory cytokine, and it is, therefore, beneficial to
attenuate its levels in response to an LPS challenge. IL-6 effects can be seen in Figures 7 and 8.
Stimulation of the intact accessory celiac branch produced a reduction of ~30% in overall IL-6
levels under that of sham controls while intact hepatic branch stimulation only produced an ~8%
reduction. Intact anterior gastric branch stimulation, however, produced increases in IL-6 levels
of 90% over sham controls. Of note is that multiple AGBes samples saturated the upper IL-6
limits of our flow cytometry methods, even when diluted. Therefore, the levels in that subgroup
were likely even higher than reported here.

Effects on IL-6 changed significantly when an efferent vagotomy was performed. The increases
seen from intact gastric branch stimulation were reduced, while the attenuation effects of the
celiac and hepatic branch stimulation were reversed. The ACBvx subset instead resulted in
increased IL-6 levels of ~18%, while the HBvx subset showed a very large initial increase in IL6 levels that began to decrease at 80-minutes post starting point. The overall IL-6 increase of
HBvx was 56% over that of sham controls.

These results indicated an anti-inflammatory effect related to stimulation of the hepatic and
accessory celiac branches in which an intact efferent fiber route is present. A similar, but proinflammatory efferent effect was expressed by anterior gastric branch stimulation.
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Figure 3.8 Averaged IL-6 cascade responses to IP injection of LPS (5 mg/kg). All samples were
curve fitted and aligned at the time they reached 5% of peak concentration, represented as time
“zero.” Time axis extends to the last time point in which all samples were still recorded.

Figure 3.9 Cumulative IL-6 concentration effects of subgroup responses to IP injection of LPS (5
mg/kg). Values represent effective areas under the curve corresponding to time points illustrated
in Figure 3.8. Error bars, s.e.m. # P < 0.1 between ACBes and AGBes subgroups.
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3.3.2.3 TNF-
 profiles
TNF- is the most commonly analyzed pro-inflammatory cytokine in VNS inflammation studies
and attenuation of TNF- response is desirable. While responses had high variability in all
subsets that we sampled and did not show statistically significant trends, we have included it in
our results to stay consistent with prior literature and further demonstrate our methods. Effects
are illustrated in Figure 3.10 and Figure 3.11.

Stimulation of the intact nerve branches appeared to have little effect on the production of TNF. AGBes and HBes subgroups showed responses that were only 17% higher than sham control,
while ACBes was nearly identical to sham. Stimulation of the accessory celiac and gastric nerve
branches with efferent vagotomies exhibited virtually identical overall TNF- responses, with
the ACBvx subset appearing to have a slightly slower rate of increase. HBvx stimulation showed
the largest effect on TNF- levels, displaying a higher peak concentration and an overall average
concentration 42% higher than sham controls.

Figure 3.10 Averaged TNF- cascade responses to IP injection of LPS (5 mg/kg). All samples
were curve fitted and aligned at the time they reached 5% of peak concentration, represented as
time “zero.” Time axis extends to the last time point in which all samples were still recorded.
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Figure 3.11 Cumulative TNF- concentration effects of subgroup responses to IP injection of
LPS (5 mg/kg). Values represent effective areas under the curve corresponding to time points
illustrated in Figure 3.10. Error bars, s.e.m.

3.3.2.4 IFN-γ profiles
We observed very distinct roles of several stimulation subgroups in the proliferation of IFN-
levels in response to IP LPS challenge. IFN- is a less commonly analyzed pro-inflammatory
cytokine that is linked to exacerbation of numerous disorders such as rheumatoid arthritis and
multiple sclerosis [85]. It has also been reported that IFN- increases the lethality of LPS and
TNF- in mice, and correlates to increased levels of IL-6 when combined with TNF- [86]. Due
to a lack of literature outlining VNS effects on IFN- levels, we believed it pertinent to present
our data. Effects are illustrated in Figure 3.12 and Figure 3.13.

Though highly variable, we found that stimulation of all three intact subdiaphragmatic branches
caused escalations of IFN- responses to the LPS over that of sham controls. The ACBes subset
showed a 3.3x increase, while AGBes subset showed 3.7x increase, and the HBes had the highest
increase at almost 6x the average level of sham controls. Meanwhile, we found that efferent
vagotomies of the accessory celiac and gastric nerve branches prevented this increase. Only the
hepatic afferent stimulation, by itself, significantly boosted systematic IFN- levels.
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Our data points towards IFN- regulation being a predominantly efferent fiber effect, with
hepatic afferents also playing a decided role.

Figure 3.12 Averaged IFN- cascade responses to IP injection of LPS (5 mg/kg). All samples
were curve fitted and aligned at the time they reached 5% of peak concentration, represented as
time “zero.” Time axis extends to the last time point in which all samples were still recorded.

Figure 3.13 Cumulative IFN- concentration effects of subgroup responses to IP injection of LPS
(5 mg/kg). Values represent effective areas under the curve corresponding to time points
illustrated in Figure 3.12. Error bars, s.e.m. # P < 0.1 compared to SubD Sham group.
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3.3.2.5 Remaining cytokine profiles
GM-CSF is typically linked to allergic inflammation, but presents with a wide range of
pathologies [87], while IL-17F acts as a pro-inflammatory cytokine often with relation to lung
inflammation [88] and IL-22 has been shown to play both a positive and negative role in
different immune disorders [89]. Thereby, regulation of any or all three of these specific
cytokines could yield new therapy options for inflammatory diseases.

Statistical quantitative analysis of elevations for these cytokines was unreasonable due to
respectively low concentration levels and inconsistent rises. Instead, we did a simple fractional
analysis of samples that rose above a nominal noise threshold for our flow cytometry methods
that is shown in Table 3.6. In doing so, we found qualitative trends of note between subgroups.

Table 3.6. Fractional Analysis of Cytokine Cascades Over Given Threshold Concentrations.
Cytokine
GM-CSF
IL-17F
IL-22
Threshold
80 pg/ml
100 pg/ml
100 pg/ml
Subset
ACBes
3/5
3/5
2/5
ACBvx
2/4
0/4
2/4
AGBes
AGBvx

3/5
2/4

3/5
1/4

3/5
1/4

HBes
HBvx

1/4
3/5

4/4
4/5

0/4
4/5

SubD Sham
2/8
3/8
1/8
Fractions are the number of animals that had cytokine cascade elevations above the given
threshold.
Colors are used for simplified interpretation and are not meant to signify results as desirable or
not. Blue cells are subsets that had over half its samples rise above threshold. Yellow cells are
subsets that had half or less of its samples rise above threshold. Red cells are subsets in which
none if its samples rose above threshold.

Accessory celiac branch stimulation was consistently effective at modulating both GM-CSF and
IL-17F, but the consistency of elevations was reduced when the branch was given an efferent
vagotomy. Simulation of the intact gastric branch also showed increased upregulation of all three
cytokines, while an efferent vagotomy to the branch prevented these increases. The hepatic
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branch showed the most effective regulatory ability. Stimulation of the intact hepatic branch
(HBes subgroup) was effective at elevating IL-17F levels, but not GM-CSF or IL-22. However,
when an efferent hepatic vagotomy (HBvx subgroup) was performed, stimulation showed
increased frequency of elevations in all three cytokines.

3.3.2.6 Cervical electrical stimulation
Electrical stimulation of the left cervical vagus nerve was applied to contrast with
subdiaphragmatic stimulation results. We did not, however, note any significant correlations
between these subgroups and the previously analyzed subdiaphragmatic subgroups.

Cervical VNS showed variable levels of overall cytokine modulation in response to an IP LPS
challenge as can be seen in Figure 3.14. There appeared to be varying attenuation effects of
cervical stimulation on levels of TNF-, IL-10, and IFN- in comparison to non-stimulated
animals, while there were virtually no changes in IL-6 levels.

Of interesting note is that there seemed to be artificially lower levels of IL-6, IL-10, and IFN- in
all cervical subgroups compared to the SubD Sham animals. This could indicate a local
inflammatory effect of the subdiaphragmatic surgery itself.

Table 3.7 shows us very little nominal difference in the responses of GM-CSF, IL-22, and IL17F, between CVes and CVns subsets.
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Figure 3.14 Cumulative cytokine concentration effects of cervical subgroup responses to IP
injection of LPS (5 mg/kg). SubD Sham group is included for comparison.

Table 3.7. Fractional Analysis of Cytokine Cascades Over Given Threshold Concentrations for
Cervical Subsets.
Cytokine
GM-CSF
IL-17F
IL-22
Threshold
80 pg/ml
100 pg/ml
100 pg/ml
Subset
CVes
1/5
1/5
1/5
CVns
1/3
1/3
2/3
Fractions are the number of animals that had cytokine cascade elevations above the given
threshold.
Colors are used for simplified interpretation and are not meant to signify results as desirable or
not. Blue cells are subsets that had over half its samples rise above threshold. Yellow cells are
subsets that had half or less of its samples rise above threshold.
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Discussion
3.4.1

Temporal IP cytokine cascade interpretation

Through these studies, we determined the temporal cascade of cytokines in response to a 5
mg/kg IP injection of LPS. To our knowledge, no previous studies have taken as consistent and
frequent time points, for as long a test period, or have incorporated as diverse a cytokine
makeup.

For IP LPS, IL-10 is the first cytokine to surface, followed by TNF-, GM-CSF, IL-17F, IL-6,
IL-22 and finally IFN-. TNF- has been characterized as one of the first cytokines to surface in
several other studies [90-92] and although not believed to be the sole initiator of other cytokines,
certainly affects the concentration and duration of presence of other cytokines [92]. The
production of IL-10 is likely independent of the cascade initiated by TNF- [91, 92], which
could explain its early appearance as well as its similar timing in IP and IV LPS administration.
Additionally, it is notable that the timing of the cytokine cascade is dependent on LPS
concentration administered [68], but was unaffected by stimulation in our study. Knowing the
cascade of cytokines could help to specifically target the attenuation of specific cytokines during
in vivo studies. For example, to attenuate IFN-, perhaps electrical stimulation should be applied
later compared to aiming for attenuation of TNF-.

We also analyzed cross-relationships between cytokine levels. We found a rough inverse
correlation between TNF- and IL-10 levels (not shown). When IL-10 had a large spike early in
the cytokine cascade, TNF- levels were notably lower. This inverse relationship has been
previously reported [93].

In addition, we compared IP to IV LPS administration, finding much greater variability with IP
administration. This was expected and has been previously reported [72, 73]. Because of this
variability, it was important that we collected blood at sufficient time points to understand the
full curve for an individual animal and adjust the data accordingly. Our curve fitting and
temporal shifting methods can be used by other researchers to account for variable IP absorption.
We urge researchers to collect data at several times, rather than an individual time point,
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especially when using IP administration of endotoxin. Studies that have evaluated cytokine
concentrations at only one time point may continue to use IV LPS to reduce the variability in
their data; however, we have also demonstrated a temporal variation in IV LPS cytokine
response that is significantly smaller but still present, and we have reason to believe that the
biological mechanisms are different between the two administration types.

Typically, infections are not immediately present in the bloodstream and must be identified in
the intraperitoneal space first [94]. This makes IP administration a more clinically and
physiologically relevant animal model. Perhaps the most difficult aspect of utilizing an IP
injection of LPS is timing of treatment. With a large variability of uptake time, it becomes very
hard to match a stimulation of the nerve to the exact start time of uptake. This should not
dissuade researchers, however, as there is little evidence to suggest that exact timing of a therapy
with relation to uptake time has had a significant impact on the effectiveness of treatment. In
previous literature, we found multiple studies that have effectively used different stimulation
techniques, timing, and durations (even continuous stimulation in some studies) to modulate
inflammatory responses [6, 11, 69, 95, 96]. We surmise that treatment timing with relation to
injection time is more important that the relation to when uptake starts. Additionally, this
variability will exist clinically and serves to better model the variable state of the body when the
treatment is given to a patient. We urge researchers to select the more physiologically relevant
model with thought to future clinical relevance rather than selecting a less relevant model that
may result in cleaner, easier to analyze data.

There is certainly a myriad of experimental aspects that could be analyzed in an inflammatory
study such as treatment type, duration, and frequency, endotoxin type, injection method and
location, as well as tissue or serum sample type and location. All of these have merit and could
significantly influence the effectiveness of said treatment. Given limited resources, we must
attempt to look at the most pertinent physiology and narrow in on those aspects and
corresponding methods. Certainly, a dedicated study comparing IP to IV methods would be
ideal. Notably, our IV data came from a chronic cuffing study in which the rats had no anesthesia
during LPS challenge [80]. While it is very possible that variability between the set-ups could
have affected cytokine response timing, we believe it to have been minimal. Our data and
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analyses are supported by Kakizaki et al [66] who’s IV versus IP comparison showed similar
delays in TNF- and IL-6 responses, as well as more defined average peaks utilizing IV versus
IP, which would indicate a higher variability in the timing of IP responses.

3.4.2

Inflammation regulation via subdiaphragmatic stimulation

Based on our results, the most suitable nerve branch and fibers to stimulate can be deciphered
based on the need to increase or decrease each of the studied cytokines. Unfortunately, the
results of stimulation vary for each cytokine. For example, to increase IL-10 levels, the intact HB
can be stimulated. This will also cause to varying degrees: a decrease in IL-6 and IL-22, an
increase in IFN- and IL-17F, and no change in TNF- or GM-CSF levels. Combining
stimulation and/or vagotomies of the three branches may yield ideal results. This would allow for
the individualization of therapy based on the desired cytokine results.

HB stimulation and ACB stimulation had the largest overall effect on cytokine production. While
the ACB causes changes, supporting claims made in previous work upon which our theory was
founded [78], the HB induces more pronounced responses in some cases. This could be due to
the larger amount of sensory fibers present in the HB (73%) compared to the ACB (69%). The
AGB has only 48% sensory fibers and showed the least modulatory effects, encouraging the idea
that there is a correlation between increased sensory fiber activation and immunomodulation
[97]. When taking these interrelations into consideration, this data suggests that there is not a
singular subdiaphragmatic branch that will induce a change in all cytokine levels. These
outcomes thereby allude to the likeliness that there is not a solitary mechanism of action
regulating cytokines, and similar effects can be achieved by stimulating multiple combinations of
nerve branches and fibers.

Afferent fibers comprise about 90% of vagal gut innervation, and a previous study by Bratton et
al. implied that the connection between the vagus and spleen was indirect [70, 98], supporting
our results indicating that afferent fibers had a large influence on some cytokine levels, such as
IL-10. Mapping has been done that shows there is a difference in termination patterns between
gastric, celiac, and hepatic afferent axons in the medulla. There are two major distribution
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patterns that emerge: one due to AGB terminals and the other due to ACB and HB terminals
[99]. This mapping, in conjunction with our findings, suggests that the region and density at
which subdiaphragmatic afferent axon terminals occur in the medulla influences the body’s
inflammatory response. It is possible that there are specific areas of the area postrema (AP) that
connect to the DMN of the vagus directly, or more likely, indirectly via the NTS. If these regions
included hepatic or celiac branch terminals, stimulation of this branch would lead to activation of
the DMN, thus the efferent vagal fibers that are initiated there [100]. More recent work has
shown that these fibers pass information to the NTS, which relays signals to the DMN.
Additionally, the NTS does not fire spontaneously, meaning that any of its transmitted
information is due to afferent stimulation [101]. The proximity of ACB and HB axon terminals
in the AP and the anti-inflammatory effects of each, lend to the idea that there is a connection
between that region and an area of the DMN that activates efferent fibers.

Efferent vagal fibers could be activated due to the indirect path previously described or due to
direct electrical stimulation. If fired indirectly, the various areas that the efferent fibers originate
from would play a role, and, therefore, the areas of the AP and NTS that receive information
from subdiaphragmatic afferents would be directly connected to the respective areas of the
DMN. Thus, afferent hepatic activation would lead directly to activation of hepatic efferents in
the DMN, and the areas that these efferent fibers innervate, versus that of the other branches,
could be responsible for differences in modulation between branches. Anatomical mapping by
Berthoud et al. has shown that while the HB innervates the liver, most of its axons supply the
pylorus, antrum and pancreas. Meanwhile, the ACB innervates the celiac and superior mesentery
ganglia, continuing to the pancreas, small and large intestines, and mesenteric branches [2].
These branches follow unique pathways except for their connections to the pancreas, possibly
linking it as an important structure in immune function. It is also possible that these efferent
fibers feed into different lymphatic areas along the intestine that regulate T cell production, thus
immune function. The unique regions that the HB innervate could have different densities of T
cells to regulate, explaining why the HB sometimes has the strongest effect. Further research is
needed to confirm the efferent pathway of the ACB and HB, allowing for a deeper understanding
of the responsibility that these branches play.
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Of important note in our study is that four out of 55 rats showed little or no response in any
cytokine levels after IP LPS administration. While we thought it most likely that this was a
biological anomaly in these animals similar to those experienced by Lenczowski et al [72, 73], it
is interesting to note that our rate of unresponsive animals was significantly less than that
experienced by them. It is curious that their last data point collected was at 90 minutes post IP
LPS injection, a time point in which ~20% of our animals had yet to show significant elevations
of IL-6, the cytokine of interest in the Lenczowski studies. We hypothesize that had they
collected samples at a later time-point, that they would have seen IL-6 elevations in a larger
number of their animals. It is also interesting to note that none of our nonresponsive animals
were in sham subgroups and all four were in stimulation subgroups that showed significant
amounts of cytokine modulation in responsive rats (two ACBes, one ACBvx, and one HBes).
Therefore, while the attenuation effect was dramatic in these four animals and we considered
them outliers for statistical purposes, it is possible that the stimulation applied to these animals
did indeed play some part in the absence of inflammatory response.

With regards to our lacking effects of subdiaphragmatic stimulation on TNF- levels in any
subset, we believe there to be two probable explanations. First, in successful studies in which
TNF- was attenuated with cervical stimulation, it was done so by performing an afferent
vagotomy before stimulation or applying a virtual vagotomy using electrical stimulation to block
afferent fibers, thereby specifically stimulating only the efferent fibers [15, 19, 69, 70]. When
afferent fibers were still present, their results were variable and did not show significant
reductions. Thereby, it is possible we saw the same effect in the subdiaphragmatic branches.
While stimulating efferent fibers, we were also stimulating the more predominant afferent fibers
of the branches and created an offsetting parasympathetic effect that prevented reductions of
TNF- levels. It is also plausible that our 100 uA pulses produced suboptimal stimulation and
were only able to successfully stimulate afferent fibers in those nerve branches. It is possible that
a larger stimulation profile would have produced better attenuation by effectively stimulating the
efferent fibers. The scope of this study did not allow for multiple stimulation parameters to be
tested, but such a study would be very beneficial to the VNS community in the future.
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Selective cervical efferent stimulation used in previous studies is also a challenge to implement
clinically. Surgical vagotomy causes vitamin deficiencies [102] and virtual vagotomy has not
been proven in a chronic animal model or clinically to the best of our knowledge. In addition,
these solutions do not account for the vagus nerve’s innervation of a vast number of organs,
causing potential inherent side effects if stimulated at the cervical level. Stimulation of the
anterior subdiaphragmatic branches of the left vagus nerve more selectively targets the organs
involved in cytokine production, and thus could reduce side effects compared to cervical VNS.

Chronic cuffing of the cervical vagus nerve has caused efferent fiber damage in rats, affecting
the ability for cervical VNS to attenuate the inflammatory response [80]. However, it is possible
that since certain modulatory effects of the subdiaphragmatic branches that we observed are due
primarily to afferent fibers, that even if the efferent fibers were damaged, some antiinflammatory effects might still be seen. The consequences of subdiaphragmatic vagotomy
should be investigated to see if it is a clinically viable option to aid in selectivity of therapy.
Alternative methods could also be used to stimulate the subdiaphragmatic branches, such as
focused ultrasound, which was recently used to modulate TNF- by activating the left cervical
vagus nerve [81].

Summary/Impact
We have outlined new methods for interpreting cytokine production and addressing the
variability in response to IP LPS, which we argue is a more suitable animal model for
inflammatory diseases than IV injections. IP and IV administration of LPS induces different
timing in the cytokine cascade for all cytokines observed except IL-10, which seems to be
produced and modulated independently of other cytokines.

We also presented a robust analysis of the effects of subdiaphragmatic stimulation on cytokine
response to IP LPS. Hepatic and accessory celiac branch stimulation produced the greatest
effects on cytokine production following the administration of IP LPS. With the possibility of
combining stimulation of various subdiaphragmatic branches and more selectively stimulating
structures involved in the inflammatory reflex, use of the subdiaphragmatic branches of the left
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vagus nerve shows promise in the regulation of cytokines as well as further defining the
inflammatory reflex. Further studies should be performed to characterize the interactions
between the AGB, ACB, and HB of the vagus nerve.
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4. AIM 3: STUDY OF CHRONIC NERVE CUFFING

Motivation
The initial goal of our chronic cuffing work was to study inflammatory cytokine effects of VNS
in a chronic rodent model. Similar to Aim 2, we wanted to determine stimulation protocols that
could control inflammation. Rather than stimulating subdiaphragmatic branches, we were to
vagotomize them instead and perform cervical VNS with different subdiaphragmatic branches
left intact. A retrograde tracer analysis was part of the experiment to verify the effectiveness of
subdiaphragmatic vagotomies to be performed. However, after many attempts at successful
implantation, we found that the tracer was being severely suppressed in virtually all subjects
from all nerve branches, indicating unexpected and more severe damage than selective
vagotomies should produce.

While unexpected, this tracer suppression opened a new and perhaps more important study on
the effects of chronic nerve cuffing itself. I continued with analysis in this direction and
produced the work that follows.

Material in sections 4.1.1 - 4.4 come directly from my paper titled “Chronic Cuffing of Cervical
Vagus Nerve Inhibits Efferent Fiber Integrity in Rat Model,” and its supplemental data, accepted
by the Journal of Neural Engineering in 2017. It should be noted that this study took place prior
to that in Aim 2, and thus certain parts may be repetitive of those in that study or were updated
and possibly improved for that study. This study also used techniques and equipment developed
in Aim 1 and therefore there may be some repetition in material from there as well. Updates to
data have been made as appropriate and are marked as such throughout this section.

Section 4.5 has been added to outline a small follow up study performed by Kelsey Wasilczuk,
supported by myself, to look at related effects of chronically cuffing a subdiaphragmatic nerve
branch.
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4.1.1

Chronic cuffing study introduction

In this study, we utilized novel combinations of verification techniques on 53 rats to analyze
multiple dynamic effects of VNS on the physiology of the nerve. These included retrograde
tracer analysis using Fluorogold (FG), electrophysiological responses to stimulation, visual and
histological analyses of nerve samples, and plasma analysis of cytokine levels (animal names and
results can be found in Appendix A). As a result, we discovered complete suppression of FG
transport to the DMN of the medulla in animals that had vagus nerves cuffed for periods ranging
from 13-71 days in length, and found insignificant modulation of inflammatory cytokines when
applying VNS therapy, as compared to corresponding acute subjects [103]. In addition, we
performed gastric emptying tests using MRI on six chronically implanted rats (details in
Appendix B) to compare with equivalent acute testing in a parallel study. Results revealed
attenuated effects on gastric emptying rates when the vagus nerve was chronically cuffed.

Our resulting hypothesis, that the rat model may be unsuited for chronic nerve stimulation
studies, is compelling and pertinent to the entire VNS community. We revealed evident flaws
related to chronic cuffing of the vagus nerve in a rat model, as it creates previously unstudied
physiological effects that suppress the fluorogold transport mechanism, and ostensibly, act to
suppress the anti-inflammatory and other effects of VNS. This hypothesis stands despite the
outward appearance and functionality of a healthy nerve using traditional methods of integrity
verification (visual, histological, electrophysiological).

Given the scarcity of related literature to verify or disprove our findings, we feel that while our
results do not invalidate the findings of past chronic studies in rats due to differences in methods
used, they do call into question the integrity of facets of some data. If indeed some undetected
aspect of the efferent (and possibly afferent) fiber physiological operation was affected by
cuffing of the peripheral nerve, then the resulting biological effects of the subject matter could
also have been attenuated or completely altered by the compromised nerve fibers.
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4.1.2

Comparative review of chronic cuff VNS studies in rats

A comparative literature review of 17 recent studies (details in Appendix C and D) employing
chronic methods of VNS varied widely in application but revealed few common methods to
contrast our experiment.

Most of the chronic VNS studies reviewed centered on biological effects related primarily to
brain activity, such as seizures (epilepsy), depression, and memory, and primarily due to
stimulation of afferent fibers of the vagus nerve [17, 104-111]. While there are likely secondary
and indirect effects to the overall autonomic peripheral nervous system response due to efferent
fiber activation from VNS, evidence suggests that VNS affects the brain primarily through
afferent fiber activation and not through indirect efferent effects [13]. Studies that focused on
primarily efferent targets of VNS were rare, with four groups specifically studying cardiac
effects [96, 112-114]. Only Meregnani et al [95] centered on the topic of inflammation in the
gastric region of the body as we sought to.

None of the reviewed literature implemented our retrograde tracer (Fluorogold) analysis into
their studies of chronic nerve stimulation. We argue this to be a definitive and critical evaluative
measure of nerve functionality. To our knowledge, we are the first to use it in a VNS study.

Merely two of the reviewed papers included a mechanism to directly record compound nerve
action potentials (CNAPs) from the nerve [16, 115]. Other groups relied instead on physiological
indicators such as changes in measured heart rate [96, 111, 112] to verify that VNS was
operating as intended or having an effect.

While histological analysis is common in developmental studies of new cuff designs [116-118],
none of the reviewed studies published a histological analysis of the effect of their cuffs on the
nerve during implantation. With such a dependence on the cuff/nerve interface for VNS studies
and the multiple variables involved in a chronic cuff implantation including materials used,
surgical techniques, and animal variances just to name a few, we felt this was a necessary
analysis to include.
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Three groups performed histochemical analyses of inflammatory cytokines. Chunchai et al [108]
measured TNF- levels in brain and plasma samples, while Chapleau et al [96] measured
multiple cytokines in serum only and Meregnani et al [95] measured various cytokine levels
directly from colon tissue samples. In comparison, we tested blood (plasma) samples on 13
different cytokine variants.

Methods
4.2.1

Experimental timing

The order and timing of multiple procedures involved in this chronic study are outlined in Figure
4.1. All parts of this experiment were organized and run to minimize unplanned variations to
timing and techniques.

Figure 4.1 Time flow diagram of our chronic experimental design. Chart outlines the overall
long-term flow of our experiment over the course of weeks, beginning with surgical implantation
and flowing though data analysis.

4.2.2

Materials

4.2.2.1 Nerve cuffs
Our standard cuff electrodes were custom made from 1x7x0.001” (75 m outer diameter)
braided Platinum Iridium (Pt/Ir) wire (Fort Wayne Metals; Fort Wayne, IN) threaded into a
medical grade silicone tubing substrate (0.03” inner diameter; A-M Systems; Carlsborg, WA). A
single strand of the wire was threaded through the inside of the cuff, following its contour, to
create an electrode that would surround over 70% of the nerve diameter when implanted. The
cranial electrode of the stimulation cuff required a larger exposed surface area due to its use as
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the grounding place for our system’s device electronics. To accomplish this, we threaded the
Pt/Ir wire around the inner and outer contours of the cuff six times (shown in Figure 4.2)
effectively increasing the electrode surface area by 15x. The lead tubing was fastened and sealed
to the cuff with a fast curing silicone adhesive (Med2-4213; NuSil; Carpinteria, CA). The cuffs
were 3 mm in length with Pt/Ir electrodes spaced approximately 1mm apart.

Figure 4.2 Photograph showing a standard stimulation cuff used in our studies. Threaded wire
electrode was used as a grounding reference for stimulation and oriented cranially.
In addition to our standard cuff design, we attempted to use three other electrode varieties:


CorTec tunnel cuff with PtIr electrodes. Cuff was 3 mm in length with a 0.6 mm inner diameter.
Stimulation cuff only was implanted on animal eRx118. (Cat. No. 1041.2008.01; CorTec;
Freiburg, Germany)



Shape memory polymer cuff fabricated by University of Texas – Dallas as presented in Figure
2g of Ware et al[61]. Our variant had only 2 electrode traces and only the stimulation cuff was
implanted on animal eRx111.



Experimental thin film cuffs using two gold traces and pads on a 12 m thick parylene substrate.
The 4.7 mm long and 2.3 mm wide cuff electrodes were gently wrapped around the isolated
vagus nerve to create ~1.5 mm diameter cuffs with separate 11 mm tabs wrapped around the

81
cuffed nerve and carotid artery for anchoring. Excess tab material was cut away and Kwik-Sil
was used to fasten the interface in place. Record and stimulation cuffs were implanted on
eRx119. The authors can be contacted for more details on this cuff design.

4.2.2.2 Devices/Headcaps
The stimulation and recording for most of our chronic rat tests were done using the Bionode; a
multipurpose implantable platform designed for physiological studies [119]. For this study, the
Bionode was typically implemented with a single stimulation and a single record channel, each
with a cuff electrode attached. The Bionode can produce bi-phasic constant current stimulation
profiles ranging from 50 A to 1.1 mA in amplitude and 50 s to 1 ms in pulse width through
the stimulation cuff electrodes. The recording electrodes get fed through a dual stage differential
amplifier. The Bionode’s interface allowed real-time recording and control of stimulations to the
implanted device, using a custom software platform.

Instead of using a fully implanted Bionode, we tested some of our animals with a tethered setup
using a cranial headcap. This was done to vary the surgical method of some animals and verify
our findings. For these animals, the headcaps were pre-built by attaching our nerve cuffs to
individual pins (PlasticsOne; Roanoke, VA) and affixing those pins to head-cap pedestals
(Plastics One) with dental cement. We also used headcaps with single implanted stimulation
cuffs for chronic gastric emptying experiments.

4.2.3

Surgical methods

4.2.3.1 General animal preparation
All surgical methods and animal handling are approved by the Institutional Animal Care and Use
Committee (IACUC). Male Sprague Dawley rats weighing between 175 – 199 g were used for
data collection and housed under standard conditions. Prior to surgery, animals were given adlibitum access to food and water. A pre-operative analgesic, butorphanol (0.5-2 mg/kg,
subcutaneous) or buprenorphine (0.05-0.1 mg/kg, subcutaneous), were administered immediately
prior to surgery and 4-6 doses thereafter for 48 hours post-operative. All surgical equipment was
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sterilized and the animals underwent standard aseptic surgical preparation. Immediately
following induction of anesthesia (isoflurane, oxygen delivered at 0.5 to 1.0 L/min, 1 to 4%), the
surgical site was shaved and scrubbed with Betadine and sterile alcohol pads.

Acute surgery followed similar general surgical procedures, but a ketamine/xylazine cocktail
with a 75 mg/kg ketamine and 5 mg/kg xylazine ratio was used as an alternative anesthetic to
ensure proper nerve function. The dosage was determined by weight. We note that due to
perceived limits to the effectiveness of this anesthetic for long periods of time, that only 90
minutes of blood collections (post LPS challenge) were collected versus the 120 minutes done
with the chronic animals.

4.2.3.2 Device implantation
With the rat in the prone position, we made incisions on the side or back of the rat to facilitate
the placement of the implantable device. A subcutaneous pocket was created and the device
inserted into the pocket, oriented, and then sutured in place. After moving the rat to the lateral
recumbent position, we created a midline incision on the neck and routed the electrodes
subcutaneously to the neck. Incisions made to implant the device were next sutured closed. With
the rat in the supine position we expanded the midline incision to start at the jaw line moving
caudally. We reflected the skin and soft tissue to expose the underlying sternohyoid and
sternocleidomastoid muscles, which sit atop the carotid sheath. Surgical retractors were carefully
placed to hold open the incision site. Using a blunt dissection technique, we gently separated the
soft and connective tissues until the trachea and carotid artery sheath could be seen. The cervical
vagus nerve sits adjacent and runs parallel to the carotid artery above the level of the carotid
bifurcation. We carefully dissected the connective tissues surrounding the vagus nerve exposing
the nerve. One or two cuff electrodes were then wrapped around the exposed vagus nerve (if two,
stimulation cuff rostral and recording cuff caudal to the omohyoid muscle) and cuffs were
secured shut with a suture or Kwik-Sil Silicone Elastomer (World Precision Instruments, Inc.;
Sarasota, FL), and any extra lead was curved into a strain relief loop and sutured to neighboring
muscle tissue or skin to minimize movement of the cuff electrode. We then sutured the incision
closed. During tethered procedures, no device was not implanted and electrodes were terminated
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into a headcap and cemented to the skull. In some cases, we routed additional leads
subcutaneously from the device to a transdermal connector port behind the shoulder blades to
guarantee power fidelity while collecting blood.

Similar surgical procedures were followed for acute LPS experiments with stimulation and
recording cuffs being placed around the cervical vagus nerve and then attached to an externally
placed Bionode for the duration of the experiment.

4.2.4

Fluorogold injection

Analysis of retrograde tracer transport of the vagal efferent fibers to the DMN has been shown to
be an effective means of verifying selective vagotomies of the five subdiaphragmatic vagal
branches in the GI tract. Each of the five branches has been shown to transport to distinct areas
of the DMN, with the left vagal branches (hepatic, accessory celiac, and ventral gastric)
accumulating in the left side of the DMN and the right branches (dorsal celiac and dorsal gastric)
to the right side of the DMN [120]. We used established methods of FG administration to verify
the physiological efficacy of the left and right vagal efferent fibers [120-122].

Approximately five days prior to blood collection, stimulation, and perfusion, we gave animals
an intraperitoneal injection of 1 mg/1 ml saline of FluoroGold (Fluorochrome, Inc.; Englewood,
CO) that labels cell bodies of intact efferent fibers in the DMN.

4.2.5

Catheter placement and blood collection

Blood samples were obtained to track circulating levels of inflammatory cytokines. We followed
procedures outlined in the NIH Guidelines for Survival Bleeding of Mice and Rats for blood
sampling. The amount of blood collected did not exceed the maximum allowed 10% of the
circulating blood volume. We surgically placed catheters in the rats ~24 hours prior to blood
collection following femoral cannulation procedures outlined in the Bioanalytical Systems, Inc.
Culex surgical manual [82] and then placed the rats into the Culex Automated In Vivo Sampling
System (Bioanalytical Systems, Inc.; West Lafayette, IN) [83] while connected to the Raturn
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caging system (Bioanalytical Systems, Inc.) [123]. We programmed the Culex system to
automatically collect ~200 L blood samples from each rat at predefined intervals of 30 minutes
over a three-hour timeframe as outlined in Figure 4.3.

The Culex was not used for acute LPS experiments. Instead, blood was obtained by punctured
leg vessels, and samples collected into K3 ETDA coated minivette tubes. Only four blood
collections were taken for acute animals at times of -30, 30, 60, and 90 minutes with respect to
LPS injections.

4.2.6

Testing procedures

4.2.6.1 LPS preparation/injection
LPS solution was prepared immediately prior to blood collections in the animals in a dose of 5
mg/kg. We measured LPS (Sigma-Aldrich, serotype O111:B4) into 1.5 ml Eppendorf tubes
using a Mettler Toledo AB54-S/FACT digital scale and added sterile saline (0.9% sodium
chloride) to the tube in a proportion of 0.2 ml saline / 1mg LPS. The solution was sonicated for
30+ minutes prior to usage. We administered LPS intravenously (chronic) or intraperitoneally
(acute) at the specified time during blood collection procedures, and before stimulation
treatments if applicable.

Figure 4.3 Time flow diagram outlines the process of blood collection on the last day of chronic
experiments. Time points are based with relation to the acute LPS injection of the animal.
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4.2.6.2 Stimulation
We performed all stimulations with balanced, bi-phasic, square wave pulses produced by either
our in-house implantable BioNode system that is described in previous work [119], or
equivalently by a National Instruments USB-6343 Multifunction Device (NI-DAQ; National
Instruments; Austin, TX) for select animals tethered with a headcap configuration. The recording
channel consisted of a differential two-stage filter/amplifier. The first stage was a low power
instrumentation amplifier (INA333; Texas Instrument; Dallas, TX) configured for a gain of 20
dB, and the second stage was an inverted operational amplifier (OPA313, Texas Instrument)
configuration designed for a gain of 40 dB and bandwidth from ~15 Hz - ~3 kHz. The total
record channel gain was 60 dB. The stimulation was produced by a common mode voltage
difference amplifier (LT6375; Linear Technology; Milpitas, CA) configured to act as a Howland
Current Pump, and controlled either by the on-chip microcontroller (nRF51822; Nordic
Semiconductor; Trondheim, Norway) paired with a digital-to-analog converter (DAC7551,
Texas Instrument) on the BioNode or the output of the NI-DAQ.

Our system has been shown to allow fully autonomous neural control (ANC) in rats by Ward et
al [42] in acute test environments, and has been used in other recent studies [124]. In our acute
experiments, we attempted ANC calibrations immediately after the first blood sample, and 30
min prior to LPS injection in the animal. During calibration, we used ANC to determine a
maximal activation profile for a Compound Nerve Action Potential (CNAP) response (B or C
fiber) to various stimulation profiles varied in amplitude and pulse duration. Due to the highly
variable environments experienced in our chronic tests however, we did not utilize the fully
autonomous functions for most of our chronic animals. Instead, we manually tested different
stimulation profiles in real-time to determine an optimal profile to induce a CNAP response. If
successful maximal nerve activation was detected, we ran stimulation for five minutes at 5 Hz at
the corresponding stimulation profile. If not, we utilized a pre-determined and default maximal
activation stimulation profile (1 mA amplitude, 1 millisecond pulse duration, 5 Hz) for the fiveminute stimulation. We utilized a stimulation frequency of 5 Hz which is in the range of normal
nerve traffic in the vagus nerve [125].
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4.2.6.3 Perfusion and brain tissue preparation
After the final blood collections, animals were deeply anesthetized with a lethal dose of
Ketamine/Xylazine followed by a transcardial perfusion with 300 ml of 0.9% saline at 40˚C,
followed by 400 ml of 4% paraformaldehyde at 4˚C. We then removed the medulla and
cryoprotected it overnight in 15% sucrose in 4% paraformaldehyde at 4˚C. Serial 40 m coronal
sections were taken with a cryostat between the level of the facial nucleus and the pyramids. We
collected sections onto gelatin-coated microscope slides, dehydrated and cleared them in alcohol
and xylene, and then placed the sections under a coverslip with DPX (Sigma-Aldrich, St. Louis,
MO).

4.2.7

Sample processing and analysis

4.2.7.1 Fluorogold imaging (of medulla)
FG images of the medulla were acquired using a LEICA DMRE microscope with a SPOT FLEX
camera controlled using SPOT Software (V5; Diagnostic Instruments, Sterling Heights, MI). We
did final post-production using Photoshop CS6 (Adobe Systems, San Jose, CA). Photoshop was
used to: (1) apply text and scale bars; (2) make minor adjustments to the color, brightness,
contrast, and sharpness of the images to match the appearance of the original material viewed
under the microscope; and (3) to organize the final layout of the figures.

4.2.7.2 Necropsy nerve extraction and imaging
Most necropsy analysis was done post perfusion, making it difficult to locate specific nerve
landmarks due to blending of tissue textures. Therefore, we visually evaluated some animals preperfusion to allow for improved observation and analysis.

We removed vagus nerve column (including carotid artery, superior cervical ganglia, and other
surrounding tissues) samples to be analyzed for Fluorogold tracer from the animal using blunt
dissection techniques, and placed them into a 4% paraformaldehyde solution.
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Samples for imaging with a fluorescent microscope were dissected and positioned on clean glass
slides to verify an optimal view. We then mounted them on gelatin coated (1.5% gelatin
solution) Corning micro slides under a Leica M205 FA Stereomicroscope with a UV ET filter
and illuminated them with a Prior Lumen 200 fluorescence illumination system. An uncoated
Corning micro slide was placed on top of the nerve, and the nerve was crushed onto the gelatin
coated slide by placing 4 lb weights on top of the slide for one hour. We then removed the
weights and the uncoated slide from the gelatin coated slide onto which the nerve had been
crushed, and let the slide dry overnight. The slides were then dehydrated in a 2-minute ascending
series of alcohols (70% EtOH, 95% EtOH, 100% EtOH x 2) and xylene (6 min x 2), and then
coverslipped with custom coverslips (Electron Microscopy Sciences).

Mosaic image z-stacks were collected with a Leica DFC310 FX camera connected to a Leica
DM5500 microscope (D filter and HCS PL Fluotar 10x/0.30 objective), using Surveyor software.
We used the mosaic image stacks to create an all-in-focus image using the Auto-Blend function
in Photoshop CC.

4.2.7.3 Blood sample processing
For cytokine analysis, fresh blood was collected in EDTA (K3EDTA at 1.75 mg/ml), centrifuged
at 2000x g for 10 min, and plasma extracted and either prepared immediately or aliquoted and
stored at -20˚C. We analyzed plasma samples using a LEGENDplex™ Rat Th Cytokine Panel
(13-plex) (Biolegend, San Diego, CA) in a V-bottom 96 well plate. This assay allowed
simultaneous analysis of 13 cytokines, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL17F, IL-22, GM-CSF, IFN- and TNF-, using a multiplexed fluorescent bead assay procedure
as described. A sandwich based immunoassay was performed on 96 well plates using bead sets
that had previously captured the analytes of interest. For each sample, we diluted plasma 4-fold
with an assay buffer before testing it. Rat plasma samples were then distributed appropriately in
duplicate on the plate and capture beads added to each well. Each analyte standard was added to
a standard well, followed by serial dilutions. This established a standard curve for each plate. We
incubated plates at room temperature for 2 hours while shaking at 500 rpm. We then washed the
plates twice by centrifugation. After washing, 25 l of biotinylated detection antibody was added
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to each well and the plates were sealed and placed on a plate shaker (500 rpm) in the dark for 60
minutes. All wells then received 25 l of the streptavidin with phycoerythrin (PE) and we
resealed and incubated the plates at room temperature in the dark on a plate shaker (500 rpm) for
30 minutes. Plates were washed again as previously, with addition of 200 l wash buffer and
centrifuged. 150 l of wash buffer was then added to each well and beads resuspended by
trituration. We then read the plates on the flow cytometer.

4.2.7.4 Flow cytometry
We read plates on one of two instruments: a CytoFlex 13 color cytometer (Beckman Coulter,
Miami, Florida) or an Attune 14 color cytometer (Thermo Fisher, Eugene, Oregon).
Allophycocyanin (APC) content was used to distinguish different capture beads. Setup for each
instrument was similar and required calibration using instrument calibration beads to ensure the
instruments were calibrated properly. The 96 well plates were automatically read by either flow
cytometer and output files generated were standard FCS files. We set the instruments to collect
4000 beads per well, ensuring approximately 250-350 beads of each cytokine per well. Prior to
running plates, we ran set-up beads included in the kit on each instrument to ensure the detection
probe (PE) was properly calibrated and the bead probe (APC) was set at previously determined
voltages to ensure the best bead separation.

4.2.7.5 Blood data extraction
Upon completion of each plate, FCS files were analyzed by MPLEX software (Doclu LLC, West
Lafayette, In). The software opened the entire 96 listmode files, and upon identification of the
bead signal (APC) and the detection signal (PE), it collected a 2-parameter plot with APC on the
x-axis and forward scatter on the y-axis. In this manner, the 13 populations of beads were
resolved. For Legendplex bead assays, two bead sizes were discriminated by forward or side
scatter and by bead intensity on the APC detection parameter. Each cytokine was then identified
by its preset bead size and dye intensity level. There were six intensity levels for the smaller
beads (A beads) and seven intensity levels for the larger (B beads). We identified the standard
curves by their location on the 96 well plates and identified duplicates. The MPLEX software
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was preset for a Legendplex assay profile which associated either A beads or B beads with the
appropriate cytokine. An automated clustering algorithm was used to fit the bead populations to
the predesignated beads, and the standard curves for all 13 cytokines were automatically
calculated, followed by production of a CSV output file with all well data.

4.2.7.6 Blood data analysis
Raw concentration signals from cytokines attached to functional beads were compared to
calibration curves calculated for each plate of samples run, and used to produce cytokine
concentration data for statistical analysis and figures. We averaged two replicates per sample
before analysis.

Multivariate analysis of variance (MANOVA) was first performed on raw sets of all 13
measured cytokine concentrations collected from plasma samples. Post-hoc ANOVA was also
performed on raw sets of each cytokine concentration. To compensate for significant noise in the
cytokine calibration curves (at low concentration levels), we converted raw data into fractions of
the total cytokine signal for each sample. To then allow for Gaussian analysis to be performed,
we computed angular arcsine transformations with equation (3.1) and corresponding Cohen’s h
effect sizes with equation (3.2):

 2 arcsin p

h

1

2

(3.1)

(3.2)

Where p is a given proportion and h is a resulting Cohen’s h effect size. ANOVA was again
performed on the angular transformations. P < 0.05 was considered statistically significant, but
we did note other scientifically significant trends that did not meet this threshold.
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4.2.7.7 Histology
To further verify the integrity of the chronically implanted vagus nerve, cuffed nerve samples
from eight rats were fixed and then embedded. We used paraffin molds for silicone cuffs with no
metal electrode and Poly-Methyl Methacrylate (PMMA) resin molds for cuffs with wire
electrodes to prevent tearing of enclosed nerves. Specific details on these processes can be found
in supplemental materials of the publication.

4.2.8

Gastric MRI scanning

Surgical procedures for implanting stimulation cuffs in rats used for gastric emptying testing are
in line with those outlined previously for headcaps, with the exception that we used only a single
stimulation cuff and no recording cuff, and we limited headcaps to only two pins to reduce
potential imaging artifact. All dietary training, scanning procedures, and image processing and
analysis techniques mirrored those methods established by Lu et al [126].

Stimulation was performed using our Bionode system utilizing our standard cuffs as described
earlier. We stimulated throughout the period of scanning, using balanced bi-phasic pulses of 600
A, 360 s, at 10 Hz. The parameters were determined by earlier collaborative testing to induce
the largest electromyography (EMG) response on the stomach wall. Stimulation was applied
continuously throughout the 4-hour test period with trains of 20 seconds on followed by 40
seconds off. During stimulation scans, we noted that some rats showed severe signs of apnea and
bradypnea resembling what was explored by Zaaimi et al [127]. These phenomena were
commonly accompanied by a corresponding arrest in observed stomach motility during
stimulation. It was not our goal here to explore this effect in detail, therefore, we excluded
animals that exhibited this trait from our data.
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Results
4.3.1

Fluorogold transport

Early in chronic VNS testing, we recognized an issue with efferent FG transport in the left
(cuffed) vagus nerves of the animals. 36 of the 44 cuffed animals showed complete suppression
of FG transport to the left side of the DMN in medulla samples, indicating a complete cervical
vagotomy of the left vagal nerve, despite the animals receiving no surgical vagotomy. In
addition, all animals demonstrated expected FG transport in the uncuffed right vagus nerve.
Based on visual analysis during necropsy, it was first considered that the cause was likely due to
surgical techniques, and mechanical stresses and migration of our cuff electrodes on the nerves.

A visual inspection of the left cervical vagus site was performed on 32 rats during necropsy.
Early inspections revealed moderate to severe cuff migration and manipulation of the nerve in
several animals. We hypothesized that these issues were causing the lack of FG transport,
prompting multiple iterations of surgical technique and materials improvements. Such included:
added lead lengths and strain relief loops, increased flexibility of the lead materials, altered lead
anchoring techniques and locations, changed wire electrode configurations within the cuffs
(including inert cuffs with no metal electrode), implanted single stimulation cuffs (versus a
second recording cuff as was standard for our study), employed multiple different surgeons, and
tried multiple types of cuffs (as presented in our methods).

These changes produced significant visual decreases in mechanical strain to the nerve and all
later subjects showed good integrity of cuffs and leads in the surgical site (shown in Figure 4.4).
Despite the adjustments and improved cuff/nerve interface integrity, FG transport results did not
improve (Figure 4.5). We, therefore, hypothesized that the cuffing of the nerve itself had a
dominant effect on nerve physiology regardless of other external stresses.
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Figure 4.4 Pre-perfusion visual inspection of two animals, both showing cuffs in correct location
with vagus nerve intact. (a) From a rat that demonstrated complete suppression of Fluorogold
transport (eRx71), while (b) demonstrated a limited but present transport (eRx103).

Figure 4.5 Fluorescent images of medulla samples from multiple cuffing variations of rats. (a)
Cuffs placed adjacent to left vagus nerve, but not enclosing it (eRx110), produced bright efferent
fiber FG transport illumination on both left and right sides of DMN. (b) Cuffed with standard
record and stimulation cuffs by visiting surgeon (eRx116), showing bright FG illumination on
the right side of the DNM from uncuffed right vagus nerve, but limited efferent transport from
the left vagus on the left side of the DMN. (c-f) All rat medulla samples showed near-complete
suppression of efferent transport on the left side. (c) Cuffed with single industry-made (CorTec;
Freiburg, Germany) tunnel electrode with 0.6mm inner diameter (eRx118). (d) Cuffed with a
single standard stimulation cuff (eRx113). (e) Cuffed with sham record and stimulation cuffs
containing no metal electrodes (eRx132). (f) Cuffed with standard record and stimulation cuffs,
but not stimulated (eRx75). Scale bars = 250 microns.
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To further explore the physiological phenomena, we extracted the right and left (still cuffed)
vagus nerve columns from 18 rats during post perfusion necropsy. These nerve samples were
observed under a fluorescence scope for signs of FG in the nerves and nodose ganglia and were
then either mounted onto a slide to be photographed or fixed for basic Hematoxylin and Eosin
(H&E) histology (n = 8). Samples that were extracted with both left and right nodose ganglia still
intact (n = 7) were analyzed using a fluorescence microscope (details shown in Figure 4.6).
Observations showed that the ganglia of the cuffed left vagus nerves and the uncuffed right
vagus nerves both contained FG illuminated cells, indicating an active FG transport in the
afferent nerve fibers, despite a severe or complete suppression of efferent fibers to the medulla as
demonstrated in Figure 4.7.

Figure 4.6 Representative fluorescence images and image mosaics of a single rat (eRx162). (a)
medulla image showing clear efferent fiber FG transport on the right side of the dorsal motor
nucleus, and significant suppression of transport on the left side. (b1) cervical column dissected
cranial to stimulation cuff on left vagus nerve, with enhanced image of nodose ganglia (b2)
showing FG illumination. (c1) cervical column of right vagus nerve and surrounding tissue, with
enhanced image of nodose ganglia (c2) showing FG illumination. Vagus nodose ganglia from
each side show similar size, shape, location, and textural illumination, indicating similar active
afferent fiber transport in both despite a suppression of efferent fiber transport in the cuffed left
vagus.
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It is important to note that FG brightness varied between animals as is common due to biological,
surgical, and tissue extraction and processing variances. Despite this inconsistency, the trends
noted above were present in all samples and there was no consistent difference observed in
density of FG illumination between nodose samples from cuffed left vagus versus un-cuffed
right vagus nerves.

Figure 4.7 Comparative fluorescence images of two separate rats demonstrating healthy FG
transport through efferent fibers to the DMN and afferent fibers to the nodose in uncuffed right
vagus nerves, but only through afferent fibers in cuffed left vagus nerves. (a) medulla image
(from eRx159) showing clear efferent fiber FG illumination on the right side of the dorsal motor
nucleus, and severe suppression of FG on the left side. (b & c) corresponding fluorescence
nodose images of the cuffed left and uncuffed right (respectively) vagus nerves (from eRx159),
with enhanced images (red boxes) highlighting FG illuminated cells on both sides. (d) medulla
image (from eRx163) also showing strong efferent fiber FG illumination on the right side of the
dorsal motor nucleus, and complete suppression of FG on the left side. (e & f) corresponding
fluorescence nodose images of the cuffed left and uncuffed right (respectively) vagus nerves
(from eRx163), with enhanced images highlighting FG illuminated cells on both sides. Red
dashed lines separate the left vagal effects from right vagal effects. Scale bars = 250 microns.
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4.3.2

Compound nerve action potential (CNAP) detection

A complex, but telling, measure to test the integrity of a peripheral nerve during VNS is to
record the responsive action potentials of the nerve to a prior electrical stimulation. CNAP
recordings can provide a direct indication of the variety and extent of nerve fibers being
activated by a given stimulation.

Recording CNAP responses in real time, however, is challenging due to multiple factors
including noise in the stimulation or recording channels, and overlap of artifact in the signal due
to the electrical stimulation and laryngeal [115, 128] and other muscle artifacts. This difficulty is
compounded by factors related to the chronic test environment. As mentioned, most reviewed
studies used pre-determined stimulation parameters and concentrated only on analyzing the
resulting biological data [96, 111, 112], or recorded the signal during testing and post-processed
the data afterwards to determine the fiber response [16, 115].

In our study, we employed two nerve cuffs (one stimulation and one recording) that allowed
simultaneous stimulation and recording in a closed-loop system [42]. Testing fiber responses
resulting from stimulation is paramount due to frequent changes in the biology of an animal
during recovery from implantation and due to foreign body response to the nerve cuffs.
Literature has shown that impedances and the resulting nerve response to electrical stimulation
can fluctuate for weeks and even months before stabilizing [129]. This was confirmed in our own
testing by fluctuations in CNAP responses seen when tested on multiple days during recovery as
seen in Figure 4.8. It is important to note that stimulation parameters shown in Figure 4.8 are
significantly lower than those utilized during functional stimulation treatments. Functional
stimulation in our LPS experiments utilized amplitudes of 1 mA or higher that were more likely
to have recruited significant C-fiber activations.

For this animal we also saw larger potentials on day 36 (with rat freely moving) than on days 23
and 27 (rat anesthetized with isoflurane). Differences could be contributed in part to effects of
being anesthetized and to peripheral stimulation effects such as laryngeal muscle and movement
artifacts. Due to practical restraints such as limited surgical space near the vagus, we did not
perform any formal testing for such artifacts in this study.
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We did not endeavor here to make conclusions based on the labeled fiber types of CNAP
responses presented in Figure 4.8, but strictly to demonstrate that diverse CNAP responses can
still be recorded over time in absence of healthy FG transport to the medulla. Using our
methodology, we successfully detected varied CNAP responses in 13 of our stimulated animals
prior to LPS administration and stimulation treatment. Despite this sign of nerve functionality in
those animals, only two of the rats showing CNAP response showed indication of efferent FG
transport, both attenuated, through the nerve. The resulting CNAPs could have strictly been the
result of remaining healthy afferent fibers, or could have included remaining intact efferent
fibers. We believe this to be a topic worthy of further exploration.

Figure 4.8 Representative CNAP responses of the left cervical vagus nerve in a rat subject
(eRx144) show variance in fiber responses to similar stimulation over multiple days after three
weeks of recovery. Similar CNAP responses were seen in multiple animals despite having
suppressed FG transport. Fiber labels were calculated using conduction velocities based on
measured distance between stimulation and recording cuff at time of chronic implantation. No
measurements were made during necropsy to verify original cuff distances.
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4.3.3

Hematoxylin and eosin (H&E) histology

Samples were sectioned either longitudinally to analyze the length of the nerve (Figure 4.9 a-d)
or transversely across the diameter of the cuff to analyze the cross section of the nerve (Figure
4.9 e-f). Industry standard H&E staining was performed on all samples using standard protocols.
We did not apply myelination specific stains to the nerve samples in this study.

Figure 4.9 Representative photomicrographs of cuffed vagus nerves stained with hematoxylin
and eosin (HE). Images (a-d) are from the same nerve (eRx143). Images (e-f) are of a separate
nerve (eRx132). (a) Longitudinally sectioned nerve encompassed by a stimulation cuff, (b)
higher magnification of (a). (c) Longitudinally sectioned nerve encompassed by a caudally
positioned recording cuff, (d) higher magnification of (c). (e) Example of a nerve cuffed with an
inert cuff with no metal electrodes sectioned in the transverse plane, (f) higher magnification of
(e). Scale bars = 1000 microns (a, c, & e) or 100 microns (b, d, & f).
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Cuffed vagus nerves were histologically normal. The cuff was surrounded by fibrous connective
tissue, epithelioid macrophages, and multinucleated giant cells; consistent with a granulomatous
foreign body inflammatory reaction. Similar inflammatory cells were identified surrounding the
epineurium (connective tissue surrounding the nerves), but not infiltrating the nerve. Such
findings suggest a perineuritis, or inflammation surrounding the nerve, but not penetrating it.
Such inflammation is commonly analyzed during cuff design and well documented in literature
[129-131].

4.3.4

Cytokine measurement from blood (plasma) samples

We used plasma cytokine concentrations to analyze the effects of VNS on modulation of
inflammatory cytokine levels in both chronic and acute environments. Only the proinflammatory cytokines IL-6 and TNF-, and anti-inflammatory cytokine IL-10 were
significantly elevated over time after injection of LPS, consistent with prior literature [66, 132,
133].

Due to a high level of variability in cytokine concentrations from sample to sample, and noise in
the cytokine calibration curves in our raw data, we performed statistical analyses using angular
transformations of proportional compositions of each cytokine compared to the overall content in
the samples and utilized Cohen’s h analysis for effect sizes. Samples collected at 90 minutes
post-LPS injection demonstrated important distinctions between effects of stimulation with
chronically and acutely cuffed vagus nerves (Figure 4.10).

Pro-inflammatory TNF- levels in acutely cuffed rats displayed higher proportions than in
chronically cuffed animals, and acutely stimulated animals showed distinctly lower proportions
than the acute controls (h = 0.44). This indicated a modulatory effect of stimulation on acutely
cuffed subjects due to VNS. Chronically cuffed rats, however, showed virtually no impact on
TNF- due to stimulation.

The second pro-inflammatory cytokine, IL-6, showed much higher proportions in chronically
cuffed animals at 90-minutes post-LPS challenge, than in their acute counterparts (h > 0.8). Both
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chronic and acute samples showed slightly lower proportions in stimulated animals versus
controls, but neither were significant.

Anti-inflammatory IL-10 cytokine proportions again revealed no difference between stimulation
and control groups in chronically cuffed rats. It did, however, show a small but statistically
significant increase (h = 0.22) in proportions due to stimulation in acutely cuffed animals over
the acute controls.

Figure 4.10 Plot shows compositional analysis with angular (arcsin) transformations of
proportional make-up in specific cytokine levels at 90 minutes post-LPS injection. Acute
subjects showed a decrease in TNF- proportion (h > 0.4) and a small (h < 0.25) but significant
increase in IL-10 proportion due to stimulation, indicating strong inflammatory modulation due
to stimulation. Chronic subjects showed no significant modulation in proportion levels due to
stimulation in any of the three cytokines, consistent with compromised vagus function after
chronic cervical cuffing. Error bars, s.e.m. *P < 0.05.

A decrease in TNF- proportion and increase in IL-10 in our acutely cuffed rats were both
convincing indications of inflammatory modulation using our Bionode system, consistent with
similar work by multiple groups mentioned earlier presenting repeatable cytokine modulation in
acute environments. Chronically cuffing the vagus nerve resulted in distinctly different cytokine
proportion trends from those of our established acute baselines. Importantly, it appeared to stunt
all ability to modulate plasma cytokine levels with stimulation. Having already established a
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critical physiological lapse in the vagus nerve’s ability to transport FG in a rat when cuffed, we
hypothesized, accordingly, that chronic vagal nerve cuffing also compromises the vagus nerve’s
ability to modulate inflammation.

4.3.5

Gastric emptying

Note: This section has been updated to reflect data from a more recent publication [134].
Gastric functions have been shown to be primarily modulated with vagal sensory and motor
signals as was investigated by Travagli et al [135], and alterations in those vagal signals can
result in altered gastric functions [136]. Accordingly, gastric physiology such as emptying rates
is a good measure to determine an altered state of vagal nerve operation. Utilizing MRI to
determine gastric functions in humans has been well documented [137-139], and a similar
approach was taken in collaborative research efforts to test gastric functions in an acute rat
model [126, 134].

To further verify our chronic cuffing hypothesis, six rats were outfitted with a single stimulation
cuff on the left vagus nerve and recovered. These rats were scanned using MRI to determine
stomach emptying rates first as non-stimulated controls, and a second time after a recovery and
re-training period, with stimulation. Those animals that produced reliable data according to our
methods were used for comparison (Figure 4.11).

Control scans with no stimulation applied revealed a similar overall emptying effect to those that
received VNS. Both groups resulted in a stomach volume reduction of ~25% from their starting
volumes after 225 minutes. This is also in line with an acute control group that showed an
average volume decrease of 25% over the same time period [134]. While the stimulation sample
size used is small due to discarded samplings, it nevertheless showed a negligible overall
variation between stimulation and control. The chronic stimulation samples do show an
increased emptying rate from the 30 – 90-minute time points which could be a result of
remaining intact efferent nerve fibers given that neither animal used for this data set showed a
complete suppression of efferent FG transport. The increased rate however slows after the 90minute point. This lacking overall effect of stimulation on stomach emptying rate of chronically
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cuffed rats contrasted with significant and continued increases in emptying rates seen between
acutely cuffed and stimulated rats that showed ~41% stomach volume reductions in the same
time period [134], and indicated a compromise of vagus nerve function likely due to chronic
cuffing.

In addition, we noted a delayed emptying period, with a slight increase in stomach volume, in
half of our chronic controls from the 30 – 75-minute time points. This increase is also a strong
indicator of an altered gastric function due to the chronic cuffing of the left vagus nerve given
that it was not observed in acute controls [126, 134].

Figure 4.11 Gastric (stomach) emptying rates of rats with chronically implanted vagus cuff
electrodes versus acute sample sets. Overall emptying with stimulation (solid lines) in a
chronically implanted animal is indistinguishable from control (dashed line) after four hours,
unlike acute stimulation, consistent with compromised vagus function after chronic cervical
cuffing. Acute stim and control sets come from collaborative publication [134]. Error bars, s.e.m.
*P < 0.05 between chronic and acute stimulation sets.

Discussion
The prominent finding in our study is that chronic cuffing of the vagus nerve in a rat creates an
unreliable model for VNS studies. To date, cuffing the nerve caused still unexplored
physiological effects, that suppressed efferent retrograde tracer transport mechanisms, affected
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the vagal anti-inflammatory response to an LPS challenge, and degraded the response of gastric
emptying rates to VNS. These adverse effects persisted despite a healthy outward appearance
through visual and histological observation, and a full functionality of the nerve to create a
CNAP response in the caudal direction from the stimulation cuff.

A shortcoming in this study was our decision not to implement a myelin specific stain such as
Luxol fast blue and utilize electron microscopy to monitor potential demyelination effects that
would be undetectable with basic H&E staining. It is therefore possible that while we did not
observe any gross nerve alteration, local demyelination could have been present that would help
explain attenuated effects of VNS in our study. Still, even observed morphological changes
cannot always be linked directly to functional deficits with respect to electrical stimulation [131].

It followed that cuffing the nerve produced inflammatory foreign body response around the
material of the cuff, creating a fibrotic layer of inflammatory cells between the nerve and inner
cuff. Thil et al [130] showed that this process most commonly resulted in a stabilized interface
after about 30 days, but also presented evidence that this foreign body response can penetrate
into the epineurium, and that even small manipulations and deformations can cause effects in the
nerve anatomy. This is supported by Tyler et al [140] whose flat interface nerve electrodes
showed that larger manipulations of the nerve caused increased breakdowns and demyelination
of nerve tissue.

Furthermore, Rydevic et al [141] demonstrated that applied pressures as small as 20 mmHg
could introduce interference with intraneural blood flow to peripheral nerves. Theoretical
pressure calculations of a split-ring cuff such as ours were presented by Naples et al [142] and
experimentally verified by Cuoco et al [143]. Using their computations and accounting for a full
133% nerve swelling effect, our cuffs could be utilized on a nerve diameter greater than 600 m
(almost double the diameter of some cervical vagus nerves we measured) and not pass the 20
mmHg pressure threshold. We accordingly believe our cuffs had sufficient diameter to cuff the
cervical vagus nerve in a rat safely.
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Even a loosely fitting cuff though, can exert minor manipulations to the outer edges of the
enclosed nerve tissue. Evidence from a study by Evans et al [144] suggested that motor fibers of
the vagus nerve of a rabbit were commonly found grouped toward the edges of the nerve.
Following this logic, it is possible that the efferent fibers in the vagus nerve of a rat would be
similarly located in the lateral part of the nerve and be most susceptible to cuffing manipulations
and related physiological effects. There is very little literature to support this claim in rats,
however.

The possibility remains that efferent nerve fiber functionality may be severely attenuated while
afferent fibers remain intact. Indeed, Phillips et al [122, 145], and more recently, Payne et al
[146], reported on motor axons’ inability to regenerate after nerve injury, while sensory axons
did. While still speculative, our results support this hypothesis by noting the illumination of FG
in the nodose ganglia of cuffed nerves while FG transport to the medulla is completely
suppressed. If this is the case, studies concentrating on afferent effects of VNS may be minimally
impaired by this cuffing effect. Moreover, if vagal efferent fibers are not working correctly, but
afferent fibers are, VNS could negatively affect para-sympathetic systems, such as the
inflammatory reflex, by sending afferent signals to the brain to increase inflammation, while
suppressing the anti-inflammatory efferent signal. Suppression of the desired anti-inflammatory
signal helps explain the lack of VNS effects in our study.

Concerning electrophysiological nerve functionality, the encapsulation process can take weeks or
months to stabilize, making the cuff/nerve interface variable during the healing process.
Sahyouni et al [129] explored short and long term electrical threshold changes that all eventually
stabilized for stimulation purposes. Our results reflected this as the CNAP response showed to be
variable during our regular four-week recovery period. Therefore, it was important to verify that
a given stimulation profile was inducing a desired CNAP response before utilizing such profile
to induce a biological response. A legitimate argument can be made that using a variable set of
pre-stimulations, such as we did, introduced an unknown variable into our methodology.
However, a number of acute studies have used pre-stimulation as a standard procedure [5, 1820], and an initial study was done on the potential benefits of a pre-stimulation period [15],
finding it not to have a noticeable effect either way on experimental results. The topic of pre-
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stimulation during VNS application is worthy of further investigation in both acute and chronic
settings.

No correlation, however, was found between different profiles of electrical stimulation through
our cuffs with varying CNAP responses, and attenuation of FG transport in the nerve. We
surmise that electrophysiological signals, while potentially affected by surgical nerve cuffing, are
not alone, a conclusive indicator of potential neural damage as CNAP response can still be
present in the absence of efferent FG transport.

In addition to the lack of retrograde transport integrity, we verified differences between
chronically and acutely cuffed nerves in two separate measures of vagal physiological control.
While noisy and variable in raw concentration levels, we nevertheless noted significant
variations in plasma cytokine responses between acutely and chronically cuffed data samples
when presented as percentages of an overall cytokine make-up: arguably a more robust method
of analysis [103]. We discovered a complete lack of cytokine modulation through VNS when
chronic cuffing was applied. Meanwhile, the influence of stimulation on gastric emptying was
also revealed to be inconsequential when chronic cuffing was utilized. We did not endeavor to
interpret specific physiological effects of either acute portion of these tests here, as they will be
thoroughly scrutinized in separate and ongoing studies for future publication. Our primary
finding was an established disparity between acutely and chronically cuffed vagus nerves, and
evidence of compromised vagus nerve functionality when chronically cuffed.

An analysis of notable distinctions in the reviewed chronic VNS literature allows us to discuss
potential pros and cons of prior studies. Nearly half of the reviewed studies utilized industrymade helical electrodes (Cyberonics). This helical design has shown to be mechanically
advantageous in reducing mechanical stresses directly to the nerve in human subjects [147]. In
rat subjects, the implantation involved wrapping the electrodes around the entire carotid sheath
rather than the nerve being dissected away from the carotid artery before being independently
cuffed [17, 95, 105-107, 113]. Anchoring to the artery conceivably allowed more support for the
cuff and significantly reduced the mechanical manipulation to the nerve itself, but also likely
resulted in less surface contact of the electrode with the nerve and, expectedly, a less-focused
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stimulation to the nerve. It is unlikely that such an arrangement would be sufficient for studies
wishing to selectively stimulate specific fiber types and accurately record CNAP responses in a
closed-loop arrangement. It would be pertinent to explore the effect this cuffing strategy might
have on retrograde tracer transport.

A second noteworthy difference in reviewed publications was in the method and length of
stimulation employed. Most studies utilized a chronic stimulation strategy that stimulated the
nerve for continuous stretches throughout days, weeks, and even months which is inconsistent
with our singular five-minute stimulation in response to an acute LPS injection. It is possible that
effects of chronic stimulation can overcome inhibition of vagal efferent fibers over the course of
time with repeated application, working through separate secondary para-sympathetic pathways.
It is also feasible that over the course of time parts of the nerve interface did heal and allow some
function of the vagal efferent fibers [146, 148, 149]. This, however, is not supported by our
results that showed no improvement of FG transport over 13-71 day recovery periods.

In summary, despite the body of previously performed studies utilizing chronic nerve cuffing for
VNS trials, we believe we are the first to employ our novel combination of integrity checks of
the nerve. To our knowledge, there was only one previous chronic VNS study that centered on
inflammatory effects in the gastric region of rats [95]. While their results are compelling, the
significance of cytokine modulation they reported is in contrast with our findings. Variations in
cuff designs, surgical techniques, or stimulation strategies they utilized could account for this,
but without further study on the integrity of nerves prepared with theirs’ and others’ methods, we
can only speculate. We have, however, presented evidence of physiological degradation of vagus
nerve functionality when utilizing our methods of chronic cuffing for VNS therapy in rats in the
form of suppressed efferent FG transport, and altered effects on inflammatory cytokine
modulation and gastric emptying. To confidently and reliably continue advancement in the
science of chronic VNS, such effects should be seriously considered and further investigated by
the VNS community as a whole.
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Chronic Cuffing of Anterior Gastric Subdiaphragmatic Nerve Branch
4.5.1

Protocols

In addition to the chronic cuffing experiments outlined above, we also performed a small subset
of seven rats with chronically cuffed anterior gastric nerve branches. To do this, we followed
similar surgical protocols to those in Aims 2 and 3. The surgical cuff placement was like that in
Aim 2, but done chronically, in a sterile surgical setup, and the cuffs were anchored as in Aim 3.
The cuffs were similar to those outlined in Aim 2 but were attached to a transdermal connector
port behind the shoulder blades as described above in Aim 3 surgical methods.

Each rat recovered for ~13 days after implantation before LPS administration, stimulation, blood
collections, and perfusions. We followed all protocols for terminal stimulation experiments done
in Aim 2, as the rats were knocked out with isoflurane and anesthetized during the blood
collection period with a ketamine/xylazine cocktail. The rats received FG injections as done in
the chronic cervical experiments ~5 days before the terminal stimulation experiment.

4.5.2

Results and analysis

FG images of the perfused medulla samples showed a similar pattern of efferent fiber damage to
those of chronic cervical cuffing experiments. In this case, the damage was more selective and
tended to be isolated to the fibers related to the anterior gastric nerve branch as shown in Figure
4.12. We can see that the inward section of cells normally illuminated by efferent transport of the
anterior gastric nerve fibers has been severely depressed. Meanwhile, the outer section of cells
representing the uncuffed accessory celiac efferent fibers remain bright. There remains a small
number of illuminated cells in the areas populated by the anterior gastric nerve. These cells could
be the result of either a few unaffected efferent gastric fibers, or could be strictly due to uncuffed
hepatic efferent fibers as they have been shown to transport into that area of the medulla as well
[120]. Analysis of the nodose of these animals showed no noticeable difference between FG
illumination of the left and right vagus nerves (not shown), complementary to those seen in the
cervical study.
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Figure 4.12 Fluorescent images of medulla samples from multiple rats with chronically cuffed
anterior gastric branches of the left cervical vagus nerve. All four images show severely or
completely suppressed gastric efferent FG transport to the medulla (inside red dashed ovals),
while strong transport remains from accessory celiac efferent fibers (inside solid yellow ovals).
Scale bars = 250 microns.

In addition to analyzing the FG images, we tested concentrations of serum cytokines as was done
in Aims 2 and 3. When comparing the resulting TNF- levels in the chronically cuffed rats
versus those of the acute subgroups from Aim 2, we saw that the chronically cuffed, and
presumably damaged, efferent fiber animals had an increased rise in cytokine levels 120 - 150
minutes after stimulation similar to that of the acute animals that received an anterior gastric
branch efferent vagotomy. This can be seen in Figure 4.13. While the results are still quite
variable with deviations outside of the standard 95% confidence interval, the pattern is further
evidence to match our conclusions from Aim 3.

We therefore have hypothesized that chronic cuffing of the subdiaphragmatic vagus branches has
the same damaging effect as we saw when chronically cuffing the cervical vagus nerve.
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Figure 4.13 Average serum TNF- levels of anterior gastric stimulation subsets performed
acutely versus a chronically cuffed subset. Curves have been shifted to have matching starting
points similar to Aim 2, but without curve interpolations. Error bars, s.e.m.

Summary/Impact
As outlined in the discussion section, this study advanced our knowledge of chronic nerve
cuffing by presenting compelling evidence of previously unknown nerve damage. The lack of
FG transport and attenuated physiological effects of the chronic nerve cuff implantations are a
new discovery. It is very possible that if a similar analysis was done on other previous chronic
nerve cuffing studies in rodents, or even larger animals, that similar results would be seen, and
could call into question previously established hypotheses.

The issue of underlying and previously undetected damage by chronic electrodes has also been
shown by Goss-Varley et al [150] in a study of intracortical microelectrode implantation. Along
with our results presented here, functional deficits attributable to the implant itself are shown to
be present. This is a potentially serious issue as we progress towards further clinical use of
implanted electrode devices and deserves more attention and dedicated study by the implantable
technologies community.
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5. FUTURE WORK: INITIAL STUDIES

Motivation
Given the evidence of difficulty in effective chronic cuffing of rats, alternative methods need to
be considered for continued animal research and clinical applications. Small animal models are
limited in many respects as test subjects due to size and physiological differences between them
and an actual human model. Therefore, we must think outside of the box to find replacement
methods and models that will effectively aid in research aims.

As a lab, CID has already thought about some alternate methods, and has done initial work on
them that show promise for continued use going forward. I have outlined a few of them in this
section that I either designed or supported in my time here.

Initial VNS Study in Pigs
Aim 3 demonstrated an unintended and previously undetected issue with chronically cuffing the
vagus nerve in a rat model. Many factors could contribute to this, but one major issue is
undoubtedly the size of the model. It is not hard to hypothesize that the sheer size of the cuffs in
relation to the nerves being cuffed create some variety of physical damage. The issue is that
while researchers are continuously improving materials for better biocompatibility and smaller
size, we are likely not yet to a place where we can effectively and safely cuff these small nerves
without a high risk of some damage.

However, humans have been implanted with vagus stimulation cuffs for years now, and while
there are inherent side-effects and the potential for undetected damage remains, it would seem
that a larger nerve is better suiting to withstand the rigors of chronic cuffing.

We therefore decided that a larger animal model, in our case a pig would provide a better means
of chronic testing of VNS. Literature review of the topic revealed that a good number of studies
have looked at either effects of LPS administration and cytokine responses in pigs [151-155] or
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VNS in pigs for multiple purposes [156-161], but to the best of my knowledge, no group had
previously used LPS and VNS in a pig model to look at the inflammatory cytokine effects of the
gastric region. Given the background literature, it made sense to progress forward with an initial
study to explore inflammatory cytokine effects of chronic VNS in a pig model.

5.2.1

Methods

5.2.1.1 Device and materials
To successfully accomplish a chronic VNS study in a pig model, a significant effort to make
multiple changes to the Bionode device, its packaging, and the cuff electrodes was required. A
brief overview of the changes made are outlined here.

5.2.1.1.1 Pig stimulation and recording cuffs
Stimulation and recording cuffs were significantly increased in size. By measuring actual
cervical vagus nerves from pig subjects, we determined a cuff of ~3 mm inner diameter was
required for our planned testing on a 30 kg pig. This is beneficial as this is also a common size
for human VNS cuffs (http://eu.cyberonics.com/en/vns-therapy-for-epilepsy/healthcareprofessionals/vns-therapy/about-products). Given the larger size of the cuff, we determined that a
horizontally threaded design such as that used in the rat cuffs would be the best option. It
allowed a pattern of PtIr wire that could encompass most of the inner circumference of the cuff
while also keeping it tightly threaded to the cuff material to prevent loose wires, and it still
allowed the cuff to be flexible and durable during implantation. Horizonal thread loops were ~1
mm in length (20 – 40 loops per cuff electrode), and the threading loops were placed ~1 cm apart
from each other (center to center). The outer wire loops were covered with fast curing silicon
adhesive (Med2-4213; NuSil; Carpinteria, CA) to isolate them and prevent shunting of current
outside of the cuffs. Cuffs used for chronic pig implantation can be seen in Figure 5.1.

I tested new cuff materials such as polyurethane but found them to be both too rigid, and
susceptible to deformation when curing silicone adhesive to the cuff during fabrication.
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Tying the cuffs shut with suture was discouraged by our surgeon so I instead left a length of
tubing on each end of the cuff and cut a spiral shape into it that would allow the edges of the cuff
to be wrapped around the nerve for added stability. This is similar to how human VNS cuffs are
designed and implanted [14].

Figure 5.1 Stimulation and recording cuffs for cervical vagus nerve of pig. Cuffs each featured
two electrodes made of horizontally threaded PtIr wire surrounding the inner cuff circumference.
Edges of cuffs were cut in a spiral to improve stability on the vagus nerve.
Electrochemical performance of our pig cuffs proved to be excellent. We tested multiple cuffs
for implantation, and comparatively tested a human Cyberonics VNS cuff. The Cyberonics cuff
produced an EIS impedance measure of ~400 Ω at 1 kHz while our pig cuffs showed impedances
of 200 - 300 Ω in most cases.

5.2.1.1.2 Stimulator changes
Upon multiple literature reviews, we determined that a stimulation amplitude of 1 mA (the max
that our default stimulator implementation would supply) may not be enough to effectively
stimulate at needed levels for a larger animal. The stimulator limits of human VNS devices can
reach 3.5 mA in charge [25]. I therefore decided to use this as our benchmark.

The change was fairly simple. We needed to replace the reference resistance of the HCS on the
Bionode from 800 Ω to 250 Ω, which changed our max current to 3.6 V. We were, of course,
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still limited by the voltage headroom of the device, but since our stimulation electrodes showed
such small impedances, this was a minimal concern.

5.2.1.1.3 Powering changes
Powering of the device was a major issue for the experiment. The Bionode had previously been
designed for wireless powering in a very specific cavity for rodent use or to be powered with a
powering coil wand with a matched network to that of the Bionode coils. A pig would not fit in
the cavity, nor was it realistic to build one of the size needed to house a pig. We had previously
utilized tethered powering in rat subjects but decided against that option as the pigs could easily
damage a tethered port on the surface of their skin, and it would add significant complexity to the
chronic surgery.

The decided solution was two parts: a battery powered Bionode, and an adjusted coil to turn on
and re-charge said battery. We decided to use a rechargeable CR1620 Lithium cell battery due to
size and capacity. The required circuitry (power management integrated circuit (PMIC) and turnoff switch) were added to integrate the battery into the Bionode circuity and a control was added
to the Dataview interface that allowed us to turn the battery off when not in use.

The battery could be turned on (and recharged) by use of an inductively coupled coil wand. An
issue however was noted after the first device was implanted. The device could not effectively be
turned on inside of the pig with the standard coils and wands due to the tissue thickness of the
pig, so we had to use a larger transmit and receive coil to get better coupling at a further distance.
Because the transmit coil was larger, the inductance was larger. Further, because our impedance
matching network is an L-match network using only capacitors, we physically could not realize a
capacitive only L-match between the large inductance and the load at 340 MHz (the Bionode’s
default powering frequency). We had to use a matching network using inductors. However,
inductors are very low Q for any size larger than a nano-Henry at 340MHz, which would result
in losses across the matching network and low power transfer efficiency. As a result, we needed
to lower the frequency of operation so that we could realize proper capacitive L-matches for the
impedance matching network for the increased inductance. We picked 13.56 MHz because it's a
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popular medical device ISM band as per the FCC and is a legal operating frequency for our
devices.

Once the Bionode devices and powering wands were tuned to operate at 13.5 – 13.9 MHz, I was
able to turn on and recharge devices at a distance of five inches or more and was able to turn the
implanted devices on inside of the pig. Recharging the device while in the pig was still a
challenge and was only minimally effective. This coil set-up is demonstrated in Figure 5.2.

Figure 5.2 Pig Bionode re-charging set-up. Large charging coil wand is connected to base station
for powering and is transmitting charge at ~13.5 MHz to the sealed bionode device below.

5.2.1.1.4 Packaging changes
Packaging of the Bionode remained very similar to that of previous versions, but a battery
needed to be added. The battery could not be inserted into the bottom of the package due to its
interference with the powering coils. Therefore, we added the battery to the top of the package,
as can be seen in Figure 5.3. This added significant complexity to the packaging as the battery
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also had to be connected through the feedthrough cap along with the recording and stimulation
leads, while also being fastened in a flat position above the connected leads.

Insulation and sealing with the fast curing silicon adhesive and medical grade epoxy became a
hinderance due to the tight space created between leads and limited access to these spaces. The
fast curing silicon adhesive was inserted into the feedthrough cap well from the side and once
cured, the entire device went through multiple rounds of hand applied coats of epoxy to seal it.
This proved to be a very in-efficient and imprecise method that led to leakages in some devices.
It also led to many design improvements that have been made for the new Bionode 5.0.

Figure 5.3 Packaged Pig Bionode for chronic implantation. Device dimensions were ~60 mm
long and ~22 mm in cylindrical diameter.

5.2.1.2 Experimental protocol
Protocols for chronic pig experiments mirrored closely those for the chronic rats in Aim 3.
Surgically, a sterile environment was kept for all procedures. The left cervical vagus nerve was
exposed first, then a pocket for the Bionode implant was formed above and behind the left
shoulder blade of the pig. We tunneled the stimulation and recording cuffs and leads to the
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cervical vagus using a trocar system. The stimulation (rostral) and recording (caudal) cuffs were
then carefully wrapped around the left vagus nerve at a maximal distance from each other (17 –
25 mm apart, center to center of cuffs). Once the cuffs were in place on the nerve, we closed and
sutured the cervical surgical site, and then pushed the device into place in the pocket behind the
shoulder blade and sealed that incision site.

Before moving the pigs for recovery, we turned the Bionode on using the 13.5 MHz powering
wand and tested for functionality. The animals were then moved and given 13 – 21 days to
recover.

An important lesson that we noted during these surgeries was that the shape of the Bionode
package should be adjusted for future possible pig implantations. The cylindrical shape of the pig
Bionodes proved to be an issue due to the difficulty we encountered trying to suture the packages
in place, and their resulting tendency to rotate during the surgical implantation. As a result, the
receiving coil in the Bionode package could shift from the planned parallel position to the skin’s
surface and cause issues with turning on and charging the devices once implanted.
In the future, a flatter and wider package would be beneficial to prevent these issues.

The day before terminal experimentation, we anesthetized the animals and tested again to ensure
that the devices would turn on and attempt to charge the batteries. Once verified, the pigs were
outfitted with catheters for LPS injection and blood collection, and then placed in Pigturn caging
facilities (BASi; West Lafayette, IN) and connected to Culex Automated Blood Sampling
systems (BASi; West Lafayette, IN) cages. The Pigturn and Culex setup and Bionode interface
used can be seen in Figure 5.4.

On the day of the terminal experimentation, we followed procedures that again mirror the rat
experiments in Aim 3. We collected blood samples 30 minutes before injecting LPS and every
30 minutes after LPS injection for 180 minutes. LPS was mixed with sterile saline and sonicated
for 30 minutes prior to administration at a concentration of 7 μg/kg. We determined this to be a
sufficient dosage based on prior literature [151] and our own prior acute tests. A 5-minute
stimulation treatment was applied 30 minutes after LPS administration using 250 μs square bi-
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phasic stimulation pulses at 5 Hz frequency. We determined the amplitude to use based on prior
CNAP responses recorded at the time of implantation. After the final blood collections, the pigs
were euthanized, and the devices were explanted for post-experimental analysis.

Figure 5.4 Image (top) showing the Pig-Turn Culex system for chronic blood collection in
moving animals. Bionode System illustration (bottom) showing the stimulation and recording
system includes implanted Bionode with cuff electrodes; base station; and computer terminal
with GUI.

117
5.2.2

Results

We unfortunately only successfully performed three chronic surgeries during this initial
experiment phase. Four animals were implanted with devices, but one suffered an infection and
had to be euthanized early. Of the remaining three, one was implanted with a dummy device,
while the other two were successfully implanted and tested on the day of implant. We, however,
discovered on the day before terminal experimentation that one of the implanted devices had
failed to hold its charge and could not be recharged. We attempted to power it manually on the
day-of the experiment with the powering wand coils, but that proved unreasonable with a freely
moving pig subject. Therefore, only one of the three animals received the planned stimulation
treatment.

Fortunately, the small sample size did reveal some encouraging results to look at. In the
successfully simulated animal we were able to consistently record CNAP responses both on the
day of implantation and on the day of experimentation (see Figure 5.5). The CNAP responses
also showed to be very similar at similar stimulation amplitudes. This indicated that the cuffs
were successfully implanted and did not significantly shift or degrade during recovery. It was
also a good indication that our cuffs and device were sufficient to stimulate the required levels
for neuromodulation (though we did not formally test for maximal CNAP response).

Figure 5.5 CNAP response from chronic stimulation in pig. Day 1 (left) shows prominent C-fiber
response at 9 ms. Day 13 (right) shows prominent C-fiber response at 9 ms, and less prominent
B-fiber response (likely multiple responses) at around 5 ms.
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In addition to CNAP response, we were able to analyze inflammatory cytokine responses from
the blood (plasma) samples collected. Flow cytometry methods used for pig samples were
similar to those outlined for Aims 2 and 3, but the panel included a slightly different mix of
cytokines (as a pig’s biology varies from that of rodents). Cytokines analyzed included IL-1 ,
IL-1ra, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, INF-, GM-CSF, and TNF-. Of these cytokines,
only four of them showed significant trends: the commonly studied TNF-a (see Figure 5.6) and
IL-6 (see Figure 5.7), and the less studied IL-8 (see Figure 5.8) and IL-1 variants.

It is interesting to note that all shown cytokines displayed significantly higher levels in the
simulated samples than they did in the non-stimulated samples. While it is difficult for us to
make any solid conclusions based on these small samples sizes, the data does appear to indicate a
pro-inflammatory effect of the stimulation. While the modulation is not in the desired direction,
as we seek reductions in levels, this could in fact be due to suboptimal stimulations causing proinflammatory effects with afferent stimulation without activating anti-inflammatory efferent
pathways. Further studies should be performed.

Figure 5.6 Plasma TNF- levels after IV LPS injection into chronically cuffed pigs. Levels were
significantly higher in stimulated subject than those not receiving VNS.
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Figure 5.7 Plasma IL-6 levels after IV LPS injection into chronically cuffed pigs. Levels were
significantly higher in stimulated subject than those not receiving VNS.

Figure 5.8 Plasma IL-8 levels after IV LPS injection into chronically cuffed pigs. Levels were
significantly higher in stimulated subject than those not receiving VNS.
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Initial Study of Ultrasound Stimulation
A second alternative method to physical cuffing of the nerve for VNS that we have looked at is
Ultrasonic stimulation. I assisted with an initial study of this in conjunction with our Aim 2
research. The result was a paper lead-authored by Kelsey Wasilczuk and co-authored by myself
titled “Modulating the inflammatory reflex in rats using low intensity focused ultrasound
stimulation of the vagus nerve,” that has been submitted to the journal Ultrasound in Medicine
and Biology in May of 2018 [162].

The abstract from that paper reads as follows. “Tumor necrosis factor alpha (TNF-) is linked to
several chronic inflammatory diseases. Electrical vagus nerve stimulation reduces serum TNF-
levels, but may cause chronic nerve damage and requires surgery. Alternatively, we propose
focused ultrasound stimulation of the vagus nerve (uVNS), which can be applied non-invasively.
In this study, we induce an inflammatory response in rats using LPS and collect blood to analyze
the effects of uVNS on cytokine concentrations. We applied one or three 5-minute pulsed
focused ultrasound stimulation treatments to the vagus nerve (250 kHz, ISPPA= 3 W/cm2).
Animals receiving a single ultrasound application had an average reduction in TNF- levels by
19%, similar to the 16% reduction observed in electrically stimulated animals. With multiple
applications, uVNS therapy statistically reduced serum TNF- levels by 73% compared to
control animals without any observed damage to the nerve. These findings suggest that uVNS
serves as a suitable way to attenuate TNF- levels.”

The reported TNF- reductions can be seen in Figure 5.9, and led us to deduce the following in
the submitted paper. “With the ability to attenuate serum TNF- levels in the blood, we see
uVNS as a promising alternative therapy for chronic inflammatory diseases. With the single
application of uVNS showing similar reductions to electrical VNS (eVNS), we believe it could
be as, or even more, effective as eVNS. Also, since critically ill or elderly patients are not good
candidates for surgery, uVNS could provide an alternative way to relieve symptoms [163].
Finally, the non-invasive nature of focused ultrasound therapy will reduce risks and costs
associated with traditional eVNS therapy. This therapy could provide people the opportunity to
choose a non-invasive, non-pharmaceutical treatment option.”
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Figure 5.9 TNF- Response to Triple Stimulation: Plot shows average serum TNF- levels for
each animal group. Animals with a cervical efferent vagotomy that were given three ultrasound
stimulation treatments (u3Vx) (n=4) have statistically significant higher levels at t=120 from
both those given three ultrasound stimulation treatments with no vagotomy (u3VNS) and those
given no stimulation (nVNS) (p<0.05). u3VNS group has a statistically lower level of TNF- at
t=120 (p=0.04). Error bars, s.e.m. [162].

Wireless ANC
ANC, as presented in Aim 3 has the potential to revolutionize stimulation treatments by
providing real-time feedback of CNAP responses to electrical stimulations, and calibrate the
stimulation using the recorded CNAP responses to a specific percentage of the optimal nerve
response. Originally developed to be used by a benchtop DAC and current source controlled by a
Matlab algorithm, our lab attempted to make ANC wireless by conforming the software
algorithm to work with the Bionode and its Dataview interface through Matlab. Jui-Wei Tsai
integrated the Matlab algorithm to communicate with the Bionode software, and I, with the
assistance of Matthew Ward, made it work wirelessly on an acute benchtop setup as shown in
Figure 5.10. This accomplishment was presented by myself at the 2016 International Conference
of the IEEE Engineering in Medicine and Biology Society in Orlando, Florida [164].
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Figure 5.10 Experimental wireless ANC setup. Standalone bionode is placed near the rat with
attached stimulation and recording electrodes attached to the left vagus nerve of the rat. Device is
being powered with inductively coupled coil wand run from the base station.

The ANC mathematical model running on the Bionode will extract fiber-type specific activation
information as a percent of maximal activation for that fiber type in that nerve and patient [42].
This introduces constant-activation stimulation and preferential fiber-type recruitment for
maximal therapy with minimal side effects. This implementation represented a dramatic
advancement in capabilities and utilization over a tethered ANC setup, and allowed stimulation,
recording, and controls all on this singular implantable device. In Figure 5.11, we see 48 trials of
B-fiber selective vagal nerve stimulation (four second durations each) in a rat. The cumulative
average of the B-fiber responses tracked closely to the desired activation level in the steady state
and adjusted to changes in the desired activation level using variable stimulus pulse durations.
This closed-loop tracking and updating allowed for specific nerve activation, which could
translate to accurate dosing of stimulation therapy in the future.
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Figure 5.11 Clockwise from top left: Bionode device with vagus nerve cuffs attached, outside of
package; Nerve fiber responses recorded by Binode; Nerve response prediction of B-fibers of a
rat vagal nerve—arrows show the algorithm tracking to target activation level by varying
stimulation amplitudes at different pulse widths [164].
This early success, however, did not translate into a consistent and usable platform. Despite
many attempts by myself and Kaitlyn Neihouser during both acute and chronic experiments, we
were rarely successful in making the algorithm work as intended. There were noted issues across
the spectrum of software and hardware. Since ANC required a complete and uninterrupted set of
calibration stimulations from a responsive nerve, there were many places where the calibration
process could be interrupted.
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Many of the noted issues are listed as follows:

Bionode device issues:


Charge imbalances in stimulation profiles caused issues in stimulation artifact
cancellation and CNAP detection.



Communication latency issues due to poor antenna reception caused missed packets and
data which affected CNAP detections



Power latency issues caused stoppages in the calibration process and required a full
restart.



System noise often occurred and affected CNAP detections.



Movement artifacts affected CNAP detections in chronic tests with un-anesthetized
animals.



Lacking grounding plane on stimulation cuff ground reference caused distorted artifact
cancellations.

ANC algorithm issues:


Algorithm could not set or account for stimulation current/voltage limits. If a maximal
nerve response was not reached before the device stimulation limits, there was no default
response and the algorithm would continue with false readings. Also, there was originally
no way for the user to easily set a stimulation limit. Therefore, the algorithm during
calibration could reach dangerously high levels of stimulation if the device allowed for it.



Zero stimulation loops often occurred where the stimulation level would go to zero and
could not increase again to calibrate, requiring the user to re-start the program.



There were no options for a manual calibration if the automatic calibration did not work.

Given the above issues, utilizing ANC consistently was not an option in Aims 2 and 3, but with
recent improvements to the Bionode stimulator, antenna, and battery circuitry, it may be worth
attempting to troubleshoot the algorithm once again to make it reliable on a truly wireless and
implanted Bionode device in the future.
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Summary/Impact
New findings in research are only useful if they are followed up with new studies that can utilize
advancements, data, and lessons learned to improve on techniques. Given our Bionode
improvements in Aim 1, and our biological discoveries and new methods formulated in Aims 2
and 3, any of the three future studies presented in this section make sense to pursue going
forward.
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6. SUMMARY AND CONCLUSIONS

Explanation of the Problem
Inflammation remains a likely cause or contributor to many diseases, ailments, and syndromes in
humans. Research of inflammation is very broad and diverse, leading to a copious variety in
methods and treatment ideas. The ultimate goal remains the same though: to treat those with
conditions and to improve the lives of human beings.

Among treatment options, VNS (and other electroceuticals) remains on the forefront of modern
medicine. While already approved and used for those with epilepsy and drug resistant
depression, VNS holds promise as a remedy for countless other inflammatory conditions, as well
as many vagal-related ailments not directly associated to inflammation.

Ultimately, VNS remains a young therapeutic option in modern medicine. The complex
biological mechanisms of the vagus nerve on the body, and the effects of stimulation on those
mechanisms, are still not well understood and often highly debated. Variation in research
methods and in turn, results, causes the research community to often backtrack looking for
answers and possible mistakes before moving forward with more confidence. The study I have
presented here follows along that exact mindset.

I looked at multiple aspects of VNS research including devices, interfaces, and experimental and
data analysis methods.

VNS Device Development: Progress and Significance
Problem and previous status. All research is limited by the tools available to complete
exploration goals. While there are significant stimulation and recording options available from
commercial and laboratory equipment for VNS studies, most are made with specific uses in mind
and are therefore limited in their versatility.
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Our Bionode device has been developed to remedy this issue to a large extent in the small
university lab setting by providing us with a modular and flexible research platform that can be
made relatively cheap and easy with basic laboratory resources. Early versions of the Bionode,
however, suffered from significant issues that had to be solved.

What I did. I held a critical role in resolving many of the issues plaguing the Bionode and
preventing its use in chronic stimulation experiments. Among the improvements made, I helped
design and test the current HCS stimulation circuit, and then did benchtop and in-vivo testing
and troubleshooting of the stimulator and solved the remaining issues preventing it from being
safely and consistently used in chronic experiments. In addition, I played a critical role in adding
new capabilities to the device circuitry such as relative impedance measurement of the
stimulation line and batter powering of the Bionode.

I also developed many of the current manufacturing and packaging techniques we are using to
successfully implant the Bionode chronically in animal subjects. These methods have proven
reliable for use in animal studies in the CID.

In addition, I did significant research on the design and development of stimulation and
recording cuff electrodes for use in our studies. The resulting cuff electrodes have now been
effectively used in rats on various nerves and in pigs for VNS.

Why we care. In my time in the CID, the Bionode has gone through multiple evolutions. It has
progressed from a highly unreliable prototype with limited stimulation and recording capabilities
to a device that can be customized for virtually any basic stimulation or recording need, be
reliably built and tested in a quick and inexpensive manner, and confidently implanted. As such,
the new Bionode 5.0 is a more useful platform than others available.

While more testing needs to be done on the Bionode 5.0, including much in-vivo testing (which
has already begun), we are finally in position to move forward with further miniaturizing the
device (size being one of its few downsides) with ASIC implementations.
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Acute Stimulation Study: Progress and Significance
Problem and previous status. The VNS community is afflicted with inconsistencies in
experimental methods. With respect to studies of inflammation, replication of results is often
difficult due to these inconsistencies. One unfortunate result of this trend is that researchers
pursue methods that will produce better looking results, disregarding other methods that may
hold more physiological significance. This is the case with LPS usage in inflammatory studies of
rats, as most groups use IV injections instead of the arguably more physiologically relevant IP
method.

In addition, much work has been done to define the “inflammatory reflex” of the body and
methods to control that reflex with stimulation. Most of these studies, however, limit the
stimulation mechanisms to the cervical level of the vagus nerve. The subdiaphragmatic nerve
branches are sometimes vagotomized for effect analysis, but never actively stimulated
themselves.

What I did. I performed, in conjunction with Kelsey Wasilczuk, an acute set of 58 rat
experiments in which we looked at the effects of IP injection of LPS and localized
subdiaphragmatic branch VNS on inflammatory cytokine levels over a 6-hour period. To analyze
the highly variable (in the time domain) cytokine responses, I developed and applied new
methods of curve fitting and alignment of the cytokine cascades.

Using my new methods, we determined that selective stimulation of subdiaphragmatic nerve
branches does induce selective modulatory effects on the resulting cytokine levels in plasma.

Why we care. We presented results that indicate evident physiological differences in
inflammatory cytokine responses to IP versus IV injection methods that go beyond simple
variations in temporal uptake. Therefore, selecting one method based on ease of use instead of
physiological relevance could be prohibitive to future translation of results to clinical
applications. Fortunately, I also produced effective new analysis methods that can be used by
future researchers to utilize IP injections in their studies.
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We also presented evidence that selective subdiaphragmatic nerve branch stimulation can be
effectively used to produce specific modulatory effects in cytokine levels. This opens the
possibility of using selective combinations of subdiaphragmatic stimulation to treat specific
inflammatory ailments in the future. A localized treatment option could result in better treatment
results and less side effects than are seen in cervical VNS.

Chronic Cuffing Study: Progress and Significance
Problem and previous status. Chronic VNS animal studies, specifically those on small animal
subjects such as rats, present many difficulties such as device and interface integration and
surgical complexity. Given the many factors involved, it is difficult for a research group to
account for all possible complications. Add the inconsistencies in experimental equipment and
methods covered earlier, it is easy to imagine issues going undiscovered.

Chronic implantation and use of electrodes is a prime example of where complexity and
inconsistencies could be detrimental to translatable experimental results.

What I did. During our chronic VNS study of 53 rats, we implemented verification methods of
nerve integrity that had not been used previously in similar chronic nerve cuffing experiments.
Upon discovery of an underlying issue with efferent FG transport after chronic cuffing of the
cervical vagus nerve, I did a comprehensive analysis of the problem and follow-up tests to
determine the severity of the issue.

I also performed a thorough literature review to determine differences in methods used of other
groups that had attempted chronic VNS experiments. As expected, methods varied greatly.

Why we care. My presentation of never before seen evidence of efferent fiber damage due to
chronic nerve cuffing brings to light significant questions about the reliability of chronic VNS in
rodent subjects and possibly even in larger animals and humans. While our methods would need
to be integrated and tested on other group’s cuffing materials, methods, and protocols for
verification, until proven otherwise, we remain skeptical of aspects of other group’s chronic
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results. FG testing is a verification technique that should be implemented into future chronic
rodent VNS studies.

Meanwhile, alternate methods of VNS that show potential to be less invasive and damaging
should continue to be investigated. Two such options, larger animal models and focused lowintensity ultrasound stimulation, were presented in chapter 5.
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APPENDIX A. OVERVIEW OF STIMULATION AND RECORDING
DEVICES

Application

Recording
Capability

Multi

4
Channels

Muscle
Denervation

Not
presented

Telemetry
Recording

1 Channel

Nerve /
Muscle
Stimulation

No

Epilepsy

2 Channel

Deep Brain
Stimulation

No

Spinal Cord
Stimulation

No

Seizure
Detection /
Stimulation

64
Channel
for ECOG

Intracortical
Stimulation

No

Stimulation
Capability
1 Channel,
Const
Current,
Bipolar
Pulses, 0 1.2 mA, 9
V max
1 Channel,
Const
Voltage,
Bipolar
Pulses, 0 11 V

No

1 Channel,
Const
Current,
Bipolar
Pulses, 0.2 30 mA, 17 V
max
2 Channels,
Const
Voltage,
Unipolar
Pulses, 0 3.5V
2 Channels,
Const
Current,
Bipolar
Pulses,
0.015 - 50
mA, 20 V
max

2 Channels,
Const
Voltage,
Monophase
pulses, 50
mV - 3 V, 35
mA max

64 Channel,
Const
Current,
Biphasic
pulses, 0.01
- 1 mA
8 Channel,
Const
current,
Bipolar
pulses, 2.3 220 uA, 20
V max

Impedance
Measure
Capability

Controls
(Active vs
Passive)

Powering
Options

Device
Size

Electronics
Type

Implant
Capability

Tested
In-Vivo

Author

Yes

Active
stimulation and
recording
control

Battery,
Inductive
power /
recharge

1.9 x
1.6 x
4.7 cm,
13.9 g

PCB, COTS

Yes, glass
case /
epoxy
coated

Yes,
rats/pigs

Bionode (2018)

No

Preprogrammed

3V Li-ion
battery

5.5 x
2.4 x
1.0 cm,
19 g

PCB, COTS

Yes,
epoxy
coated

Yes, rats

Dennis et al.
(2003)

No

Passive
recording

Battery

1.9 cc,
3.9 g

Commercial,
Data
Science
International
PhysioTel

Yes

Yes, mice

Weiergraber et
al. (2005)

No

Preprogrammed

Inductive
power

2.4mm
dia,
16.7mm
long

ASIC
w/custom
wirebond &
die
attachments

Yes,
hemetic
glass or
ceramic
package

Yes,
injectable
in
humans

Kane et al.
(2011) BION

No

Reprogrammable

Battery

6.5 x
4.9 cm
flat, 68
g

Commercial,
Medtronic
Nexframe

Yes

Yes,
sheep

Stanslaski et
al. (2012)

Battery

2.4 x
1.7 cm
PCB,
10-14g,
1.43 cm
hight

PCB, COTS

No, head
or jacket
mount

Not
presented

Ewing et al.
(2013)

PCB, COTS

Yes,
epoxy
coated

Yes, rats

Xu et al. (2015)

No

Preset
parameters

No, in-vitro
pre test

Reprogrammable

Inductive
power

2.2 x
2.3 x
0.7 cm
PCB,
3.8 g;
3.8 x
6.5 x
2.5 cm
external
module,
20 g

No

Programmable,
closed-loop
feedback

Inductive
power

4.8 x
3.3 mm
chip, 2 x
2 cm rx
coil

ASIC

No,
assume
tethered

Yes

Kassiri et al.
(2016)

Yes

Active
stimulation
control

Inductive
power

4.4 x
4.4 x
0.9 cm
PCB
stack

ASICs,
multiple

No

No

Hasanuzzaman
et al (2018)

Table illustrates other reported devices’ capabilities compared to that of the Bionode as relate to
our desired factors (implantable, recording and stimulating, flexible, and configurable): Blue =
Bionode capabilities; Green = more capability than the Bionode; Red = lacks capabilities of the
Bionode; White = similar in capability to the Bionode.
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APPENDIX B. CHRONICALLY CUFFED RAT DETAILS

Experimental Results/Details of Chronically Cuffed Cervical Vagus Nerve on Rats
Animal
Name
eRx62
eRx63
eRx104
eRx105
eRx106
eRx110
eRx114
eRx115
eRx127
eRx128
eRx132
eRx137
eRx138
9909
9932
eRx75
eRx66
9915
eRx61
eRx80
eRx83
eRx88
eRx111
eRx113
eRx64
9937
eRx53
eRx55
eRx68
eRx81
eRx118
eRx102
eRx103
eRx108
eRx109
eRx71
eRx72
eRx116
eRx119
eRx141
eRx142
eRx143
eRx144
eRx147
eRx148
eRx150
eRx152

H&E Histology

Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Normal
Normal
Normal
Normal
Normal
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Not observed
Normal
Normal
Normal
Not observed
Not observed
Not observed
Not observed
Not observed

Visual Inspection

N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
N/A (not cuffed)
Moderate migration
Severe migration
Severe migration
Moderate migration
Severe migration
Moderate migration
Severe migration
Severe migration
not observed
Severe migration
not observed
not observed
not observed
not observed
Severe migration
not observed
not observed
Moderate migration
not observed
not observed
Moderate migration
Moderate migration
Moderate migration
not observed
Mild or no migration
not observed
not observed
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration
Mild or no migration

CNAP Detected in
Stimulation?
N/A (control)
N/A (control)
N/A (dummy device)
N/A (dummy device)
N/A (dummy device)
N/A (dummy headcap)
N/A (dummy headcap)
N/A (dummy headcap)
N/A (no metal in cuff)
N/A (no metal in cuff)
N/A (no metal in cuff)
N/A (no metal in cuff)
N/A (no metal in cuff)
N/A (not powered)
N/A (not powered)
N/A (not powered)
No detection / bad signal
Possible CNAP / ambiguous
No detection / bad signal
No detection / bad signal
No detection / bad signal
No detection / bad signal
No detection / no recording
No detection / no recording
Possible CNAP / ambiguous
Possible CNAP / ambiguous
Possible CNAP / ambiguous
Possible CNAP / ambiguous
No detection / bad signal
Possible CNAP / ambiguous
No detection / no recording
Conclusive CNAP
Conclusive CNAP
Conclusive CNAP
Conclusive CNAP
No detection / bad signal
Possible CNAP / ambiguous
Possible CNAP / ambiguous
No detection / bad signal
Possible CNAP / ambiguous
Conclusive CNAP
Possible CNAP / ambiguous
Conclusive CNAP
Conclusive CNAP
Conclusive CNAP
Possible CNAP / ambiguous
Conclusive CNAP

FG Transport to
Medulla RV (not
cuffed)
N/A (control)
N/A (control)
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport

FG Transport to
Medulla LV (cuffed)
N/A (control)
N/A (control)
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Expected transport
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Heavy suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Light suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Heavy suppression
Moderate suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression
Complete suppression

Cytokine Analysis

Days
Implanted

Control (no device)
Control (no device/LPS)
Control (dummy device)
Control (dummy device)
Control (dummy device)
Control (dummy device)
Control (dummy device)
Control (dummy, no LPS)
NA (no blood collection)
NA (no blood collection)
Control (no metal in cuff)
Control (no metal in cuff)
Control (no metal in cuff)
Control (no stimulation)
Control (no stimulation)
Control (no stimulation)
NA (no blood collection)
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Control (no LPS)
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Stimulated
Control (no LPS)

N/A
N/A
22
23
23
21
17
17
32
32
38
30
30
71
42
13
45
57
62
37
29
21
18
18
51
38
48
44
21
37
14
23
22
21
21
44
13
17
14
27
26
26
36
36
36
34
34

Table illustrates results from chronic testing for 47 rats: Blue = a good or expected result; Red =
a bad or unexpected result; Yellow = indeterminant result; White = not tested or not applicable in
that animal.

* “Moderate” migration was defined as an electrode(s) that was generally in the correct location
but had moved laterally ~1mm or less and/or appeared to have rotated ~30 degrees or less. The
nerve still appeared to be intact and encompassed in the cuff electrode. “Severe” was be defined
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as an electrode(s) that had obvious migrations of >1mm laterally, rotation of >30 degrees, and/or
signs of significant pulling or tearing of the encompassed vagus nerve.

** “Heavy” suppression was quantified as having no more than 15 illuminated cells in any given
medulla section. “Moderate” suppression was quantified as having more than 15 illuminated
cells in any given medulla section, but still had a majority of cells suppressed. “Light”
suppression was quantified as having observable cell suppression, but the majority of cells
illuminated.

*** Highlighted (green) and italicized items indicate animals that were included in our cytokine
analyses.
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APPENDIX C. GASTRIC EMPTYING RAT DETAILS

Experimental Results/Details of Chronically Cuffed Cervical Vagus Nerve on Rats Used for
Gastric Emptying Experiments
Animal
Name

eRx157
eRx159
eRx160
eRx161
eRx162
eRx163

Control
Scan
Good
Results
Good
Results
Good
Results
Good
Results
Good
Results
Breathing
Issues

Stimulation
Scan

N/A

Necropsy Nerve
Inspection

N/A

FG Transport to
Medulla RV (not
cuffed)
N/A

Good Results Mild or no migration Expected Transport
Total Apnia,
Stopped Stim Mild or no migration Expected Transport
Apnia During
Stim
Mild or no migration Expected Transport
Good Results
Apnia During
Stim

Mild or no migration Expected Transport
Moderate
Migration/Pulling
Expected Transport

FG Transport to
Medulla LV (cuffed)

Medulla FG
Brightness

Nodose FG
Brightness

Days
Implanted

N/A

N/A

N/A

23

Heavy Suppression

Bright

Bright

34

Moderate Suppression Bright

Dull But Present

35

Complete Suppression Bright

Bright

47

Moderate Suppression Bright

Bright

46

Complete Suppression Dull But Present

Dull But Present

48

Table illustrates results from chronic testing for 6 rats: Blue = a good or expected result; Red = a
bad or unexpected result; Yellow = indeterminant result; White = not tested or not applicable in
that animal.

* “Moderate” migration was defined as an electrode(s) that was generally in the correct location
but had moved laterally ~1mm or less and/or appeared to have rotated ~30 degrees or less. The
nerve still appeared to be intact and encompassed in the cuff electrode.

** “Heavy” suppression was quantified as having no more than 15 illuminated cells in any given
medulla section. “Moderate” suppression was quantified as having more than 15 illuminated
cells in any given medulla section, but still had a majority of cells suppressed.

*** eRx157 knocked its headcap off before the scheduled stimulation scan and was euthanized.
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APPENDIX D. OVERVIEW OF 17 PREVIOUS STUDIES USING CHRONIC VAGUS NERVE CUFFING
Topic

Animals

Biological Topic

Cuffs

Tests
Done

Reference

Nerve
Cuffed

Breed (Rat)

Weight

Sample
Size

Cuff Type

Cuff Inner
Diameter

Duration
Cuffed

Cuffing Technique

CNAP
Recorded

Nerve
Histology

Fluorogold
Used

Inflammation
Measured

Author

Seizure suppression

Fiber
Target
(Afferent /
Efferent)
Afferent

Left

Sprague-Dawley

--

34

--

--

4 days

Nerve isolated (assumed),
cuffed

No

No

No

No

Krahl et al. (2001) [104]

Anti-depression

Afferent

Left

Sprague-Dawley

275g+

5-6 per
group

Cyberonics
helical

1mm
(assumed)

2 days + (1
hour to 90
days)

Cuffs wrapped around nerve
& carotid; leads suture to
muscle

No

No

No

No

Dorr et al. (2006) [105]

Tremor suppression

Afferent

Left

Long-Evans

7

Cyberonics
helical

1mm

4+ days

Cuffs wrapped around nerve
& carotid

No

No

No

No

Handforth et al. (2001) [106]

Hippocampal
neuronal plasticity

Afferent

Left

Sprague-Dawley

300350g
250300g

6 per
group

Cyberonics
helical

--

2 days + 1
month

Cuffs wrapped around nerve
& carotid

No

No
(Brain)

No

No

Biggio et al. (2009) [107]

Neuroprotective
effects in brain

Afferent

Left

Wistar

Variable

24

Cyberonics
helical

--

13 weeks

Cuffs wrapped around nerve
(carotid unspecified)

No

No
(Brain)

No

Yes (Plasma,
brain)

Chunchai et al. (2016) [108]

Brain biomarkers /
anti-depression

Afferent

Left

Sprague-Dawley

29

Cyberonics
helical

--

4 weeks

References Dorr et al.

No

No

No

No

Cunningham et al. (2008) [17]

Anti-depression

Afferent

Left

Sprague-Dawley

250350g
250300g

45

Self-sizing spiral
cuff

1mm

8 weeks

Nerve isolated; wrapped with
cuff

No

No
(Brain)

No

No

Grimonprez et al. (2015) [109]

Body weight / fat
mass

Both
Possible

Left

Sprague-Dawley

250300g

13 max
per
group

Cyberonics
helical

--

2 days + 4
weeks

Cuffs wrapped around nerve
(carotid unspecified)

No

No

No

No

Banni et al. (2012) [165]

Pain memory

Afferent

Left

Sprague-Dawley

300350g

8 max
per
group

PVS sheath

1 mm

16 days

Nerve isolated; pvc around
nerve; leads sutured to
cleidomastoid

No

No

No

No

Zhang et al. (2013) [110]

Fear / memory
conditioning

Afferent

Left

Sprague-Dawley

250300g

40

Silicone tube

1 mm

13 days

Nerve isolated; cuffed

No

No

No

No

Pena et al. (2014) [111]

Enhanced memory

Both

Left

Long-Evans

350450g

64

PVC sheath

1 mm

~3 days

Nerve isolated; pvc around
nerve; leads sutured to
cleidomastoid; bone wax
inside cuff

Yes

No

No

No

Clark et al. (1998) [16]

Bowel
Inflammation

Both

Left

Sprague-Dawley

--

48

Cyberonics
helical

--

17 days

Cuffs wrapped around nerve
& carotid

No

No
(Colon)

No

Yes (Colon)

Meregnani et al. (2011) [95]

Cardiac remodeling
(heart failure)

Both

Left

Sprague-Dawley

--

63

Silicone tube

0.75 mm

14 weeks

Nerve isolated; cuffed/sutured
shut; strain relief cuff placed
around nerve cuff and artery

No

No

No

No

Agarwal et al. (2016) [112]

Hypertension,
Cardiovascular
damage

Both

Right

Rat (not
specified)

--

24

Wire with KwikSil

wrapped
wire

4-5 weeks

Nerve isolated; wire wrapped
around; Kwik-Sil
encapsulated

No

No

No

Yes (Serum)

Chapleau et al. (2016) [96]

Negative heart
impacts
Artery pressure /
heart rate

Both

Right

Sprague-Dawley

9

10 weeks

No

No

No

Lee et al. (2016) [113]

Sprague-Dawley

--

0.5 mm

up to 3 months

Cuffs wrapped around nerve
& carotid
Nerve isolated, cuffed/sutured
shut

No

Right

Cyberonics
helical
Silicone tube

1.5 mm

Both

250300g
250350g

No

No

No

No

Zheng et al. (2014) [114]

Larynx action
potentials

Efferent

Left

Wistar

250350g

21
chronic

Self-sizing
silicone tube

1 mm

8 weeks

Nerve isolated, cuffed

Yes

No

No

No

El Tahry et al. (2011) [115]

Inflammation /
Gastric Emptying

Efferent

Left

Sprague-Dawley

190300g

53

Silicone tube

0.75 mm

13-71 days

Nerve isolated, cuffed

Yes

Yes

Yes

Yes (Plasma)

Somann et al (2017)*

*This study included for comparison purposes.
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APPENDIX E. STIMULATION DETAILS OF 17 PREVIOUS STUDIES

Stimulation Details of 17 Previous Studies Using Chronic Vagus Nerve Cuffing.
Stimulation Parameters

Stimulation Protocols

Additional Stimulation Details

Reference

Amplitude

Pulse Width (s)

Frequency
(Hz)

Pulse Details

Stimulation Duration

Stimulation Timeline

Delivery Mechanism

Stimulation Verification

Author

1 mA

500

20

Square-wave
pulses

15 minute continuous
pulse train

Half stimulated after 2 days, the remainder
after 4 days

-

-

Krahl et al. (2001) [104]

0.25 mA

500

20

-

30 sec on, 5 min off,
continuous

1 hour, 1 day, 3 day, 2-week, 3-week, & 3month VNS groups

Implanted Cyberonics 102 Pulse
Stimulator

Lead impedance check, no
functional test presented

Dorr et al. (2006) [105]

0.5 mA

500

20

Balanced biphasic

5 min continuous pulse
train

4+ day recovery, then 5 consecutive 20 min
treatments (5 min baseline, 5 min acute VNS,
10 min post period)

A-M Systems Model 2100 stimulator,
tethered to headcap

-

Handforth et al. (2001) [106]

1.5 mA

500

30

-

30 sec on, 5 min off,
continuous

2 day recovery, then 3 hour or 1 month VNS

Implanted Cyberonics stimulator

-

Biggio et al. (2009) [107]

0.5 - 0.75 mA

500

20

-

14 sec on, 48 sec off,
continuous

1 week recovery, then 12 week VNS

Implanted Cyberonics Demipulse
stimulator

-

Chunchai et al. (2016) [108]

0.25 mA

250

20

-

30 sec per 5 min,
continuous

1 week recovery, then 2 hour or 3 week VNS

Implanted Cyberonics stimulator

-

Cunningham et al. (2008) [17]

0.25, 0.5, or 1 mA

250

30

-

7 sec on, 18 sec off,
continuous

1 week recovery, 5 week baseline, then 2
week VNS

Stimulator tethered to headcap

Daily impedance test with 1mA
square wave

Grimonprez et al. (2015) [109]

1.5 mA

500

30

-

30 sec on, 5 min off,
continuous

2 day recovery, then 3 hour or 4 week VNS

Implanted Cyberonics Demipulse
Model 103 stimulator

Dedicated test pre-implant

Banni et al. (2012) [165]

0.04 or 0.4 mA

500

1

-

30 seconds acute VNS
pre or post conditioning

5 day recovery, pre-condition day, then 3
consecutive conditioning days

A-M Systems Model 2100 stimulator,
tethered through neck incision

Respiration and behavioral
response to VNS

Zhang et al. (2013) [110]

0.4 mA

500

30

-

30 seconds

1 week recovery, then 5 conditioning/
treatment days (acute VNS on day 4)

Tucker Davis Tech. MS4 stimulator,
tethered to headcap

Respiration response to 0.2 mA,
60 Hz, 10 sec VNS

Pena et al. (2014) [111]

0.2, 0.4, or 0.8 mA

500

20

Biphasic pulses

30 seconds

2 day recovery, then condition testing with
acute VNS

Undefined stimulator, tethered
through neck incision

Action potentials recorded

Clark et al. (1998) [16]

1 mA

500

5

-

10 sec on, 90 sec off,
continuous

12 day recovery, then 3 hour VNS per day (5
days)

Grass Technologies stimulator chain,
tethered through head connector

-

Meregnani et al. (2011) [95]

0.05 - 0.25 mA

200

20

-

10 sec on, 50 sec off,
continuous

7 day recovery, then 6 week VNS

Undefined pulse generator and
connection.

Respiration and heart rate
response

Agarwal et al. (2016) [112]

3V

1000

5

Charge balanced

1 hour on, 1 hour off,
continuous

3-4 day recovery, then 4 week VNS

Implanted Harald Stauss Scientific
Model RNS stimulator

Heart rate and blood pressure
response

Chapleau et al. (2016) [96]

1 mA

500

20

-

7 sec on, 66 sec off,
continuous

10 week VNS

Implanted Cyberonics Demipulse
Model 103 stimulator

-

Lee et al. (2016) [113]

0.1 - 1 mA

200

20

Rectangular pulses

Various, intermittent

6 weeks intermittent VNS

Implanted Unimec ISE1000SA pulse
generator

Heart rate and artery pressure

Zheng et al. (2014) [114]

0.04 - 0.8 mA

500

-

Block-pulses

Various to determine
dose response curves

5 days / week, for 8 weeks

Undefined stimulator tethered to
headcap

Action potentials recorded

El Tahry et al. (2011) [115]

Various (1 mA typical)

Various (1 ms
typical)

5

Balanced biphasic
square pulses

5 - 10 min precalibration, 5 min
treatment

13 – 71 day recovery, then pre-calibration
VNS 30 min before, acute VNS 30 min after
endotoxin

Bionode, fully implanted or tethered
to headcap

Direct recording, separate
recording cuff

Somann et al (2017)*

136

*This study included for comparison purpose.
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